PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
19059369-5	2009	Consistently, biomolecular and functional experiments showed that resiniferatoxin (RTX), a selective TRPV1 receptor agonist, increased the expression and the activity of TRAP and cathepsin K, two specific osteoclast biomarkers.	resiniferatoxin	66-81	transient receptor potential cation channel subfamily V member 1	Homo sapiens	101-106
19059369-5	2009	Consistently, biomolecular and functional experiments showed that resiniferatoxin (RTX), a selective TRPV1 receptor agonist, increased the expression and the activity of TRAP and cathepsin K, two specific osteoclast biomarkers.	resiniferatoxin	66-81	TRAP	Homo sapiens	170-174
19059369-5	2009	Consistently, biomolecular and functional experiments showed that resiniferatoxin (RTX), a selective TRPV1 receptor agonist, increased the expression and the activity of TRAP and cathepsin K, two specific osteoclast biomarkers.	resiniferatoxin	66-81	cathepsin K	Homo sapiens	179-190
19059369-5	2009	Consistently, biomolecular and functional experiments showed that resiniferatoxin (RTX), a selective TRPV1 receptor agonist, increased the expression and the activity of TRAP and cathepsin K, two specific osteoclast biomarkers.	resiniferatoxin	83-86	transient receptor potential cation channel subfamily V member 1	Homo sapiens	101-106
19059369-5	2009	Consistently, biomolecular and functional experiments showed that resiniferatoxin (RTX), a selective TRPV1 receptor agonist, increased the expression and the activity of TRAP and cathepsin K, two specific osteoclast biomarkers.	resiniferatoxin	83-86	TRAP	Homo sapiens	170-174
19059369-5	2009	Consistently, biomolecular and functional experiments showed that resiniferatoxin (RTX), a selective TRPV1 receptor agonist, increased the expression and the activity of TRAP and cathepsin K, two specific osteoclast biomarkers.	resiniferatoxin	83-86	cathepsin K	Homo sapiens	179-190
19378721-0	2009	Resiniferatoxin mediated ablation of TRPV1+ neurons removes TRPA1 as well.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	37-42
19378721-0	2009	Resiniferatoxin mediated ablation of TRPV1+ neurons removes TRPA1 as well.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	60-65
19378721-1	2009	OBJECTIVES: Resiniferatoxin, the most potent agonist of inflammatory pain/vanilloid receptor/cation channel (TRPV1) can be used for neuron subtype specific ablation of pain generating cells at the level of the peripheral nervous system by Ca(2+)-excytotoxicity.	resiniferatoxin	12-27	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	93-107
19378721-1	2009	OBJECTIVES: Resiniferatoxin, the most potent agonist of inflammatory pain/vanilloid receptor/cation channel (TRPV1) can be used for neuron subtype specific ablation of pain generating cells at the level of the peripheral nervous system by Ca(2+)-excytotoxicity.	resiniferatoxin	12-27	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	109-114
19049892-4	2009	Aerosolized resiniferatoxin (RTX, 0.5 microM) and hypertonic saline (7%) produced a cough response dependent and independent of TRPV1 activation, respectively.	resiniferatoxin	12-27	transient receptor potential cation channel subfamily V member 1	Cavia porcellus	128-133
19275664-4	2009	Initially, the focus was on the development of TRPV1 agonists e.g. capsaicin and resiniferatoxin (RTX) as analgesic agents through the desensitization/denervation approach.	resiniferatoxin	81-96	transient receptor potential cation channel subfamily V member 1	Homo sapiens	47-52
19275664-4	2009	Initially, the focus was on the development of TRPV1 agonists e.g. capsaicin and resiniferatoxin (RTX) as analgesic agents through the desensitization/denervation approach.	resiniferatoxin	98-101	transient receptor potential cation channel subfamily V member 1	Homo sapiens	47-52
18824169-0	2008	Intrathecal delivery of resiniferatoxin (RTX) reduces detrusor overactivity and spinal expression of TRPV1 in spinal cord injured animals.	resiniferatoxin	24-39	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	101-106
19012737-5	2009	Resiniferatoxin (RTX) treatment or dorsal rhizotomy ablated TRPV1-expressing primary afferents but did not affect TRPV1- and vesicular glutamate transporter-2-expressing dorsal horn neurons.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	60-65
19012737-5	2009	Resiniferatoxin (RTX) treatment or dorsal rhizotomy ablated TRPV1-expressing primary afferents but did not affect TRPV1- and vesicular glutamate transporter-2-expressing dorsal horn neurons.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	60-65
18824169-0	2008	Intrathecal delivery of resiniferatoxin (RTX) reduces detrusor overactivity and spinal expression of TRPV1 in spinal cord injured animals.	resiniferatoxin	41-44	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	101-106
18824169-9	2008	Overall, our results show that intrathecal administration of RTX effectively reduces detrusor overactivity and reduces intravesical pressure in models of complete chronic spinal cord transection by suppressing the activity of TRPV1 expressing afferent fibres.	resiniferatoxin	61-64	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	226-231
18669865-4	2008	Treatment with the ultrapotent TRPV1 agonist resiniferotoxin (RTX) eliminated TRPV1-expressing dorsal root ganglion neurons and their central terminals in the spinal dorsal horn and significantly reduced the basal amplitude of glutamatergic excitatory postsynaptic currents (EPSCs) evoked from primary afferents.	resiniferatoxin	62-65	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	31-36
19085565-2	2008	Transient receptor potential vanilloid-1 (TRPV1) is an ion channel activated by the tussive agents capsaicin, resiniferatoxin, and protons.	resiniferatoxin	110-125	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	0-40
19085565-2	2008	Transient receptor potential vanilloid-1 (TRPV1) is an ion channel activated by the tussive agents capsaicin, resiniferatoxin, and protons.	resiniferatoxin	110-125	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	42-47
18951825-11	2008	RTX is expected to produce important savings (-31%) if used after failure of one or more TNFalpha therapies.	resiniferatoxin	0-3	tumor necrosis factor	Homo sapiens	89-97
18625695-5	2008	Resiniferatoxin (RTX) is a TRPV1 agonist that, in high doses, defunctionalises C and Adelta fibres.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	27-32
18625695-5	2008	Resiniferatoxin (RTX) is a TRPV1 agonist that, in high doses, defunctionalises C and Adelta fibres.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	27-32
18669865-4	2008	Treatment with the ultrapotent TRPV1 agonist resiniferotoxin (RTX) eliminated TRPV1-expressing dorsal root ganglion neurons and their central terminals in the spinal dorsal horn and significantly reduced the basal amplitude of glutamatergic excitatory postsynaptic currents (EPSCs) evoked from primary afferents.	resiniferatoxin	62-65	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	78-83
18619501-3	2008	RTX treatment significantly attenuated BmK venom-induced c-Fos expression in all laminaes of bilateral L4-L5 lumbar spinal cord, especially in superficial laminaes.	resiniferatoxin	0-3	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	57-62
18828909-6	2008	or pharmacologically with resiniferatoxin (RTX), a lesioning agent for TRPV1-expressing neurons.	resiniferatoxin	26-41	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	71-76
18828909-6	2008	or pharmacologically with resiniferatoxin (RTX), a lesioning agent for TRPV1-expressing neurons.	resiniferatoxin	43-46	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	71-76
18828909-13	2008	Following intracisternal treatment with RTX, C57BL/6J mice demonstrated a block of noxious heat at both 48 and 55 degrees C. RTX-treated TRPV1 k.o.	resiniferatoxin	40-43	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	137-142
18828909-13	2008	Following intracisternal treatment with RTX, C57BL/6J mice demonstrated a block of noxious heat at both 48 and 55 degrees C. RTX-treated TRPV1 k.o.	resiniferatoxin	125-128	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	137-142
18405883-7	2008	RESULTS: The TRPV1 agonists capsaicin and resiniferatoxin facilitated LTP but suppressed LTD. Alterations were mediated by TRPV1 because the TRPV1 selective antagonists capsazepine and SB366791 blocked the actions of capsaicin.	resiniferatoxin	42-57	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	13-18
18755179-3	2008	A robust increase in intracellular Ca(2+) was elicited by a variety of TRPV1 agonists with similar rank order of potency between both cultures: resiniferatoxin>tinyatoxin>capsaicin>N-arachidonoyl-dopamine (NADA).	resiniferatoxin	144-159	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	71-76
18405883-7	2008	RESULTS: The TRPV1 agonists capsaicin and resiniferatoxin facilitated LTP but suppressed LTD. Alterations were mediated by TRPV1 because the TRPV1 selective antagonists capsazepine and SB366791 blocked the actions of capsaicin.	resiniferatoxin	42-57	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	123-128
18405883-7	2008	RESULTS: The TRPV1 agonists capsaicin and resiniferatoxin facilitated LTP but suppressed LTD. Alterations were mediated by TRPV1 because the TRPV1 selective antagonists capsazepine and SB366791 blocked the actions of capsaicin.	resiniferatoxin	42-57	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	123-128
18579164-3	2008	Resiniferatoxin (RTX) is an ultra-potent transient receptor potential vanilloid type 1 channel (TRPV1) agonist and can selectively remove TRPV1-expressing primary afferent neurons.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	96-101
18579164-3	2008	Resiniferatoxin (RTX) is an ultra-potent transient receptor potential vanilloid type 1 channel (TRPV1) agonist and can selectively remove TRPV1-expressing primary afferent neurons.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	138-143
18579164-3	2008	Resiniferatoxin (RTX) is an ultra-potent transient receptor potential vanilloid type 1 channel (TRPV1) agonist and can selectively remove TRPV1-expressing primary afferent neurons.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	96-101
18579164-3	2008	Resiniferatoxin (RTX) is an ultra-potent transient receptor potential vanilloid type 1 channel (TRPV1) agonist and can selectively remove TRPV1-expressing primary afferent neurons.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	138-143
18579164-7	2008	In RTX-treated rats, the delta-opioid receptor on TRPV1-immunoreactive dorsal root ganglion neurons and afferent terminals in the spinal cord was diminished.	resiniferatoxin	3-6	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	50-55
18579164-9	2008	Interestingly, intrathecal injection of [D-Pen(2),d-Pen(5)]-enkephalin or [D-Ala(2),Glu(4)]-deltorphin produced a large and prolonged increase in the nociceptive threshold in RTX-treated rats.	resiniferatoxin	175-178	proenkephalin	Rattus norvegicus	60-70
17933570-4	2008	Thus, we next examined whether the depletion of CSPAs with resiniferatoxin (RTX) modified the change of spinal NR1 and pNR1 expression induced by CCI.	resiniferatoxin	76-79	glutamate ionotropic receptor NMDA type subunit 1	Rattus norvegicus	111-114
18635498-7	2008	RTX-induced conduction blockade has an inherent drawback of TRPV1 agonists, the initial excitation (pain); therefore, a local anesthetic should be injected to prevent it.	resiniferatoxin	0-3	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	60-65
18635503-1	2008	BACKGROUND: Resiniferatoxin (RTX) is a potent agonist of the transient receptor potential vanilloid 1 channel (TRPV1) found in peripheral nociceptors.	resiniferatoxin	12-27	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	111-116
18635503-1	2008	BACKGROUND: Resiniferatoxin (RTX) is a potent agonist of the transient receptor potential vanilloid 1 channel (TRPV1) found in peripheral nociceptors.	resiniferatoxin	29-32	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	111-116
18635503-9	2008	Cell responses to VTD partially recovered, to 42% of control, after incubation in RTX-free medium for 24 h. CONCLUSION: RTX at 10 microM directly and acutely inhibited voltage-dependent Ca(2+) channels, in a TRPV1-independent manner.	resiniferatoxin	120-123	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	208-213
17933570-8	2008	Interestingly, RTX treatment significantly attenuated the CCI-induced upregulation of NR1 and pNR1 in spinal laminae I-II and V-VI, but not laminae III-IV as compared with that of vehicle-treated CCI rats.	resiniferatoxin	15-18	glutamate ionotropic receptor NMDA type subunit 1	Rattus norvegicus	86-89
18460982-0	2008	Preventive effect of TRPV1 agonists capsaicin and resiniferatoxin on ischemia/reperfusion-induced renal injury in rats.	resiniferatoxin	50-65	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	21-26
18460982-7	2008	In addition, resiniferatoxin (20 microg/kg, subcutaneous), a more selective and potent TRPV1 agonist, showed a renoprotective effect on ischemia/reperfusion-induced renal injury, in a qualitatively similar way to cases seen with capsaicin.	resiniferatoxin	13-28	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	87-92
18321652-10	2008	Resinferatoxin (RTX), an ultrapotent transient receptor potential vanilloid type 1 (TRPV1) agonist, was used to inactivate TRPV1 containing nerve fibers/cell bodies.	resiniferatoxin	0-14	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	37-82
18437086-6	2008	However, when primary sensory neurons were ablated by injection of the neurotoxin and TRPV1 agonist, resiniferatoxin, pancreatitis was ameliorated in wild-type mice but not in null mice, indicating that nerves bearing TRPV1 are part of the inflammatory pathway in acute pancreatitis because disappearance significantly reduced the inflammatory response.	resiniferatoxin	101-116	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	86-91
18437086-6	2008	However, when primary sensory neurons were ablated by injection of the neurotoxin and TRPV1 agonist, resiniferatoxin, pancreatitis was ameliorated in wild-type mice but not in null mice, indicating that nerves bearing TRPV1 are part of the inflammatory pathway in acute pancreatitis because disappearance significantly reduced the inflammatory response.	resiniferatoxin	101-116	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	218-223
18321652-10	2008	Resinferatoxin (RTX), an ultrapotent transient receptor potential vanilloid type 1 (TRPV1) agonist, was used to inactivate TRPV1 containing nerve fibers/cell bodies.	resiniferatoxin	0-14	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	84-89
18321652-10	2008	Resinferatoxin (RTX), an ultrapotent transient receptor potential vanilloid type 1 (TRPV1) agonist, was used to inactivate TRPV1 containing nerve fibers/cell bodies.	resiniferatoxin	0-14	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	123-128
18321652-10	2008	Resinferatoxin (RTX), an ultrapotent transient receptor potential vanilloid type 1 (TRPV1) agonist, was used to inactivate TRPV1 containing nerve fibers/cell bodies.	resiniferatoxin	16-19	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	37-82
18321652-10	2008	Resinferatoxin (RTX), an ultrapotent transient receptor potential vanilloid type 1 (TRPV1) agonist, was used to inactivate TRPV1 containing nerve fibers/cell bodies.	resiniferatoxin	16-19	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	84-89
18321652-10	2008	Resinferatoxin (RTX), an ultrapotent transient receptor potential vanilloid type 1 (TRPV1) agonist, was used to inactivate TRPV1 containing nerve fibers/cell bodies.	resiniferatoxin	16-19	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	123-128
18029293-2	2008	VR1 can be selectively ablated by resiniferatoxin (RTX), an ultra-potent excitotoxic agonist, when injected into sensory ganglia.	resiniferatoxin	34-49	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	0-3
18261748-11	2008	4-MOLDA and OEA failed to alter the heat threshold but inhibited the threshold drop induced by the TRPV1 receptor agonist resiniferatoxin.	resiniferatoxin	122-137	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	99-104
18312687-7	2008	Resiniferatoxin (RTX) binding, a measure of TRPV1 expression is increased and decreased in DRG and paw skin of hyperalgesic and hypoalgesic mice, respectively.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	44-49
18312687-7	2008	Resiniferatoxin (RTX) binding, a measure of TRPV1 expression is increased and decreased in DRG and paw skin of hyperalgesic and hypoalgesic mice, respectively.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	44-49
18029293-2	2008	VR1 can be selectively ablated by resiniferatoxin (RTX), an ultra-potent excitotoxic agonist, when injected into sensory ganglia.	resiniferatoxin	51-54	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	0-3
18032552-6	2008	Intrapelvic administration of capsaicin or a specific TRPV1 agonist, resiniferatoxin, resulted in a dose-dependent increase in multi-unit ARNA and SP release, and these effects were blocked by the TRVP1 blocker capsazepine.	resiniferatoxin	69-84	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	54-59
18199335-1	2008	Resiniferatoxin (RTX) is an ultrapotent capsaicin analog that binds to the transient receptor potential channel, vanilloid subfamily member 1 (TRPV1).	resiniferatoxin	0-15	transient receptor potential cation channel subfamily V member 1	Homo sapiens	143-148
18199335-1	2008	Resiniferatoxin (RTX) is an ultrapotent capsaicin analog that binds to the transient receptor potential channel, vanilloid subfamily member 1 (TRPV1).	resiniferatoxin	17-20	transient receptor potential cation channel subfamily V member 1	Homo sapiens	143-148
18199335-8	2008	Recovery studies showed that physiologic sensory function could return as early as two weeks post-RTX treatment, however, immunohistochemical examination of the DRG revealed a partial, but significant reduction in the number of the TRPV1-positive neurons.	resiniferatoxin	98-101	transient receptor potential cation channel subfamily V member 1	Homo sapiens	232-237
17883394-6	2007	Scya2 mRNA was localized by in situ hybridization-immunocytochemical double-labeling to a subpopulation of vanilloid receptor-1 (transient receptor potential vanilloid subtype 1) containing neurons, and its expression was increased by direct transient receptor potential vanilloid subtype 1 stimulation with the vanilloid agonist resiniferatoxin, indicating sensitivity to nociceptive afferent activity.	resiniferatoxin	330-345	C-C motif chemokine ligand 2	Rattus norvegicus	0-5
18852901-11	2008	CONCLUSION: TRPV1B expression, together with low TRPV1 expression, may explain the vanilloid paradox: even genuinely TRPV1 mRNA positive cells can be spared with therapeutic (up to micromolar) doses of RTX.	resiniferatoxin	202-205	transient receptor potential cation channel subfamily V member 1	Homo sapiens	12-17
17711510-0	2007	Increased expression of transient receptor potential vanilloid subfamily 1 in the bladder predicts the response to intravesical instillations of resiniferatoxin in patients with refractory idiopathic detrusor overactivity.	resiniferatoxin	145-160	transient receptor potential cation channel subfamily V member 1	Homo sapiens	24-74
17711510-10	2007	Transcript levels before treatment correlated significantly with the therapeutic effect of resiniferatoxin (P = 0.004), with higher TRPV1 mRNA expression in responders (median 1.50, range 0.89-2.78) than nonresponders (0.74, 0.34-1.32).	resiniferatoxin	91-106	transient receptor potential cation channel subfamily V member 1	Homo sapiens	132-137
17711510-12	2007	CONCLUSION: Successful intravesical resiniferatoxin treatment is closely associated with the over-expression of TRPV1 in the bladder mucosa and submucosa in patients with IDO.	resiniferatoxin	36-51	transient receptor potential cation channel subfamily V member 1	Homo sapiens	112-117
17517374-5	2007	TRPV1 and TRPA1 RNA were significantly decreased in DRG from RTX-treated rats, indicating functional colocalization of TRPA1 and TRPV1 in sensory nociceptors.	resiniferatoxin	61-64	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	0-5
17705161-2	2007	RTX, a capsaicin analogue devoid of severe pungent properties, acts by desensitizing the transient receptor potential vanilloid type 1 (TRPV1) receptor and inactivating C-fibers.	resiniferatoxin	0-3	transient receptor potential cation channel subfamily V member 1	Homo sapiens	89-134
17705161-2	2007	RTX, a capsaicin analogue devoid of severe pungent properties, acts by desensitizing the transient receptor potential vanilloid type 1 (TRPV1) receptor and inactivating C-fibers.	resiniferatoxin	0-3	transient receptor potential cation channel subfamily V member 1	Homo sapiens	136-141
17698245-2	2007	In this study we measured PACAP-like immunoreactivity with radioimmunoassay in the rat plasma and showed a two-fold elevation in response to systemic stimulation of capsaicin-sensitive sensory nerves by resiniferatoxin, but not after local excitation of cutaneous afferents.	resiniferatoxin	203-218	adenylate cyclase activating polypeptide 1	Rattus norvegicus	26-31
17698245-3	2007	Neurogenic plasma extravasation in the plantar skin induced by intraplantar capsaicin or resiniferatoxin, as well as carrageenan-induced paw edema were significantly diminished by intraperitoneal PACAP-38.	resiniferatoxin	89-104	adenylate cyclase activating polypeptide 1	Rattus norvegicus	196-201
17442052-6	2007	Capsaicin, anandamide, resiniferatoxin and olvanil mediated increases in [Ca(2+)](i) were inhibited by the TRPV1 antagonists capsazepine and iodo-resiniferatoxin with potencies (K(B)) of approximately 70 nmol/L and 2 nmol/L, respectively.	resiniferatoxin	23-38	transient receptor potential cation channel subfamily V member 1	Homo sapiens	107-112
17517374-5	2007	TRPV1 and TRPA1 RNA were significantly decreased in DRG from RTX-treated rats, indicating functional colocalization of TRPA1 and TRPV1 in sensory nociceptors.	resiniferatoxin	61-64	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	10-15
17517374-5	2007	TRPV1 and TRPA1 RNA were significantly decreased in DRG from RTX-treated rats, indicating functional colocalization of TRPA1 and TRPV1 in sensory nociceptors.	resiniferatoxin	61-64	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	119-124
17517374-5	2007	TRPV1 and TRPA1 RNA were significantly decreased in DRG from RTX-treated rats, indicating functional colocalization of TRPA1 and TRPV1 in sensory nociceptors.	resiniferatoxin	61-64	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	129-134
17291600-6	2007	Lipopolysaccharide significantly increased lung SP and CGRP concentrations, which was prevented by resiniferatoxin pretreatment.	resiniferatoxin	99-114	tachykinin 1	Mus musculus	48-50
17626206-8	2007	We then established that localized intra-abdominal desensitization of TRPV1 channels with intraperitoneal resiniferatoxin blocks the T(b) response to systemic AMG0347; the extent of desensitization was determined by using a comprehensive battery of functional tests.	resiniferatoxin	106-121	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	70-75
17291600-6	2007	Lipopolysaccharide significantly increased lung SP and CGRP concentrations, which was prevented by resiniferatoxin pretreatment.	resiniferatoxin	99-114	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	55-59
17482651-4	2007	TRPV1-expressing sensory neurons were removed by resiniferatoxin (RTX).	resiniferatoxin	49-64	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	0-5
17540346-7	2007	Resiniferatoxin (RTX; 2 microg/ml, 100 microl), an ultra potent analog of capsaicin, was injected locally into the left hindpaw to functionally inactivate TRPV-1 containing sensory terminals.	resiniferatoxin	0-15	transient receptor potential cation channel subfamily V member 1	Homo sapiens	155-161
17482651-4	2007	TRPV1-expressing sensory neurons were removed by resiniferatoxin (RTX).	resiniferatoxin	66-69	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	0-5
17482651-6	2007	In RTX-treated rats, the alpha(2A)-AR-immunoreactivity co-expressed with TRPV1-expressing terminals in the spinal cord was eliminated.	resiniferatoxin	3-6	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	73-78
17169618-3	2007	We examined how sensitization and subsequent desensitization of the TRPV1 by resiniferatoxin (RTX), affected the responses of SARs to inhaled ammonia.	resiniferatoxin	77-92	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	68-73
17169618-3	2007	We examined how sensitization and subsequent desensitization of the TRPV1 by resiniferatoxin (RTX), affected the responses of SARs to inhaled ammonia.	resiniferatoxin	94-97	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	68-73
16982866-3	2006	Furthermore, exposure of these cells to TRPV1 agonists, capsaicin (CAP) and resiniferatoxin (RTX), triggered cell death.	resiniferatoxin	76-91	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	40-45
17239544-2	2007	In this study, we determined if removal of TRPV1-expressing afferent neurons by resiniferatoxin (RTX), an ultrapotent capsaicin analog, influences the development of opioid analgesic tolerance.	resiniferatoxin	80-95	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	43-48
17239544-2	2007	In this study, we determined if removal of TRPV1-expressing afferent neurons by resiniferatoxin (RTX), an ultrapotent capsaicin analog, influences the development of opioid analgesic tolerance.	resiniferatoxin	97-100	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	43-48
17214968-5	2007	These data support the hypothesis that (E)-capsaicin, resiniferatoxin, capsazepine, and SB366791 are all mitochondrial inhibitors, able to activate apoptosis and/or necrosis via non-receptor mediated mechanisms, and also support the use of TRPV1 ligands as anti-cancer agents.	resiniferatoxin	54-69	transient receptor potential cation channel subfamily V member 1	Homo sapiens	240-245
17004230-1	2007	AIMS: Resiniferatoxin (RTX), a vanilloid compound and agonist of the transient receptor potential channel 1 (TRPV1), is known for its beneficial effects on neurogenic detrusor overactivity.	resiniferatoxin	6-21	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	109-114
17004230-1	2007	AIMS: Resiniferatoxin (RTX), a vanilloid compound and agonist of the transient receptor potential channel 1 (TRPV1), is known for its beneficial effects on neurogenic detrusor overactivity.	resiniferatoxin	23-26	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	109-114
16887920-6	2006	Intrapericardial resiniferatoxin (RTX) (0.2 microg/ml, 0.2 ml, 1 min), which desensitizes TRPV1-containing nerve endings, abolished excitatory responses to both BK (n = 8) and CAP (n = 7), and to AC (n = 5) but not to somatic stimuli.	resiniferatoxin	17-32	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	90-95
16887920-6	2006	Intrapericardial resiniferatoxin (RTX) (0.2 microg/ml, 0.2 ml, 1 min), which desensitizes TRPV1-containing nerve endings, abolished excitatory responses to both BK (n = 8) and CAP (n = 7), and to AC (n = 5) but not to somatic stimuli.	resiniferatoxin	34-37	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	90-95
16982866-7	2006	In contrast, the caspase-3 inhibitor z-DEVD-fmk protected microglia from CAP- or RTX-induced toxicity.	resiniferatoxin	81-84	caspase 3	Rattus norvegicus	17-26
16982866-3	2006	Furthermore, exposure of these cells to TRPV1 agonists, capsaicin (CAP) and resiniferatoxin (RTX), triggered cell death.	resiniferatoxin	93-96	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	40-45
16982866-6	2006	Treatment of cells with CAP or RTX led to increased mitochondrial cytochrome c release and enhanced immunoreactivity to cleaved caspase-3.	resiniferatoxin	31-34	caspase 3	Rattus norvegicus	128-137
16769810-5	2006	Resiniferatoxin (RTX) is a specific TRPV1 agonist that, in high doses, selectively destroys C and Adelta fibers.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	36-41
16627674-7	2006	However, they potentiated citric acid- and resiniferatoxin-induced cough, an effect that was completely prevented by the TRPV1 receptor antagonist capsazepine.	resiniferatoxin	43-58	transient receptor potential cation channel subfamily V member 1	Cavia porcellus	121-126
16597917-3	2006	As shown by fura-2 ratio measurements while cells were incubated in a temperature-regulated chamber, significant [Ca(2+)](cyt) elevation was elicited by rapid changes in bath temperature, application of TRPV1 receptor agonists capsaicin and resiniferatoxin, or a cold receptor stimulator, icilin.	resiniferatoxin	241-256	transient receptor potential cation channel subfamily V member 1	Homo sapiens	203-208
16627674-3	2006	Irritant agents, including capsaicin, resiniferatoxin, and citric acid, elicit cough in humans and in experimental animals through the activation of the transient receptor potential vanilloid 1 (TRPV1).	resiniferatoxin	38-53	transient receptor potential cation channel subfamily V member 1	Homo sapiens	153-193
16627674-3	2006	Irritant agents, including capsaicin, resiniferatoxin, and citric acid, elicit cough in humans and in experimental animals through the activation of the transient receptor potential vanilloid 1 (TRPV1).	resiniferatoxin	38-53	transient receptor potential cation channel subfamily V member 1	Homo sapiens	195-200
16769810-5	2006	Resiniferatoxin (RTX) is a specific TRPV1 agonist that, in high doses, selectively destroys C and Adelta fibers.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	36-41
16769810-11	2006	RTX treatment and ganglionectomy significantly reduced pancreatic edema by 46% (P < 0.001) and NK-1R internalization by 80% and 51% (P < 0.001 and P < 0.05, respectively).	resiniferatoxin	0-3	tachykinin receptor 1	Rattus norvegicus	98-103
16769810-12	2006	RTX administration also significantly reduced MPO activity by 47% (P < 0.05).	resiniferatoxin	0-3	myeloperoxidase	Rattus norvegicus	46-49
16288992-5	2005	The various TRPV1 agonists activated pTRPV1 in a dose-dependent manner in the order of potency of resiniferatoxin (RTX) > olvanil > capsaicin > phorbol 12-phenylacetate 13-acetate 20-homovanillate (PPAHV), phorbol 12,13-dinonanoate 20-homovanillate (PDNHV).	resiniferatoxin	98-113	transient receptor potential cation channel subfamily V member 1	Homo sapiens	12-17
16467418-1	2006	Systemic administration of resiniferatoxin (RTX), an ultrapotent capsaicin analogue, removes transient receptor potential vanilloid type 1 (TRPV1)-expressing afferent neurons and impairs thermal but not mechanical nociception in adult animals.	resiniferatoxin	27-42	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	93-138
16467418-1	2006	Systemic administration of resiniferatoxin (RTX), an ultrapotent capsaicin analogue, removes transient receptor potential vanilloid type 1 (TRPV1)-expressing afferent neurons and impairs thermal but not mechanical nociception in adult animals.	resiniferatoxin	27-42	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	140-145
16467418-1	2006	Systemic administration of resiniferatoxin (RTX), an ultrapotent capsaicin analogue, removes transient receptor potential vanilloid type 1 (TRPV1)-expressing afferent neurons and impairs thermal but not mechanical nociception in adult animals.	resiniferatoxin	44-47	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	93-138
16467418-1	2006	Systemic administration of resiniferatoxin (RTX), an ultrapotent capsaicin analogue, removes transient receptor potential vanilloid type 1 (TRPV1)-expressing afferent neurons and impairs thermal but not mechanical nociception in adult animals.	resiniferatoxin	44-47	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	140-145
16467418-3	2006	The effect of morphine and (D-Ala2,N-Me-Phe4,Gly-ol5)-enkephalin (DAMGO) was measured by testing the paw mechanical withdrawal threshold in rats treated with RTX or vehicle.	resiniferatoxin	158-161	proenkephalin	Rattus norvegicus	54-64
16467418-4	2006	RTX treatment deleted TRPV1-immunoreactive dorsal root ganglion neurons and nerve terminals in the spinal dorsal horn.	resiniferatoxin	0-3	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	22-27
16091583-9	2006	Upon heterologous expression in HEK 293 cells, TRPV1(VAR) potentiated the ability of cotransfected TRPV1 to confer calcium influx in response to resiniferatoxin.	resiniferatoxin	145-160	transient receptor potential cation channel subfamily V member 1	Homo sapiens	47-52
16091583-9	2006	Upon heterologous expression in HEK 293 cells, TRPV1(VAR) potentiated the ability of cotransfected TRPV1 to confer calcium influx in response to resiniferatoxin.	resiniferatoxin	145-160	transient receptor potential cation channel subfamily V member 1	Homo sapiens	99-104
16814689-5	2006	The destruction of capsaicin-sensitive primary afferents by resiniferatoxin (RTX) pretreatment selectively decreased BV-induced spinal Fos expression but did not affect BV-induced antinociception.	resiniferatoxin	60-75	FBJ osteosarcoma oncogene	Mus musculus	135-138
16814689-5	2006	The destruction of capsaicin-sensitive primary afferents by resiniferatoxin (RTX) pretreatment selectively decreased BV-induced spinal Fos expression but did not affect BV-induced antinociception.	resiniferatoxin	77-80	FBJ osteosarcoma oncogene	Mus musculus	135-138
16288992-5	2005	The various TRPV1 agonists activated pTRPV1 in a dose-dependent manner in the order of potency of resiniferatoxin (RTX) > olvanil > capsaicin > phorbol 12-phenylacetate 13-acetate 20-homovanillate (PPAHV), phorbol 12,13-dinonanoate 20-homovanillate (PDNHV).	resiniferatoxin	115-118	transient receptor potential cation channel subfamily V member 1	Homo sapiens	12-17
15913603-3	2005	The kinetic parameters inferred from [(125)I]-resiniferatoxin binding were in concordance with data of TRPV1 receptors expressed in other tissues.	resiniferatoxin	46-61	transient receptor potential cation channel subfamily V member 1	Homo sapiens	103-108
16298071-6	2005	Heat hyperalgesia assessment after chemical desensitization of TRPV1 by resiniferatoxin demonstrates a possible role for TRPV2 in inflammation at high temperatures (>56 degrees C).	resiniferatoxin	72-87	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	63-68
16298071-6	2005	Heat hyperalgesia assessment after chemical desensitization of TRPV1 by resiniferatoxin demonstrates a possible role for TRPV2 in inflammation at high temperatures (>56 degrees C).	resiniferatoxin	72-87	transient receptor potential cation channel, subfamily V, member 2	Rattus norvegicus	121-126
16037081-0	2005	Activation of transient receptor potential vanilloid 1 (TRPV1) by resiniferatoxin.	resiniferatoxin	66-81	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	14-54
16037081-0	2005	Activation of transient receptor potential vanilloid 1 (TRPV1) by resiniferatoxin.	resiniferatoxin	66-81	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	56-61
16037081-2	2005	Resiniferatoxin (RTX), an ultrapotent agonist of TRPV1, is under investigation for treatment of urinary bladder hyper-reflexia and chronic pain conditions.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	49-54
16037081-2	2005	Resiniferatoxin (RTX), an ultrapotent agonist of TRPV1, is under investigation for treatment of urinary bladder hyper-reflexia and chronic pain conditions.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	49-54
16037081-3	2005	Here, we have determined the characteristics of RTX-induced responses in cells expressing native and cloned rat TRPV1.	resiniferatoxin	48-51	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	112-117
15936040-1	2005	After 7 years from its cloning, the transient receptor potential vanilloid type-1 (TRPV1) channel remains the sole membrane receptor mediating the pharmacological effects of the hot chilli pepper pungent component, capsaicin, and of the Euphorbia toxin, resiniferatoxin.	resiniferatoxin	254-269	transient receptor potential cation channel subfamily V member 1	Homo sapiens	36-81
15936040-1	2005	After 7 years from its cloning, the transient receptor potential vanilloid type-1 (TRPV1) channel remains the sole membrane receptor mediating the pharmacological effects of the hot chilli pepper pungent component, capsaicin, and of the Euphorbia toxin, resiniferatoxin.	resiniferatoxin	254-269	transient receptor potential cation channel subfamily V member 1	Homo sapiens	83-88
15925202-8	2005	GTTR uptake was enhanced by the TRPV1 agonists, resiniferatoxin and anandamide, in Ca2+-free media.	resiniferatoxin	48-63	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	32-37
15913603-5	2005	Addition of capsaicin, (R)-methanandamide and resiniferatoxin to prostate cells induced a dose-dependent increase in the intracellular calcium concentration that was reversed by the vanilloid TRPV1 receptor antagonist capsazepine.	resiniferatoxin	46-61	transient receptor potential cation channel subfamily V member 1	Homo sapiens	192-197
16173059-3	2005	TRPV1 antagonists and reduction of calcium concentrations in treatment solutions attenuated calcium flux, induction of interleukin-6 and 8 gene expression, and IL-6 secretion by cells treated with capsaicin or resiniferatoxin.	resiniferatoxin	210-225	transient receptor potential cation channel subfamily V member 1	Homo sapiens	0-5
15878709-5	2005	Dog TRPV1 was activated by various known TRPV1 agonists in a concentration-dependent manner: Ag23 = resiniferatoxin > olvanil approximately arvanil > capsaicin > phorbol 12-phenylacetate 13-acetate 20-homovanillate (PPAHV) > N-oleoyldopamine (OLDA).	resiniferatoxin	100-115	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	4-9
15878709-5	2005	Dog TRPV1 was activated by various known TRPV1 agonists in a concentration-dependent manner: Ag23 = resiniferatoxin > olvanil approximately arvanil > capsaicin > phorbol 12-phenylacetate 13-acetate 20-homovanillate (PPAHV) > N-oleoyldopamine (OLDA).	resiniferatoxin	100-115	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	41-46
15659291-3	2005	Pretreatment with resiniferatoxin [200 microg/kg, subcutaneous (s.c.)] blocked the PMA-induced nociceptive behaviour, suggesting that vanilloid VR1 receptor-expressing primary sensory neurons play a major role in this response.	resiniferatoxin	18-33	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	144-147
15918513-1	2005	A vanilloid receptor (VR1, now known as TRPV1) is an ion channel activated by vanilloids, including capsaicin (CAP) and resiniferatoxin (RTX), which are pungent ingredients of plants.	resiniferatoxin	120-135	transient receptor potential cation channel subfamily V member 1	Homo sapiens	22-25
15918513-1	2005	A vanilloid receptor (VR1, now known as TRPV1) is an ion channel activated by vanilloids, including capsaicin (CAP) and resiniferatoxin (RTX), which are pungent ingredients of plants.	resiniferatoxin	120-135	transient receptor potential cation channel subfamily V member 1	Homo sapiens	40-45
15918513-1	2005	A vanilloid receptor (VR1, now known as TRPV1) is an ion channel activated by vanilloids, including capsaicin (CAP) and resiniferatoxin (RTX), which are pungent ingredients of plants.	resiniferatoxin	137-140	transient receptor potential cation channel subfamily V member 1	Homo sapiens	22-25
15918513-1	2005	A vanilloid receptor (VR1, now known as TRPV1) is an ion channel activated by vanilloids, including capsaicin (CAP) and resiniferatoxin (RTX), which are pungent ingredients of plants.	resiniferatoxin	137-140	transient receptor potential cation channel subfamily V member 1	Homo sapiens	40-45
15733558-0	2005	Sensory nerve desensitization by resiniferatoxin improves glucose tolerance and increases insulin secretion in Zucker Diabetic Fatty rats and is associated with reduced plasma activity of dipeptidyl peptidase IV.	resiniferatoxin	33-48	dipeptidylpeptidase 4	Rattus norvegicus	188-211
15733558-6	2005	Further, when administered to overtly diabetic rats at 19 weeks of age, resiniferatoxin markedly improved glucose tolerance at two weeks after administration and this was accompanied by an increased insulin response to oral glucose as well as a reduction in the plasma levels of dipeptidyl peptidase IV.	resiniferatoxin	72-87	dipeptidylpeptidase 4	Rattus norvegicus	279-302
15356216-2	2005	Vanillamides are unmatched in terms of structural simplicity, straightforward synthesis, and safety compared with the more powerful TRPV1 agonists, like the structurally complex phorboid compound resiniferatoxin.	resiniferatoxin	196-211	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	132-137
15708075-1	2005	OBJECTIVES: To study TRPV1 immunoreactivity in the urothelium of patients with neurogenic detrusor overactivity (NDO) before and after treatment with resiniferatoxin (RTX) and controls.	resiniferatoxin	150-165	transient receptor potential cation channel subfamily V member 1	Homo sapiens	21-26
15708075-3	2005	In patients with NDO, TRPV1 suburothelial nerve density is increased, which is reversed by successful treatment with intravesical RTX.	resiniferatoxin	130-133	transient receptor potential cation channel subfamily V member 1	Homo sapiens	22-27
15708075-9	2005	In 5 patients who responded clinically to RTX, basal cell layer and total urothelial TRPV1 immunoreactivity decreased significantly after treatment (P = 0.032 and P = 0.016, respectively).	resiniferatoxin	42-45	transient receptor potential cation channel subfamily V member 1	Homo sapiens	85-90
16173059-3	2005	TRPV1 antagonists and reduction of calcium concentrations in treatment solutions attenuated calcium flux, induction of interleukin-6 and 8 gene expression, and IL-6 secretion by cells treated with capsaicin or resiniferatoxin.	resiniferatoxin	210-225	interleukin 6	Homo sapiens	119-138
16173059-3	2005	TRPV1 antagonists and reduction of calcium concentrations in treatment solutions attenuated calcium flux, induction of interleukin-6 and 8 gene expression, and IL-6 secretion by cells treated with capsaicin or resiniferatoxin.	resiniferatoxin	210-225	interleukin 6	Homo sapiens	160-164
15579007-3	2004	Small molecule agonists of VR1, including capsaicin and RTX, are currently utilized for a number of clinical syndromes, including intractable neuropathic pain, spinal detrusor hyperreflexia, and bladder hypersensitivity; however, antagonists of VR1 have yet to reach the clinic.	resiniferatoxin	56-59	transient receptor potential cation channel subfamily V member 1	Homo sapiens	27-30
15601931-12	2004	Finally, intravesical instillation of anandamide (50 microm) increased c-fos expression in the spinal cord, which was reduced by capsazepine or by resiniferatoxin pretreatment.	resiniferatoxin	147-162	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	71-76
15579007-3	2004	Small molecule agonists of VR1, including capsaicin and RTX, are currently utilized for a number of clinical syndromes, including intractable neuropathic pain, spinal detrusor hyperreflexia, and bladder hypersensitivity; however, antagonists of VR1 have yet to reach the clinic.	resiniferatoxin	56-59	transient receptor potential cation channel subfamily V member 1	Homo sapiens	245-248
15601931-8	2004	The anandamide-evoked effect was blocked by capsazepine or by instillation of resiniferatoxin, the ultrapotent TRPV1 agonist, into the bladders 24 hr before the anandamide challenge.	resiniferatoxin	78-93	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	111-116
15492017-8	2004	Pretreatment with the ultrapotent TRPV-1 agonist resiniferatoxin (RTX; 2, 20, or 200 microg kg(-1), i.p.)	resiniferatoxin	49-64	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	34-40
15492017-8	2004	Pretreatment with the ultrapotent TRPV-1 agonist resiniferatoxin (RTX; 2, 20, or 200 microg kg(-1), i.p.)	resiniferatoxin	66-69	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	34-40
15220301-12	2004	In rats (n = 12) pretreated with resiniferatoxin to destroy muscle afferents containing VR1, capsaicin and H+ responses were blunted.	resiniferatoxin	33-48	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	88-91
15548449-11	2004	CONCLUSION: The present findings provide the evidence of the presence of TRPV1 on normal human urothelium where it could have important implications in the mechanism of action of intravesical vanilloids (capsaicin and resiniferatoxin).	resiniferatoxin	218-233	transient receptor potential cation channel subfamily V member 1	Homo sapiens	73-78
15245821-9	2004	In the 5 patients who responded to RTX, there was a significant decrease in P2X3-positive fibres (p=0.032), whereas in non-responders, P2X3-IR nerve fibre density did not change significantly.	resiniferatoxin	35-38	purinergic receptor P2X 3	Homo sapiens	76-80
15245821-11	2004	There was a significant decrease in P2X3 immunoreactivity in responders to RTX, indicating a potential pathophysiological role for the P2X3 expressing fibres.	resiniferatoxin	75-78	purinergic receptor P2X 3	Homo sapiens	36-40
15245821-11	2004	There was a significant decrease in P2X3 immunoreactivity in responders to RTX, indicating a potential pathophysiological role for the P2X3 expressing fibres.	resiniferatoxin	75-78	purinergic receptor P2X 3	Homo sapiens	135-139
15124026-4	2004	Administration of the potent TRPV1 agonist resiniferatoxin (RTX) to neuronal perikarya induces calcium cytotoxicity by opening the TRPV1 ion channel and selectively ablates nociceptive neurons.	resiniferatoxin	43-58	transient receptor potential cation channel subfamily V member 1	Homo sapiens	29-34
15130764-7	2004	Combined exposure to RTX and ROPA produced a sustained and complete cell cycle blockade in IEC-18 cells, associated with depletion of cyclin D1 and sustained enhancement of p21(Waf1/Cip1) levels.	resiniferatoxin	21-24	cyclin D1	Rattus norvegicus	134-143
15130764-7	2004	Combined exposure to RTX and ROPA produced a sustained and complete cell cycle blockade in IEC-18 cells, associated with depletion of cyclin D1 and sustained enhancement of p21(Waf1/Cip1) levels.	resiniferatoxin	21-24	KRAS proto-oncogene, GTPase	Rattus norvegicus	173-176
15130764-7	2004	Combined exposure to RTX and ROPA produced a sustained and complete cell cycle blockade in IEC-18 cells, associated with depletion of cyclin D1 and sustained enhancement of p21(Waf1/Cip1) levels.	resiniferatoxin	21-24	cyclin-dependent kinase inhibitor 1A	Rattus norvegicus	177-181
15130764-7	2004	Combined exposure to RTX and ROPA produced a sustained and complete cell cycle blockade in IEC-18 cells, associated with depletion of cyclin D1 and sustained enhancement of p21(Waf1/Cip1) levels.	resiniferatoxin	21-24	cyclin-dependent kinase inhibitor 1A	Rattus norvegicus	182-186
14996838-1	2004	Vanilloid receptor 1 (TRPV1), a membrane-associated cation channel, is activated by the pungent vanilloid from chili peppers, capsaicin, and the ultra potent vanilloid from Euphorbia resinifera, resiniferatoxin (RTX), as well as by physical stimuli (heat and protons) and proposed endogenous ligands (anandamide, N-arachidonyldopamine, N-oleoyldopamine, and products of lipoxygenase).	resiniferatoxin	195-210	transient receptor potential cation channel subfamily V member 1	Homo sapiens	22-27
14996838-1	2004	Vanilloid receptor 1 (TRPV1), a membrane-associated cation channel, is activated by the pungent vanilloid from chili peppers, capsaicin, and the ultra potent vanilloid from Euphorbia resinifera, resiniferatoxin (RTX), as well as by physical stimuli (heat and protons) and proposed endogenous ligands (anandamide, N-arachidonyldopamine, N-oleoyldopamine, and products of lipoxygenase).	resiniferatoxin	212-215	transient receptor potential cation channel subfamily V member 1	Homo sapiens	22-27
14996838-9	2004	Based on our data we propose a model of the TM3/4 region of TRPV1 bound to capsaicin or RTX that may aid in the development of potent TRPV1 antagonists with utility in the treatment of sensory disorders.	resiniferatoxin	88-91	tropomyosin 4	Rattus norvegicus	44-49
14996838-9	2004	Based on our data we propose a model of the TM3/4 region of TRPV1 bound to capsaicin or RTX that may aid in the development of potent TRPV1 antagonists with utility in the treatment of sensory disorders.	resiniferatoxin	88-91	transient receptor potential cation channel subfamily V member 1	Homo sapiens	60-65
14996838-9	2004	Based on our data we propose a model of the TM3/4 region of TRPV1 bound to capsaicin or RTX that may aid in the development of potent TRPV1 antagonists with utility in the treatment of sensory disorders.	resiniferatoxin	88-91	transient receptor potential cation channel subfamily V member 1	Homo sapiens	134-139
15217452-0	2004	Intravesical resiniferatoxin decreases spinal c-fos expression and increases bladder volume to reflex micturition in rats with chronic inflamed urinary bladders.	resiniferatoxin	13-28	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	46-51
15217452-1	2004	OBJECTIVE: To evaluate the effect of intravesical resiniferatoxin on spinal c-fos expression and bladder volume at reflex micturition in rats with chronic urinary bladder inflammation.	resiniferatoxin	50-65	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	76-81
15217452-8	2004	CONCLUSION: Intravesical resiniferatoxin decreases c-fos expression and increases bladder capacity in chronically inflamed rat bladders.	resiniferatoxin	25-40	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	51-56
15146439-6	2004	To impair the function of capsaicin-sensitive afferents, the capsaicin receptor (VR1/TRPV1) agonist resiniferatoxin (RTX) was injected subcutaneously (30, 70, and 100 microg/kg on 3 subsequent days) 7 days before CFA administration.	resiniferatoxin	100-115	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	61-79
15146439-6	2004	To impair the function of capsaicin-sensitive afferents, the capsaicin receptor (VR1/TRPV1) agonist resiniferatoxin (RTX) was injected subcutaneously (30, 70, and 100 microg/kg on 3 subsequent days) 7 days before CFA administration.	resiniferatoxin	100-115	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	81-84
15146439-6	2004	To impair the function of capsaicin-sensitive afferents, the capsaicin receptor (VR1/TRPV1) agonist resiniferatoxin (RTX) was injected subcutaneously (30, 70, and 100 microg/kg on 3 subsequent days) 7 days before CFA administration.	resiniferatoxin	100-115	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	85-90
15146439-11	2004	Plasma SOM-like immunoreactivity increased 4-fold on the twenty-first day, and was inhibited by RTX pretreatment, as well as by daily administration of TT-232.	resiniferatoxin	96-99	somatostatin	Rattus norvegicus	7-10
15124026-4	2004	Administration of the potent TRPV1 agonist resiniferatoxin (RTX) to neuronal perikarya induces calcium cytotoxicity by opening the TRPV1 ion channel and selectively ablates nociceptive neurons.	resiniferatoxin	43-58	transient receptor potential cation channel subfamily V member 1	Homo sapiens	131-136
15124026-4	2004	Administration of the potent TRPV1 agonist resiniferatoxin (RTX) to neuronal perikarya induces calcium cytotoxicity by opening the TRPV1 ion channel and selectively ablates nociceptive neurons.	resiniferatoxin	60-63	transient receptor potential cation channel subfamily V member 1	Homo sapiens	29-34
15124026-4	2004	Administration of the potent TRPV1 agonist resiniferatoxin (RTX) to neuronal perikarya induces calcium cytotoxicity by opening the TRPV1 ion channel and selectively ablates nociceptive neurons.	resiniferatoxin	60-63	transient receptor potential cation channel subfamily V member 1	Homo sapiens	131-136
15049988-13	2004	CONCLUSIONS: The decrease of PGP9.5 and TRPV1 immunoreactive nerve fibres in responders to resiniferatoxin (to levels in control tissues) suggests that the increased numbers of nerve fibres in patients with NDO are mainly of sensory origin and express TRPV1.	resiniferatoxin	91-106	ubiquitin C-terminal hydrolase L1	Homo sapiens	29-35
15049988-13	2004	CONCLUSIONS: The decrease of PGP9.5 and TRPV1 immunoreactive nerve fibres in responders to resiniferatoxin (to levels in control tissues) suggests that the increased numbers of nerve fibres in patients with NDO are mainly of sensory origin and express TRPV1.	resiniferatoxin	91-106	transient receptor potential cation channel subfamily V member 1	Homo sapiens	40-45
15049988-13	2004	CONCLUSIONS: The decrease of PGP9.5 and TRPV1 immunoreactive nerve fibres in responders to resiniferatoxin (to levels in control tissues) suggests that the increased numbers of nerve fibres in patients with NDO are mainly of sensory origin and express TRPV1.	resiniferatoxin	91-106	transient receptor potential cation channel subfamily V member 1	Homo sapiens	252-257
15125461-7	2004	It is reported that resiniferatoxin, [6]-gingerol and lafutidine are compounds that activate VR1 and/or capsaicin-sensitive afferent neurons.	resiniferatoxin	20-35	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	93-96
14694538-10	2004	Resiniferatoxin reduced CYP-induced up-regulation of p-CREB in DRG, suggesting that cystitis can reveal an altered CREB phosphorylation that may be mediated by capsaicin-sensitive bladder afferents.	resiniferatoxin	0-15	cAMP responsive element binding protein 1	Homo sapiens	55-59
14992587-0	2004	Resiniferatoxin binds to the capsaicin receptor (TRPV1) near the extracellular side of the S4 transmembrane domain.	resiniferatoxin	0-15	transient receptor potential cation channel subfamily V member 1	Homo sapiens	29-47
14992587-0	2004	Resiniferatoxin binds to the capsaicin receptor (TRPV1) near the extracellular side of the S4 transmembrane domain.	resiniferatoxin	0-15	transient receptor potential cation channel subfamily V member 1	Homo sapiens	49-54
14992587-2	2004	Resiniferatoxin (RTX), a potent agonist of TRPV1, and iodoresiniferatoxin (I-RTX), a potent antagonist of TRPV1, both bind with higher affinity to the rat TRPV1 (rTRPV1) than the human (hTRPV1) isoform.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	43-48
14992587-2	2004	Resiniferatoxin (RTX), a potent agonist of TRPV1, and iodoresiniferatoxin (I-RTX), a potent antagonist of TRPV1, both bind with higher affinity to the rat TRPV1 (rTRPV1) than the human (hTRPV1) isoform.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	162-168
14992587-2	2004	Resiniferatoxin (RTX), a potent agonist of TRPV1, and iodoresiniferatoxin (I-RTX), a potent antagonist of TRPV1, both bind with higher affinity to the rat TRPV1 (rTRPV1) than the human (hTRPV1) isoform.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	43-48
14980619-0	2004	Structure-activity relationships of simplified resiniferatoxin analogues with potent VR1 agonism elucidates an active conformation of RTX for VR1 binding.	resiniferatoxin	47-62	vault RNA 1-1	Homo sapiens	85-88
14980619-0	2004	Structure-activity relationships of simplified resiniferatoxin analogues with potent VR1 agonism elucidates an active conformation of RTX for VR1 binding.	resiniferatoxin	47-62	vault RNA 1-1	Homo sapiens	142-145
14694538-10	2004	Resiniferatoxin reduced CYP-induced up-regulation of p-CREB in DRG, suggesting that cystitis can reveal an altered CREB phosphorylation that may be mediated by capsaicin-sensitive bladder afferents.	resiniferatoxin	0-15	cAMP responsive element binding protein 1	Homo sapiens	115-119
14764132-0	2004	Endothelial nitric oxide synthase expression in neurogenic urinary bladders treated with intravesical resiniferatoxin.	resiniferatoxin	102-117	nitric oxide synthase 3	Homo sapiens	0-33
14764132-1	2004	OBJECTIVE: To investigate endothelial nitric oxide synthase (eNOS) immunoreactivity in bladder biopsies from patients with neurogenic detrusor overactivity (NDO) before and after treatment with intravesical resiniferatoxin, and compare this with control material; the distribution of two other vascular markers, von Willebrand Factor (vWF) and the vascular endothelial growth factor (VEGF), was also studied.	resiniferatoxin	207-222	nitric oxide synthase 3	Homo sapiens	26-59
14764132-7	2004	There was a trend to higher eNOS values before treatment in those responding than in those not responding to resiniferatoxin (P = 0.059), and a significant reduction in eNOS immunoreactivity after successful treatment (P = 0.016).	resiniferatoxin	109-124	nitric oxide synthase 3	Homo sapiens	28-32
12941436-2	2003	In the present study we examined the effects of AEA and the naturally occurring cannabinoid 2 (CB(2)) receptor agonist palmitylethanolamide (PEA) on basal and resiniferatoxin (RTX)-induced release of calcitonin gene-related peptide (CGRP) and somatostatin in vivo.	resiniferatoxin	159-174	calcitonin-related polypeptide alpha	Rattus norvegicus	200-231
14764132-10	2004	CONCLUSIONS: The trend for higher eNOS expression in patients with NDO who responded to resiniferatoxin suggests that increased vasculature or vasodilatation in the suburothelium may be necessary for successful intravesical treatment.	resiniferatoxin	88-103	nitric oxide synthase 3	Homo sapiens	34-38
14672807-0	2004	[3H]Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution.	resiniferatoxin	4-19	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	64-69
14672807-0	2004	[3H]Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution.	resiniferatoxin	4-19	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	88-93
14672807-0	2004	[3H]Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution.	resiniferatoxin	4-19	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	95-99
14672807-2	2004	The radiolabelled vanilloid agonist [3H]resiniferatoxin (RTX) has been used to indicate the presence of TRPV1 receptor protein in the brain but low specific binding has complicated interpretation of this data.	resiniferatoxin	57-60	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	104-109
14742669-2	2004	IBTU competitively inhibited 45Ca2+ uptake into CHO cells heterologously expressing rat TRPV1, whether induced by capsaicin or resiniferatoxin (Ki = 99 +/- 23 and 93 +/- 34 nM, respectively).	resiniferatoxin	127-142	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	88-93
14742669-4	2004	In contrast to its antagonism of vanilloid-induced calcium uptake, IBTU (30 microM) inhibited [3H]resiniferatoxin binding to TRPV1 by less than 10%.	resiniferatoxin	98-113	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	125-130
14742669-5	2004	We hypothesize that these dramatically distinct potencies reflect different fractions of TRPV1 in this system: namely, a minor plasma membrane fraction controlling 45Ca2+ uptake, and the predominant intracellular fraction that dominates the [3H]resiniferatoxin binding measurements.	resiniferatoxin	245-260	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	89-94
14637384-3	2003	RTX application to DRG cells identified as type 1, 2 or 5, cell types known to express VR1, induced large inward currents.	resiniferatoxin	0-3	transient receptor potential cation channel subfamily V member 1	Homo sapiens	87-90
14530214-5	2003	Capsaicin and resiniferatoxin (RTX) can inhibit LPS- and IFN-gamma-mediated NO production, and iNOS protein and mRNA expression with similar IC50 values of around 10 microm.	resiniferatoxin	14-29	interferon gamma	Homo sapiens	57-66
14530214-5	2003	Capsaicin and resiniferatoxin (RTX) can inhibit LPS- and IFN-gamma-mediated NO production, and iNOS protein and mRNA expression with similar IC50 values of around 10 microm.	resiniferatoxin	14-29	nitric oxide synthase 2	Homo sapiens	95-99
14530214-5	2003	Capsaicin and resiniferatoxin (RTX) can inhibit LPS- and IFN-gamma-mediated NO production, and iNOS protein and mRNA expression with similar IC50 values of around 10 microm.	resiniferatoxin	31-34	interferon gamma	Homo sapiens	57-66
12941436-2	2003	In the present study we examined the effects of AEA and the naturally occurring cannabinoid 2 (CB(2)) receptor agonist palmitylethanolamide (PEA) on basal and resiniferatoxin (RTX)-induced release of calcitonin gene-related peptide (CGRP) and somatostatin in vivo.	resiniferatoxin	176-179	calcitonin-related polypeptide alpha	Rattus norvegicus	200-231
12608892-2	2003	Stimulation of TRPV1-expressing cells, but not control Sf 9 cells, with resiniferatoxin (RTX), capsaicin or anandamide, produced an increase in cytosolic free Ca(2+) concentration ([Ca(2+)](i)), with EC(50) values of 166 pM, 24.5 nM and 3.89 microM respectively.	resiniferatoxin	72-87	transient receptor potential cation channel subfamily V member 1	Homo sapiens	15-20
12922928-2	2003	The C-5 halogenation of the vanillyl moiety of resiniferatoxin, an ultrapotent agonist of vanilloid TRPV1 receptors, results in a potent antagonist for these receptors.	resiniferatoxin	47-62	complement C5	Homo sapiens	4-7
12922928-2	2003	The C-5 halogenation of the vanillyl moiety of resiniferatoxin, an ultrapotent agonist of vanilloid TRPV1 receptors, results in a potent antagonist for these receptors.	resiniferatoxin	47-62	transient receptor potential cation channel subfamily V member 1	Homo sapiens	100-105
12608892-2	2003	Stimulation of TRPV1-expressing cells, but not control Sf 9 cells, with resiniferatoxin (RTX), capsaicin or anandamide, produced an increase in cytosolic free Ca(2+) concentration ([Ca(2+)](i)), with EC(50) values of 166 pM, 24.5 nM and 3.89 microM respectively.	resiniferatoxin	89-92	transient receptor potential cation channel subfamily V member 1	Homo sapiens	15-20
12388656-5	2002	The slope of Schild plot from the resiniferatoxin efferent studies deviated from unity (~0.6), suggesting complex interactions at VR1 binding site(s).	resiniferatoxin	34-49	transient receptor potential cation channel subfamily V member 1	Cavia porcellus	130-133
12522087-9	2003	We conclude that VR1 is able to couple to Ca2+ mobilization by a Ca2+ dependent mechanism, mediated by capsaicin and RTX, and a Ca2+ independent mechanism mediated by RTX alone.	resiniferatoxin	117-120	transient receptor potential cation channel subfamily V member 1	Homo sapiens	17-20
12522087-9	2003	We conclude that VR1 is able to couple to Ca2+ mobilization by a Ca2+ dependent mechanism, mediated by capsaicin and RTX, and a Ca2+ independent mechanism mediated by RTX alone.	resiniferatoxin	167-170	transient receptor potential cation channel subfamily V member 1	Homo sapiens	17-20
12746222-7	2003	Unilateral intraplantar injection of the VR1 receptor agonist resiniferatoxin (RTX, 0.048 nmol) induced a profound drop of heat threshold to the innocuous range with a maximal effect (8-10 degrees C drop) 5 min after RTX administration.	resiniferatoxin	62-77	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	41-44
12746222-7	2003	Unilateral intraplantar injection of the VR1 receptor agonist resiniferatoxin (RTX, 0.048 nmol) induced a profound drop of heat threshold to the innocuous range with a maximal effect (8-10 degrees C drop) 5 min after RTX administration.	resiniferatoxin	79-82	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	41-44
12746222-7	2003	Unilateral intraplantar injection of the VR1 receptor agonist resiniferatoxin (RTX, 0.048 nmol) induced a profound drop of heat threshold to the innocuous range with a maximal effect (8-10 degrees C drop) 5 min after RTX administration.	resiniferatoxin	217-220	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	41-44
12684478-8	2003	Immunofluorescence labeling showed a diminished vanilloid receptor 1 immunoreactivity in dorsal root ganglia neurons and the spinal dorsal horn of RTX-treated rats.	resiniferatoxin	147-150	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	48-68
12684478-10	2003	In RTX-treated rats, IB(4)-labeled terminals in the dorsal horn were significantly reduced, and CTB-labeled terminals appeared to sprout into lamina II of the spinal dorsal horn.	resiniferatoxin	3-6	phosphate cytidylyltransferase 1B, choline	Rattus norvegicus	96-99
12473388-5	2003	In VR1-HEK293 cells and dorsal root ganglion neurones, Ca(2+) responses were induced by resiniferatoxin>capsaicin=olvanil>PPAHV; all four were full agonists.	resiniferatoxin	88-103	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	3-6
12473388-8	2003	Olvanil had a Hill coefficient of approximately 1 whilst capsaicin, resiniferatoxin and PPAHV had Hill coefficients of approximately 2 in VR1-HEK293 cells.	resiniferatoxin	68-83	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	138-141
12473388-10	2003	These data show that resiniferatoxin, capsaicin, olvanil and PPAHV, but not scutigeral and isovelleral, are agonists at recombinant rat VR1 receptors and endogenous vanilloid receptors on dorsal root ganglion neurones and in the rat mesenteric arterial bed.	resiniferatoxin	21-36	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	136-139
12522087-0	2003	Activation of vanilloid receptor 1 by resiniferatoxin mobilizes calcium from inositol 1,4,5-trisphosphate-sensitive stores.	resiniferatoxin	38-53	transient receptor potential cation channel subfamily V member 1	Homo sapiens	14-34
12522087-1	2003	1 Capsaicin and resiniferatoxin (RTX) stimulate Ca2+ influx by activating vanilloid receptor 1 (VR1), a ligand-gated Ca2+ channel on sensory neurones.	resiniferatoxin	16-31	transient receptor potential cation channel subfamily V member 1	Homo sapiens	74-94
12522087-1	2003	1 Capsaicin and resiniferatoxin (RTX) stimulate Ca2+ influx by activating vanilloid receptor 1 (VR1), a ligand-gated Ca2+ channel on sensory neurones.	resiniferatoxin	16-31	transient receptor potential cation channel subfamily V member 1	Homo sapiens	96-99
12522087-1	2003	1 Capsaicin and resiniferatoxin (RTX) stimulate Ca2+ influx by activating vanilloid receptor 1 (VR1), a ligand-gated Ca2+ channel on sensory neurones.	resiniferatoxin	33-36	transient receptor potential cation channel subfamily V member 1	Homo sapiens	74-94
12522087-1	2003	1 Capsaicin and resiniferatoxin (RTX) stimulate Ca2+ influx by activating vanilloid receptor 1 (VR1), a ligand-gated Ca2+ channel on sensory neurones.	resiniferatoxin	33-36	transient receptor potential cation channel subfamily V member 1	Homo sapiens	96-99
12522087-4	2003	3 In Ca2+ -free media, RTX caused a transient elevation in intracellular free Ca2+ concentration in hVR1-HEK293 cells (pEC(50) 6.45+/-0.05) but not in wild type cells.	resiniferatoxin	23-26	transient receptor potential cation channel subfamily V member 1	Homo sapiens	100-104
12522087-7	2003	These data suggest that RTX causes Ca2+ mobilization from inositol 1,4,5-trisphosphate-sensitive Ca2+ stores in hVR1-HEK293 cells.	resiniferatoxin	24-27	transient receptor potential cation channel subfamily V member 1	Homo sapiens	112-116
12438527-1	2002	We have synthesized iodinated resiniferatoxin bearing a 4-hydroxy-5-iodo-3-methoxyphenylacetate ester (I-RTX) and have characterized its activity on rat and human TRPV1 (VR1) receptors, as well as in behavioral assays of nociception.	resiniferatoxin	30-45	transient receptor potential cation channel subfamily V member 1	Homo sapiens	163-168
12438527-1	2002	We have synthesized iodinated resiniferatoxin bearing a 4-hydroxy-5-iodo-3-methoxyphenylacetate ester (I-RTX) and have characterized its activity on rat and human TRPV1 (VR1) receptors, as well as in behavioral assays of nociception.	resiniferatoxin	30-45	transient receptor potential cation channel subfamily V member 1	Homo sapiens	170-173
14599363-9	2002	For both rVR1 and hVR1, time-response waveforms elicited by resiniferatoxin increased more gradually compared to other agonists.	resiniferatoxin	60-75	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	9-13
12270505-0	2002	Nerve growth factor regulates galanin and c-jun overexpression occurring in dorsal root ganglion cells after intravesical resiniferatoxin application.	resiniferatoxin	122-137	nerve growth factor	Rattus norvegicus	0-19
12270505-6	2002	Results suggest that the changes induced in bladder sensory neurons by intravesical resiniferatoxin are due, at least in part, to the temporary deprivation of bladder-derived neurotrophic factors, namely nerve growth factor, in those neurons.	resiniferatoxin	84-99	nerve growth factor	Rattus norvegicus	204-223
14599363-9	2002	For both rVR1 and hVR1, time-response waveforms elicited by resiniferatoxin increased more gradually compared to other agonists.	resiniferatoxin	60-75	transient receptor potential cation channel subfamily V member 1	Homo sapiens	18-22
11906962-9	2002	We determined CGRP and NO release from rat stomach and specific [(3)H]-resiniferatoxin (RTX) binding to gastric vanilloid receptor subtype 1 (VR1), which binds capsaicin, using EIA, a microdialysis system and a radioreceptor assay, respectively.	resiniferatoxin	71-86	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	112-140
12007523-1	2002	Very recently, a membrane receptor (vanilloid receptor type 1 [VR-1]) sensitive to capsaicin or resiniferatoxin (RTX) was identified in small- and medium-sized dorsal root ganglion neurons that give rise to most unmyelinated sensory fibers.	resiniferatoxin	96-111	transient receptor potential cation channel subfamily V member 1	Homo sapiens	63-67
12007523-1	2002	Very recently, a membrane receptor (vanilloid receptor type 1 [VR-1]) sensitive to capsaicin or resiniferatoxin (RTX) was identified in small- and medium-sized dorsal root ganglion neurons that give rise to most unmyelinated sensory fibers.	resiniferatoxin	113-116	transient receptor potential cation channel subfamily V member 1	Homo sapiens	63-67
11934585-0	2002	Synthesis and in vitro evaluation of a novel iodinated resiniferatoxin derivative that is an agonist at the human vanilloid VR1 receptor.	resiniferatoxin	55-70	transient receptor potential cation channel subfamily V member 1	Homo sapiens	124-127
11906962-9	2002	We determined CGRP and NO release from rat stomach and specific [(3)H]-resiniferatoxin (RTX) binding to gastric vanilloid receptor subtype 1 (VR1), which binds capsaicin, using EIA, a microdialysis system and a radioreceptor assay, respectively.	resiniferatoxin	88-91	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	112-140
11906962-9	2002	We determined CGRP and NO release from rat stomach and specific [(3)H]-resiniferatoxin (RTX) binding to gastric vanilloid receptor subtype 1 (VR1), which binds capsaicin, using EIA, a microdialysis system and a radioreceptor assay, respectively.	resiniferatoxin	88-91	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	142-145
12208893-6	2002	RESULTS: The majority of the parental SCC cells underwent apoptosis after a 12-hour exposure to 100 micro M capsaicin or 10 micro M resiniferatoxin.	resiniferatoxin	132-147	serpin family B member 3	Homo sapiens	38-41
12243775-4	2002	Olvanil and resiniferatoxin were also effective agonists (EC(50) values of 0.0087 +/- 0.0035 micro M and 0.067 +/- 0.014 micro M, respectively), but 12-phenylacetate 13-acetate 20-homovanillate (PPAHV) and anandamide showed little agonist activity up to 10 micro M. As with human and rat VR1, guinea pig VR1 was also activated by pH below 6.0 and by noxious heat (>42 degrees C).	resiniferatoxin	12-27	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	288-291
12243775-4	2002	Olvanil and resiniferatoxin were also effective agonists (EC(50) values of 0.0087 +/- 0.0035 micro M and 0.067 +/- 0.014 micro M, respectively), but 12-phenylacetate 13-acetate 20-homovanillate (PPAHV) and anandamide showed little agonist activity up to 10 micro M. As with human and rat VR1, guinea pig VR1 was also activated by pH below 6.0 and by noxious heat (>42 degrees C).	resiniferatoxin	12-27	transient receptor potential cation channel subfamily V member 1	Cavia porcellus	304-307
11906962-9	2002	We determined CGRP and NO release from rat stomach and specific [(3)H]-resiniferatoxin (RTX) binding to gastric vanilloid receptor subtype 1 (VR1), which binds capsaicin, using EIA, a microdialysis system and a radioreceptor assay, respectively.	resiniferatoxin	71-86	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	142-145
11425572-3	2001	We report here the rationale for the design, the synthesis, and the in vitro characterization of activity in assays for [(3)H]resiniferatoxin binding and (45)Ca influx using heterologously expressed rat VR1.	resiniferatoxin	126-141	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	203-206
11752091-6	2002	The data demonstrate that VR1 receptor agonists capsaicin and resiniferatoxin lead to a sustained increase in intracellular calcium and sodium in a concentration-dependent manner, followed by cell death.	resiniferatoxin	62-77	transient receptor potential cation channel subfamily V member 1	Homo sapiens	26-29
11927161-10	2002	Intravesical resiniferatoxin decreased VR1 immunoreactivity transiently.	resiniferatoxin	13-28	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	39-42
11834295-1	2002	Specific [3H]resiniferatoxin (RTX) binding detects the vanilloid receptor type I (VR1).	resiniferatoxin	13-28	transient receptor potential cation channel subfamily V member 1	Homo sapiens	55-85
11834295-1	2002	Specific [3H]resiniferatoxin (RTX) binding detects the vanilloid receptor type I (VR1).	resiniferatoxin	30-33	transient receptor potential cation channel subfamily V member 1	Homo sapiens	55-85
11576949-9	2001	Serum OPG declines for the first 2 weeks after RTX owing to functioning allograft and decreases again for the next 2 weeks because of steroids and possible immunosuppressive agents.	resiniferatoxin	47-50	TNF receptor superfamily member 11b	Homo sapiens	6-9
11564021-1	2001	OBJECTIVE: To determine the morphology of bladder mucosa and the integrity of its mucin coat in patients with detrusor hyper-reflexia treated with intravesical resiniferatoxin.	resiniferatoxin	160-175	LOC100508689	Homo sapiens	82-87
11166956-6	2001	In contrast, resiniferatoxin and its analog, phorbol 12-phenylacetate 13-acetate 20-homovanillate, was more potent in activating the CAP-activated channels in cultured sensory neurons than VR1.	resiniferatoxin	13-28	transient receptor potential cation channel subfamily V member 1	Homo sapiens	189-192
11278420-1	2001	The endogenous ligand of CB(1) cannabinoid receptors, anandamide, is also a full agonist at vanilloid VR1 receptors for capsaicin and resiniferatoxin, thereby causing an increase in cytosolic Ca(2+) concentration in human VR1-overexpressing (hVR1-HEK) cells.	resiniferatoxin	134-149	vault RNA 1-1	Homo sapiens	102-105
11124944-3	2001	Upon exposure to resiniferatoxin, VR1eGFP- or VR1epsilon-expressing cells exhibited pharmacological responses similar to those of cells expressing the untagged VR1.	resiniferatoxin	17-32	transient receptor potential cation channel subfamily V member 1	Homo sapiens	34-49
11124944-3	2001	Upon exposure to resiniferatoxin, VR1eGFP- or VR1epsilon-expressing cells exhibited pharmacological responses similar to those of cells expressing the untagged VR1.	resiniferatoxin	17-32	transient receptor potential cation channel subfamily V member 1	Homo sapiens	34-37
11124944-7	2001	Nociceptive primary sensory neurons endogenously express VR1, and resiniferatoxin treatment induced a sudden increase in [Ca(2+)](i) and mitochondrial disruption which was cell-selective, as glia and non-VR1-expressing neurons were unaffected.	resiniferatoxin	66-81	transient receptor potential cation channel subfamily V member 1	Homo sapiens	204-207
11125018-5	2001	Capsaicin and RTX induced large nondesensitizing currents in Xenopus laevis oocytes expressing VR1 (EC50 values were 1300 nM and 0.2 nM, respectively), whereas I-RTX induced no current per se at concentrations up to 10 microM.	resiniferatoxin	14-17	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	95-98
11587243-8	2001	The potent VR1 agonist resiniferatoxin, now in phase II clinical trials, appears to be superior to capsaicin in terms of its tolerability profile.	resiniferatoxin	23-38	transient receptor potential cation channel subfamily V member 1	Homo sapiens	11-14
11595435-6	2001	(2) VR-1 agonists (capsaicin, resiniferatoxin, piperine) protect against gastric ulcer of the rat parallel with their sensory stimulating potencies.	resiniferatoxin	30-45	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	4-8
11718993-10	2001	Systemic resiniferatoxin administration, however, decreases VR1 expression in dorsal root ganglia by 65-80%, an effect that persists for at least 2 months.	resiniferatoxin	9-24	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	60-63
10478560-4	1999	Irritation, as shown by the noxious excitation of vesical sensory innervation, was measured by the c-fos response evoked by a single application of resiniferatoxin.	resiniferatoxin	148-163	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	99-104
10903936-1	2000	BACKGROUND: Vanilloids, such as capsaicin and resiniferatoxin (RTX), are recognized at the cell surface by vanilloid receptor type 1 (VR1), which has recently been cloned.	resiniferatoxin	46-61	transient receptor potential cation channel subfamily V member 1	Homo sapiens	107-137
10903936-1	2000	BACKGROUND: Vanilloids, such as capsaicin and resiniferatoxin (RTX), are recognized at the cell surface by vanilloid receptor type 1 (VR1), which has recently been cloned.	resiniferatoxin	63-66	transient receptor potential cation channel subfamily V member 1	Homo sapiens	107-137
10604645-7	1999	RESULTS: Within one hour after RTX, cystatin C (mean+/-SE) almost halved from 6.69+/-0.45 mg/l to 3.69+/-0.38 mg/l while creatinine declined from 862 +/-65.4 to 633+/-62.9 micromol/l.	resiniferatoxin	31-34	cystatin C	Homo sapiens	36-46
11269923-7	2000	Intravesical capsaicin or RTX decreased, in a similar way, the number of CGRP and SP-IR (immunoreactive) fibers coursing in the muscular layer and the mucosa.	resiniferatoxin	26-29	calcitonin-related polypeptide alpha	Rattus norvegicus	73-77
11269923-13	2000	We conclude that intravesical capsaicin or RTX were equally effective in terms of reducing the number of SP and CGRP-IR fibers and increasing the volume threshold for reflex micturition.	resiniferatoxin	43-46	calcitonin-related polypeptide alpha	Rattus norvegicus	112-116
11050376-1	2000	Capsaicin, resiniferatoxin, protons or heat have been shown to activate an ion channel, termed the rat vanilloid receptor-1 (rVR1), originally isolated by expression cloning for a capsaicin sensitive phenotype.	resiniferatoxin	11-26	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	103-123
11050376-1	2000	Capsaicin, resiniferatoxin, protons or heat have been shown to activate an ion channel, termed the rat vanilloid receptor-1 (rVR1), originally isolated by expression cloning for a capsaicin sensitive phenotype.	resiniferatoxin	11-26	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	125-129
10601669-1	2000	The present study assessed the effect of a single subcutaneous injection of resiniferatoxin (RTX), an ultrapotent capsaicin analogue, on the activity of spinal cholecystokinin (CCK) systems, by using electrophysiological and in situ hybridization techniques.	resiniferatoxin	76-91	cholecystokinin	Rattus norvegicus	177-180
10601669-1	2000	The present study assessed the effect of a single subcutaneous injection of resiniferatoxin (RTX), an ultrapotent capsaicin analogue, on the activity of spinal cholecystokinin (CCK) systems, by using electrophysiological and in situ hybridization techniques.	resiniferatoxin	93-96	cholecystokinin	Rattus norvegicus	177-180
10601669-9	2000	In situ hybridization showed that RTX treatment caused a marked and significant increase in the number of dorsal root ganglion (DRG) neurone profiles expressing CCKB receptor mRNA, whereas only a small increase was observed for CCKA receptor mRNA expressing neurone profiles.	resiniferatoxin	34-37	cholecystokinin B receptor	Rattus norvegicus	161-174
10601669-12	2000	Since CCK functions as a physiological antagonist of morphine, it is suggested that RTX treatment enhances the activity of spinal CCK systems, leading to the reduced effect of morphine and increased effect of the CCKB receptor antagonist CI-988.	resiniferatoxin	84-87	cholecystokinin	Rattus norvegicus	6-9
10601669-12	2000	Since CCK functions as a physiological antagonist of morphine, it is suggested that RTX treatment enhances the activity of spinal CCK systems, leading to the reduced effect of morphine and increased effect of the CCKB receptor antagonist CI-988.	resiniferatoxin	84-87	cholecystokinin	Rattus norvegicus	130-133
10601669-12	2000	Since CCK functions as a physiological antagonist of morphine, it is suggested that RTX treatment enhances the activity of spinal CCK systems, leading to the reduced effect of morphine and increased effect of the CCKB receptor antagonist CI-988.	resiniferatoxin	84-87	cholecystokinin B receptor	Rattus norvegicus	213-226
10510454-0	1999	Resiniferatoxin-type phorboid vanilloids display capsaicin-like selectivity at native vanilloid receptors on rat DRG neurons and at the cloned vanilloid receptor VR1.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	162-165
10478560-5	1999	As to the desensitizing power, resiniferatoxin produced a dose-dependent effect with a maximum at 100 nM, which decreased Fos-immunoreactive cell numbers to less than 10% of controls.	resiniferatoxin	31-46	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	122-125
10478560-7	1999	As to the irritating power, the saturation dose of resiniferatoxin (100 nM) produced a very weak c-fos activation in lumbosacral spinal cord segments.	resiniferatoxin	51-66	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	97-102
9580328-5	1998	Capsaicin and resiniferatoxin were found to activate both isoforms of c-jun-NH2-kinase (JNK), with a maximal activity after 30 min of treatment.	resiniferatoxin	14-29	mitogen-activated protein kinase 8	Homo sapiens	70-86
9804700-3	1998	Inflammation in the guinea pig induced by a resiniferatoxin challenge (with NK-1 receptor activation mediating the subsequent increase in vascular permeability) is inhibited in a dose-dependent manner by the oral preadmininstration of 17 (IC50 (1 h) = 0.008 mg/kg; IC90 (24 h) = 1.8 mg/kg), indicating that this compound has good oral bioavailbility and peripheral duration of action.	resiniferatoxin	44-59	substance-P receptor	Cavia porcellus	76-89
9787950-15	1998	Thus, the degree of pre-existing histologically proven damage of the graft may serve as an indicator for the antiproteinuric efficacy of ACE inhibitor therapy after RTx.	resiniferatoxin	165-168	angiotensin I converting enzyme	Homo sapiens	137-140
17038971-3	1998	In spite of this, ultrapotent capsaicin analogues such as resiniferatoxin, which also interact with the vanilloid receptor subtype 1, are being studied.	resiniferatoxin	58-73	transient receptor potential cation channel subfamily V member 1	Homo sapiens	104-132
9580328-5	1998	Capsaicin and resiniferatoxin were found to activate both isoforms of c-jun-NH2-kinase (JNK), with a maximal activity after 30 min of treatment.	resiniferatoxin	14-29	mitogen-activated protein kinase 8	Homo sapiens	88-91
7741700-15	1995	These findings support the hypothesis that capsaicin and resiniferatoxin elicit an excitatory response on sensory nerves in skeletal muscle in vitro to cause the efferent release of CGRP.	resiniferatoxin	57-72	calcitonin-related polypeptide alpha	Rattus norvegicus	182-186
8595209-0	1995	Increased levels of GMAP, VIP and nitric oxide synthase, and their mRNAs, in lumbar dorsal root ganglia of the rat following systemic resiniferatoxin treatment.	resiniferatoxin	134-149	vasoactive intestinal peptide	Rattus norvegicus	26-29
8595209-6	1995	The increase in number of VIP-, or NOS-positive neurones persisted up to 4 weeks after RTX treatment and declined thereafter.	resiniferatoxin	87-90	vasoactive intestinal peptide	Rattus norvegicus	26-29
8595209-9	1995	Our findings suggest that RTX can cause changes (messenger plasticity) in galanin, VIP and NOS expression in capsaicin-sensitive sensory neurones of the rat, similar to those described following axotomy.	resiniferatoxin	26-29	vasoactive intestinal peptide	Rattus norvegicus	83-86
8846425-7	1995	A role for NK2 receptor stimulation has also been clearly demonstrated in bronchoconstriction induced by various agents known to induce the release of tachykinins (capsaicin, resiniferatoxin, citric acid, sodium metabisulfite diethyl ether, serotonin, and bradykinin), in allergen-induced airway constriction in the guinea pig sensitized to ovalbumin, and in hyperpnea-induced bronchoconstriction.	resiniferatoxin	175-190	substance-K receptor	Cavia porcellus	11-23
9222561-5	1997	Capsaicin, resiniferatoxin (RTX) and olvanil each evoked a concentration-dependent increase in CGRP release with pEC50 values of 6.55 +/- 0.07, 7.90 +/- 0.24 and 6.19 +/- 0.15 respectively.	resiniferatoxin	11-26	calcitonin-related polypeptide alpha	Rattus norvegicus	95-99
9222561-5	1997	Capsaicin, resiniferatoxin (RTX) and olvanil each evoked a concentration-dependent increase in CGRP release with pEC50 values of 6.55 +/- 0.07, 7.90 +/- 0.24 and 6.19 +/- 0.15 respectively.	resiniferatoxin	28-31	calcitonin-related polypeptide alpha	Rattus norvegicus	95-99
9237666-3	1997	By screening a rat cDNA library with labelled resiniferatoxin, we unexpectedly isolated a novel rat phosphotriesterase homologue, here named rpr-1, that encodes a 349 amino acid, 39 kDa protein (confirmed by in vitro translation).	resiniferatoxin	46-61	phosphotriesterase related	Rattus norvegicus	141-146
9237666-4	1997	Northern blotting and in situ hybridisation show expression primarily in proximal tubules of the kidney, in which rpr-1 distribution correlates with resiniferatoxin-binding activity.	resiniferatoxin	149-164	phosphotriesterase related	Rattus norvegicus	114-119
8906816-4	1996	In the present study, we examined the effect of capsaicin and its analogue, resiniferatoxin, on the activation of NF-kappa B induced by different agents including TNF.	resiniferatoxin	76-91	nuclear factor kappa B subunit 1	Homo sapiens	114-124
8906816-4	1996	In the present study, we examined the effect of capsaicin and its analogue, resiniferatoxin, on the activation of NF-kappa B induced by different agents including TNF.	resiniferatoxin	76-91	tumor necrosis factor	Homo sapiens	163-166
8906816-6	1996	Resiniferatoxin was at least eight times as potent as capsaicin in inhibiting NF-kappa B activation.	resiniferatoxin	0-15	nuclear factor kappa B subunit 1	Homo sapiens	78-88
8995034-3	1996	Particularly in children with CRI and after RTx, pre-existing insulin resistance may be aggravated by exogenous rhGH therapy.	resiniferatoxin	44-47	insulin	Homo sapiens	62-69
8995034-4	1996	Patients after RTx had significantly higher pretreatment insulin levels than controls (p < 0.001).	resiniferatoxin	15-18	insulin	Homo sapiens	57-64
8782884-2	1996	In addition, RTX causes changes in neuropeptide and nitric oxide synthase expression in lumbar DRG neurons, similar to those described following axotomy; this latter phenomenon is referred to as messenger plasticity.	resiniferatoxin	13-16	pyroglutamylated RFamide peptide	Rattus norvegicus	35-47
7955356-0	1994	The calcitonin gene-related peptide (CGRP) phenotype is expressed early and up-regulated by resiniferatoxin (RTX) in mouse sensory neurons.	resiniferatoxin	92-107	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	4-35
7621890-0	1995	Proton inhibition of [3H]resiniferatoxin binding to vanilloid (capsaicin) receptors in rat spinal cord.	resiniferatoxin	25-40	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	52-62
7621890-2	1995	We have used the [3H]resiniferatoxin binding assay utilizing rat spinal cord membranes to elucidate the possible interaction of protons at the vanilloid (capsaicin) receptor.	resiniferatoxin	21-36	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	143-173
7955356-0	1994	The calcitonin gene-related peptide (CGRP) phenotype is expressed early and up-regulated by resiniferatoxin (RTX) in mouse sensory neurons.	resiniferatoxin	92-107	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	37-41
7955356-0	1994	The calcitonin gene-related peptide (CGRP) phenotype is expressed early and up-regulated by resiniferatoxin (RTX) in mouse sensory neurons.	resiniferatoxin	109-112	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	4-35
7955356-0	1994	The calcitonin gene-related peptide (CGRP) phenotype is expressed early and up-regulated by resiniferatoxin (RTX) in mouse sensory neurons.	resiniferatoxin	109-112	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	37-41
7955356-3	1994	Treatment of cultures with the capsaicin analog resiniferatoxin (RTX; 0.3-30 nM) significantly augmented CGRP immunoreactivity per neuron at all ages investigated without increasing the number of CGRP-immunoreactive cells.	resiniferatoxin	48-63	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	105-109
7955356-3	1994	Treatment of cultures with the capsaicin analog resiniferatoxin (RTX; 0.3-30 nM) significantly augmented CGRP immunoreactivity per neuron at all ages investigated without increasing the number of CGRP-immunoreactive cells.	resiniferatoxin	65-68	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	105-109
7955356-5	1994	This RTX-induced increase in CGRP immunoreactivity was completely blocked by Ruthenium red (RR).	resiniferatoxin	5-8	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	29-33
7955356-7	1994	These results suggest that: (1) early expression of the CGRP phenotype is regulated in a cell-autonomous way in developing mouse DRG neurons in vitro; and (2) the RTX-induced increase in CGRP biosynthesis is most likely the result of activating the capsaicin/RTX receptor rather than directly activating the protein kinase C (PKC) pathway in vitro.	resiniferatoxin	163-166	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	56-60
7955356-7	1994	These results suggest that: (1) early expression of the CGRP phenotype is regulated in a cell-autonomous way in developing mouse DRG neurons in vitro; and (2) the RTX-induced increase in CGRP biosynthesis is most likely the result of activating the capsaicin/RTX receptor rather than directly activating the protein kinase C (PKC) pathway in vitro.	resiniferatoxin	163-166	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	187-191
8015709-0	1994	Characterization by [3H]resiniferatoxin binding of a human vanilloid (capsaicin) receptor in post-mortem spinal cord.	resiniferatoxin	24-39	transient receptor potential cation channel subfamily V member 1	Homo sapiens	59-89
8057776-0	1994	[3H]resiniferatoxin binding by the human vanilloid (capsaicin) receptor.	resiniferatoxin	4-19	transient receptor potential cation channel subfamily V member 1	Homo sapiens	41-71
8057776-2	1994	Specific [3H]resiniferatoxin (RTX) binding is thought to represent the vanilloid (capsaicin) receptor.	resiniferatoxin	13-28	transient receptor potential cation channel subfamily V member 1	Homo sapiens	71-101
8057776-2	1994	Specific [3H]resiniferatoxin (RTX) binding is thought to represent the vanilloid (capsaicin) receptor.	resiniferatoxin	30-33	transient receptor potential cation channel subfamily V member 1	Homo sapiens	71-101
8015392-8	1994	Both expressed bacterial fusion proteins and cytoplasmic fractions from COS cells transfected with an expression vector encoding RTX-42 showed [3H]resiniferatoxin binding activity (IC50 approximately 10 nM).	resiniferatoxin	147-162	phosphorylated adaptor for RNA export	Rattus norvegicus	129-135
8015392-9	1994	RBP-26 is expressed in non-neuronal and capsaicin-insensitive neuronal tissues, and shows distinct binding characteristics from the resiniferatoxin binding site defined on DRG membranes.	resiniferatoxin	132-147	phosphorylated adaptor for RNA export	Rattus norvegicus	0-6
8355200-1	1993	Specific [3H]resiniferatoxin (RTX) binding is thought to represent the postulated vanilloid (capsaicin) receptor.	resiniferatoxin	13-28	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	71-112
8204528-7	1994	The benefit of CTx could also be demonstrated in a randomized trial comparing RTx alone versus CTx/RTx with a reduction of local and distant failures and significantly improved survival in the CTM arm.	resiniferatoxin	78-81	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	15-18
8301598-11	1994	Moreover, RTX and capsaicin both release tachykinins that act on both NK-1 and NK-2 receptor subtypes.	resiniferatoxin	10-13	substance-K receptor	Cavia porcellus	79-92
8246148-0	1993	Competitive inhibition by capsazepine of [3H]resiniferatoxin binding to central (spinal cord and dorsal root ganglia) and peripheral (urinary bladder and airways) vanilloid (capsaicin) receptors in the rat.	resiniferatoxin	45-60	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	163-173
8355200-1	1993	Specific [3H]resiniferatoxin (RTX) binding is thought to represent the postulated vanilloid (capsaicin) receptor.	resiniferatoxin	30-33	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	71-112
1637122-0	1992	Inhibition of insulin-stimulated glycogen synthesis in skeletal muscle by resiniferatoxin is probably due to a mechanism involving CGRP.	resiniferatoxin	74-89	calcitonin related polypeptide alpha	Homo sapiens	131-135
1811172-1	1991	We have recently reported the specific binding of [3H]resiniferatoxin to sensory ganglion membranes; this binding appears to represent the postulated vanilloid (capsaicin) receptor.	resiniferatoxin	50-69	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	139-180
1722940-0	1991	Resiniferatoxin-, capsaicin- and CGRP-evoked porcine coronary vasodilatation is independent of EDRF mechanisms but antagonized by CGRP(8-37).	resiniferatoxin	0-15	calcitonin related polypeptide alpha	Homo sapiens	130-134
1724624-0	1991	Ruthenium-red inhibits CGRP release by capsaicin and resiniferatoxin but not by ouabain, bradykinin or nicotine in guinea-pig heart: correlation with effects on cardiac contractility.	resiniferatoxin	53-68	calcitonin related polypeptide alpha	Homo sapiens	23-27
1724624-13	1991	Perfusion with resiniferatoxin evoked a RR-sensitive, clear-cut increased CGRP-LI output without any effects on contractile force or heart rate.	resiniferatoxin	15-30	calcitonin related polypeptide alpha	Homo sapiens	74-78
1724624-21	1991	It is concluded that RR selectively inhibits capsaicin- and resiniferatoxin-induced excitation of cardiac sensory nerves as revealed by inhibition of both CGRP-LI release and the cardiostimulatory action of capsaicin.	resiniferatoxin	60-75	calcitonin related polypeptide alpha	Homo sapiens	155-159
2085772-3	1990	We report here that treatment of newborn rats with resiniferatoxin caused a substantial (47%) loss of dorsal root ganglia neurons in adults and an almost complete loss of calcitonin gene related peptide-like immunoreactivity in both dorsal root ganglia and gasserian ganglia.	resiniferatoxin	51-66	calcitonin-related polypeptide alpha	Rattus norvegicus	171-181
34741999-3	2022	Resiniferatoxin was injected into left trigeminal ganglia to ablate TRPV1-expressing neurons.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	68-73
1723514-5	1990	The action of resiniferatoxin was blocked by Ruthenium Red, a proposed antagonist at the cation channel coupled to the capsaicin receptor.	resiniferatoxin	14-29	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	119-137
2322999-4	1990	In CD-1 mice, we have used pretreatment with RTX to show that the erythema and edema responses to phorbol and 12-deoxyphorbol esters in significant part involve this neurogenic inflammatory pathway.	resiniferatoxin	45-48	CD1 antigen complex	Mus musculus	3-7
2322999-8	1990	DBA/2J mice, which are similar to CD-1 mice in their susceptibility to PMA promotion, responded similarly to CD-1: the edema response was blocked partially by RTX pretreatment during the early phase (up to 8 h) of inflammation.	resiniferatoxin	159-162	CD1 antigen complex	Mus musculus	109-113
25524130-7	2015	RESULTS: In RTX-pretreated mice, the autoantibody-induced joint swelling, arthritis severity score, MMP and MPO activities, as well as histopathological alterations were significantly greater compared to non-pretreated animals.	resiniferatoxin	12-15	myeloperoxidase	Mus musculus	108-111
34375451-1	2021	AIM: To evaluate if treatment with resiniferatoxin (RTX) is capable of lowering the plasma levels of PGE2 and TNF-alpha, as well as histopathological parameters in inflammation of pulp tissue in a mouse experimental model.	resiniferatoxin	35-50	tumor necrosis factor	Mus musculus	110-119
34827631-3	2021	Methods and Materials: We evaluated the immunologic profile of 10 OPV patients treated with RTX as adjuvant by using the ELISA testing for anti-Dsg-1 and -3 titers and the immunophenotyping for B and T-cell lymphocyte subpopulations and compared them with the PDAI score for clinical remission.	resiniferatoxin	92-95	desmoglein 1	Homo sapiens	144-156
34827631-4	2021	Results: A significant difference in medians between baseline, end of RTX therapy, and 6 months after RTX therapy was observed in Dsg-3 titer (p < 0.001), in the CD8 (p = 0.009), and CD20 counts (p < 0.001).	resiniferatoxin	70-73	desmoglein 3	Homo sapiens	130-135
34827631-4	2021	Results: A significant difference in medians between baseline, end of RTX therapy, and 6 months after RTX therapy was observed in Dsg-3 titer (p < 0.001), in the CD8 (p = 0.009), and CD20 counts (p < 0.001).	resiniferatoxin	70-73	CD8a molecule	Homo sapiens	162-165
34827631-4	2021	Results: A significant difference in medians between baseline, end of RTX therapy, and 6 months after RTX therapy was observed in Dsg-3 titer (p < 0.001), in the CD8 (p = 0.009), and CD20 counts (p < 0.001).	resiniferatoxin	70-73	keratin 20	Homo sapiens	183-187
34827631-4	2021	Results: A significant difference in medians between baseline, end of RTX therapy, and 6 months after RTX therapy was observed in Dsg-3 titer (p < 0.001), in the CD8 (p = 0.009), and CD20 counts (p < 0.001).	resiniferatoxin	102-105	desmoglein 3	Homo sapiens	130-135
34827631-4	2021	Results: A significant difference in medians between baseline, end of RTX therapy, and 6 months after RTX therapy was observed in Dsg-3 titer (p < 0.001), in the CD8 (p = 0.009), and CD20 counts (p < 0.001).	resiniferatoxin	102-105	CD8a molecule	Homo sapiens	162-165
34827631-4	2021	Results: A significant difference in medians between baseline, end of RTX therapy, and 6 months after RTX therapy was observed in Dsg-3 titer (p < 0.001), in the CD8 (p = 0.009), and CD20 counts (p < 0.001).	resiniferatoxin	102-105	keratin 20	Homo sapiens	183-187
34827631-6	2021	Only the anti-Dsg-3 titer at the end of RTX therapy demonstrated a slight positive correlation with the PDAI score at baseline (p = 0.046, r = 0.652).	resiniferatoxin	40-43	desmoglein 3	Homo sapiens	14-19
34726701-9	2021	The effect of RTX and Methotrexate was additive in terms of seroconversion rates (23% vs 50% in patients receiving RTX in monotherapy, p= 0.12) and SARS-CoV-2 spike antibody levels (3.80 AU/ml, 95% confidence interval, CI 3.80-7.50 AU/ml vs 75 AU/ml, 95% CI 3.8-353 AU/ml in patients receiving RTX in monotherapy p= 0.025).	resiniferatoxin	14-17	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	159-164
34375451-1	2021	AIM: To evaluate if treatment with resiniferatoxin (RTX) is capable of lowering the plasma levels of PGE2 and TNF-alpha, as well as histopathological parameters in inflammation of pulp tissue in a mouse experimental model.	resiniferatoxin	52-55	tumor necrosis factor	Mus musculus	110-119
34375451-9	2021	In addition, treatment with RTX significantly decreased (*p<0.05) the plasma levels of PGE2 and TNF-alpha at 14 and 18 hours after pulp damage, as well as the infiltrate of inflammatory cells at 18 hours after pulp damage, similarly to treatment with ibuprofen and dexamethasone.	resiniferatoxin	28-31	tumor necrosis factor	Mus musculus	96-105
34416255-4	2021	We used resiniferatoxin (RTX), a TRPV1 agonist, to differentiate the two.	resiniferatoxin	8-23	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	33-38
34745116-4	2021	Systemic ultrapotent Transient receptor potential vanilloid 1 (TRPV1) agonist (resiniferatoxin, RTX) treatment-induced sensory denervation resulted in a significant decrease in IL-23 expression in this model, while the recombinant IL-23 treatment induced IL-17A expression was intact after RTX treatment.	resiniferatoxin	79-94	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	21-61
34745116-4	2021	Systemic ultrapotent Transient receptor potential vanilloid 1 (TRPV1) agonist (resiniferatoxin, RTX) treatment-induced sensory denervation resulted in a significant decrease in IL-23 expression in this model, while the recombinant IL-23 treatment induced IL-17A expression was intact after RTX treatment.	resiniferatoxin	79-94	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	63-68
34745116-4	2021	Systemic ultrapotent Transient receptor potential vanilloid 1 (TRPV1) agonist (resiniferatoxin, RTX) treatment-induced sensory denervation resulted in a significant decrease in IL-23 expression in this model, while the recombinant IL-23 treatment induced IL-17A expression was intact after RTX treatment.	resiniferatoxin	79-94	interleukin 23, alpha subunit p19	Mus musculus	177-182
34745116-4	2021	Systemic ultrapotent Transient receptor potential vanilloid 1 (TRPV1) agonist (resiniferatoxin, RTX) treatment-induced sensory denervation resulted in a significant decrease in IL-23 expression in this model, while the recombinant IL-23 treatment induced IL-17A expression was intact after RTX treatment.	resiniferatoxin	79-94	interleukin 17A	Mus musculus	255-261
34745116-4	2021	Systemic ultrapotent Transient receptor potential vanilloid 1 (TRPV1) agonist (resiniferatoxin, RTX) treatment-induced sensory denervation resulted in a significant decrease in IL-23 expression in this model, while the recombinant IL-23 treatment induced IL-17A expression was intact after RTX treatment.	resiniferatoxin	96-99	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	21-61
34745116-4	2021	Systemic ultrapotent Transient receptor potential vanilloid 1 (TRPV1) agonist (resiniferatoxin, RTX) treatment-induced sensory denervation resulted in a significant decrease in IL-23 expression in this model, while the recombinant IL-23 treatment induced IL-17A expression was intact after RTX treatment.	resiniferatoxin	96-99	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	63-68
34745116-4	2021	Systemic ultrapotent Transient receptor potential vanilloid 1 (TRPV1) agonist (resiniferatoxin, RTX) treatment-induced sensory denervation resulted in a significant decrease in IL-23 expression in this model, while the recombinant IL-23 treatment induced IL-17A expression was intact after RTX treatment.	resiniferatoxin	96-99	interleukin 23, alpha subunit p19	Mus musculus	177-182
34416255-4	2021	We used resiniferatoxin (RTX), a TRPV1 agonist, to differentiate the two.	resiniferatoxin	25-28	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	33-38
34252037-1	2021	Systemic treatment with resiniferatoxin (RTX) induces small-fiber sensory neuropathy by damaging TRPV1-expressing primary sensory neurons and causes distinct thermal sensory impairment and tactile allodynia, which resemble the unique clinical features of postherpetic neuralgia.	resiniferatoxin	24-39	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	97-102
34504955-1	2021	Both a silent resident phosphatidylinositol lipid and a "hot" vanilloid agonist capsaicin or resiniferatoxin have been shown to share the same inter-subunit binding pocket between a voltage sensor like domain and a pore domain in TRPV1.	resiniferatoxin	93-108	transient receptor potential cation channel subfamily V member 1	Homo sapiens	230-235
34259041-3	2021	Local cardiac and intrathecal administration of an ultra-potent noncompetitive, dominant negative agonist resiniferatoxin (RTX) can ablate these TRPV1 sensitive afferents.	resiniferatoxin	106-121	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	145-150
34259041-3	2021	Local cardiac and intrathecal administration of an ultra-potent noncompetitive, dominant negative agonist resiniferatoxin (RTX) can ablate these TRPV1 sensitive afferents.	resiniferatoxin	123-126	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	145-150
34098041-0	2021	Bone Mesenchymal Stem Cells Attenuate Resiniferatoxin-induced Neuralgia via Inhibiting TRPA1-PKCdelta-P38/MAPK-p-P65 pathway in Mice.	resiniferatoxin	38-53	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	87-92
34098041-0	2021	Bone Mesenchymal Stem Cells Attenuate Resiniferatoxin-induced Neuralgia via Inhibiting TRPA1-PKCdelta-P38/MAPK-p-P65 pathway in Mice.	resiniferatoxin	38-53	mitogen-activated protein kinase 14	Mus musculus	102-110
34098041-0	2021	Bone Mesenchymal Stem Cells Attenuate Resiniferatoxin-induced Neuralgia via Inhibiting TRPA1-PKCdelta-P38/MAPK-p-P65 pathway in Mice.	resiniferatoxin	38-53	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	113-116
34098041-8	2021	Our research suggested that activation of PKCdelta-CaMKIIalpha-P38/MAPK-p-P65 pathway and mushroom dendritic spines abnormal increase in the spinal cord is the main mechanism of RTX induced neuropathic pain, and transplant of BMSCs to the damaged nerve may offer promising approach for neuropathic pain.	resiniferatoxin	178-181	protein kinase C, delta	Mus musculus	42-50
34098041-8	2021	Our research suggested that activation of PKCdelta-CaMKIIalpha-P38/MAPK-p-P65 pathway and mushroom dendritic spines abnormal increase in the spinal cord is the main mechanism of RTX induced neuropathic pain, and transplant of BMSCs to the damaged nerve may offer promising approach for neuropathic pain.	resiniferatoxin	178-181	mitogen-activated protein kinase 14	Mus musculus	63-71
34098041-8	2021	Our research suggested that activation of PKCdelta-CaMKIIalpha-P38/MAPK-p-P65 pathway and mushroom dendritic spines abnormal increase in the spinal cord is the main mechanism of RTX induced neuropathic pain, and transplant of BMSCs to the damaged nerve may offer promising approach for neuropathic pain.	resiniferatoxin	178-181	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	74-77
34421597-10	2021	This statement is mainly derived from our studies with resiniferatoxin (RTX) a potent TRPV1 agonist but also from protein therapeutics using a conjugate of Substance P and saporin.	resiniferatoxin	55-70	transient receptor potential cation channel subfamily V member 1	Homo sapiens	86-91
34421597-10	2021	This statement is mainly derived from our studies with resiniferatoxin (RTX) a potent TRPV1 agonist but also from protein therapeutics using a conjugate of Substance P and saporin.	resiniferatoxin	72-75	transient receptor potential cation channel subfamily V member 1	Homo sapiens	86-91
34252037-1	2021	Systemic treatment with resiniferatoxin (RTX) induces small-fiber sensory neuropathy by damaging TRPV1-expressing primary sensory neurons and causes distinct thermal sensory impairment and tactile allodynia, which resemble the unique clinical features of postherpetic neuralgia.	resiniferatoxin	41-44	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	97-102
34252037-3	2021	In this study, we found that RTX-induced neuropathy is associated with alpha2delta-1 upregulation in the dorsal root ganglion (DRG) and increased physical interaction between alpha2delta-1 and GluN1 in the spinal cord synaptosomes.	resiniferatoxin	29-32	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	193-198
34252037-4	2021	RNAscope in situ hybridization showed that RTX treatment significantly increased alpha2delta-1 expression in DRG neurons labeled with calcitonin gene-related peptide, isolectin B4, NF200, and tyrosine hydroxylase.	resiniferatoxin	43-46	neurofilament, heavy polypeptide	Mus musculus	181-186
34252037-8	2021	In addition, RTX-induced tactile allodynia was attenuated in alpha2delta-1 knock-out mice and in mice in which GluN1 was conditionally knocked out in DRG neurons.	resiniferatoxin	13-16	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	111-116
35461090-2	2022	The treatment of PCNSL is ineffective partly due to the blood-brain barrier (BBB) restriction of delivery of many drugs including anti-CD20 (Rituximab; RTX) which is a standard treatment for systemic B-cell lymphomas.	resiniferatoxin	152-155	keratin 20	Homo sapiens	135-139
34081758-5	2021	Both BTx and RTx can increase the OS with a pronounced benefit for patients with KRAS wild-type tumors.	resiniferatoxin	13-16	KRAS proto-oncogene, GTPase	Homo sapiens	81-85
35482725-1	2022	Resiniferatoxin (RTX), an extract from the spurge plant Euphorbia resinifera, is a potent agonist of the transient receptor potential cation channel subfamily V member 1 (TRPV1), mainly expressed on peripheral nociceptors-a prerequisite for nociceptive heat perception.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	171-176
35610228-2	2022	Here, we use thermal titration methods and cryo-EM in an attempt to obtain temporal resolution of the conformational trajectory of the vanilloid receptor TRPV1 with resiniferatoxin (RTx) bound.	resiniferatoxin	165-180	transient receptor potential cation channel subfamily V member 1	Homo sapiens	154-159
35610228-2	2022	Here, we use thermal titration methods and cryo-EM in an attempt to obtain temporal resolution of the conformational trajectory of the vanilloid receptor TRPV1 with resiniferatoxin (RTx) bound.	resiniferatoxin	182-185	transient receptor potential cation channel subfamily V member 1	Homo sapiens	154-159
35610228-5	2022	Greater understanding of the RTx-mediated long-range allostery of TRPV1 could help further the therapeutic potential of RTx, which is a promising drug candidate for pain relief associated with advanced cancer or knee arthritis.	resiniferatoxin	29-32	transient receptor potential cation channel subfamily V member 1	Homo sapiens	66-71
35610228-5	2022	Greater understanding of the RTx-mediated long-range allostery of TRPV1 could help further the therapeutic potential of RTx, which is a promising drug candidate for pain relief associated with advanced cancer or knee arthritis.	resiniferatoxin	120-123	transient receptor potential cation channel subfamily V member 1	Homo sapiens	66-71
35482725-1	2022	Resiniferatoxin (RTX), an extract from the spurge plant Euphorbia resinifera, is a potent agonist of the transient receptor potential cation channel subfamily V member 1 (TRPV1), mainly expressed on peripheral nociceptors-a prerequisite for nociceptive heat perception.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	171-176
35350319-5	2022	We demonstrate that endogenous TRPV1 is functional and causes Ca2+ influx upon activation with pharmacological activators (resiniferatoxin (RTX) and capsaicin) at nanomolar concentration, which enhances the generation of osteoclasts, whereas the TRPV1 inhibitor (5"-IRTX) reduces osteoclast differentiation.	resiniferatoxin	123-138	transient receptor potential cation channel subfamily V member 1	Homo sapiens	31-36
35411376-7	2022	Antibody levels were significantly lower in the groups treated with TNF inhibitor (TNFi) with methotrexate (MTX), abatacept, mycophenolate mofetil (MMF), MMF or mizoribine (MMF/MZR) combined with calcineurin inhibitor (CNI), and rituximab or cyclophosphamide (RTX/CPA) compared with those treated with sulfasalazine and/or bucillamine or CNI (p<0.01).	resiniferatoxin	260-263	tumor necrosis factor	Homo sapiens	68-71
35350319-5	2022	We demonstrate that endogenous TRPV1 is functional and causes Ca2+ influx upon activation with pharmacological activators (resiniferatoxin (RTX) and capsaicin) at nanomolar concentration, which enhances the generation of osteoclasts, whereas the TRPV1 inhibitor (5"-IRTX) reduces osteoclast differentiation.	resiniferatoxin	123-138	transient receptor potential cation channel subfamily V member 1	Homo sapiens	246-251
35350319-5	2022	We demonstrate that endogenous TRPV1 is functional and causes Ca2+ influx upon activation with pharmacological activators (resiniferatoxin (RTX) and capsaicin) at nanomolar concentration, which enhances the generation of osteoclasts, whereas the TRPV1 inhibitor (5"-IRTX) reduces osteoclast differentiation.	resiniferatoxin	140-143	transient receptor potential cation channel subfamily V member 1	Homo sapiens	31-36
35350319-5	2022	We demonstrate that endogenous TRPV1 is functional and causes Ca2+ influx upon activation with pharmacological activators (resiniferatoxin (RTX) and capsaicin) at nanomolar concentration, which enhances the generation of osteoclasts, whereas the TRPV1 inhibitor (5"-IRTX) reduces osteoclast differentiation.	resiniferatoxin	140-143	transient receptor potential cation channel subfamily V member 1	Homo sapiens	246-251
35350319-7	2022	The slow release of capsaicin or RTX at a nanomolar concentration from a polysaccharide-based hydrogel enhances bone marrow macrophage (BMM) differentiation into osteoclasts whereas release of 5"-IRTX, an inhibitor of TRPV1, prevents macrophage fusion and osteoclast formation.	resiniferatoxin	33-36	transient receptor potential cation channel subfamily V member 1	Homo sapiens	218-223
35040120-4	2022	In this study, we show that intact GGH is not indispensable for the chemosensitivity and growth of acute lymphoblastic leukemia (ALL) cells, whereas GGH lacking N-terminal signal peptide (GGH-DeltaN ) confers the significant drug resistance of ALL cells to the antifolates MTX and RTX.	resiniferatoxin	281-284	gamma-glutamyl hydrolase	Homo sapiens	188-191
2790819-3	1989	We report here that pretreatment of CD-1 mice with resiniferatoxin blocked the early (3 h) erythema and edema (6 h) in response to phorbol 12-myristate 13-acetate (PMA), whereas the edema at later times (12-24 h) was only partially blocked.	resiniferatoxin	51-66	CD1 antigen complex	Mus musculus	36-40
35043639-1	2022	Resiniferatoxin (1) is a complex daphnane diterpenoid with a highly oxygenated 5/7/6-membered ABC-ring system.	resiniferatoxin	0-15	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	94-97
35418262-0	2022	Extracellular signal-regulated kinase phosphorylation enhancement and NaV1.7 sodium channel upregulation in rat dorsal root ganglia neurons contribute to resiniferatoxin-induced neuropathic pain: The efficacy and mechanism of pulsed radiofrequency therapy.	resiniferatoxin	154-169	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	70-76
35418262-6	2022	In the DRG of rats with RTX-induced mechanical allodynia, NaV1.7, a voltage-gated Na+ channel, was upregulated following the enhancement of extracellular signal-regulated kinase phosphorylation.	resiniferatoxin	24-27	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	58-64
35418262-9	2022	Both early PRF therapy and late PRF therapy combined with early tramadol treatment suppressed NaV1.7 upregulation in the DRG of rats with RTX-induced mechanical allodynia.	resiniferatoxin	138-141	sodium voltage-gated channel alpha subunit 9	Rattus norvegicus	94-100
35418262-10	2022	Therefore, NaV1.7 upregulation in DRG is related to the development of RTX-induced neuropathic pain; moreover, PRF therapy may be effective in the clinical management of patients with PHN via NaV1.7 upregulation inhibition.	resiniferatoxin	71-74	sodium voltage-gated channel alpha subunit 9	Homo sapiens	11-17
35418262-10	2022	Therefore, NaV1.7 upregulation in DRG is related to the development of RTX-induced neuropathic pain; moreover, PRF therapy may be effective in the clinical management of patients with PHN via NaV1.7 upregulation inhibition.	resiniferatoxin	71-74	sodium voltage-gated channel alpha subunit 9	Homo sapiens	192-198
33956874-4	2021	Mice were treated with Resiniferatoxin (RTX), a potent activator of Transient Receptor Potential Vanilloid 1 (TRPV1) channels, which significantly ablated corneal sensory neurons, exhibited delayed disease progression that was exemplified with decreased bacterial corneal burdens and altered neutrophil trafficking.	resiniferatoxin	23-38	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	68-108
6787158-5	1981	Plasma apo E and apo B concentrations increased by 100% in the PTU-treated group and 40-50% in the RTx-group.	resiniferatoxin	99-102	apolipoprotein E	Rattus norvegicus	7-12
34015320-10	2021	To date, only resiniferatoxin, a TRPV1 agonist, has been evaluated in clinical trials for cancer pain and showed preliminary positive results.	resiniferatoxin	14-29	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	33-38
33956874-4	2021	Mice were treated with Resiniferatoxin (RTX), a potent activator of Transient Receptor Potential Vanilloid 1 (TRPV1) channels, which significantly ablated corneal sensory neurons, exhibited delayed disease progression that was exemplified with decreased bacterial corneal burdens and altered neutrophil trafficking.	resiniferatoxin	23-38	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	110-115
33956874-4	2021	Mice were treated with Resiniferatoxin (RTX), a potent activator of Transient Receptor Potential Vanilloid 1 (TRPV1) channels, which significantly ablated corneal sensory neurons, exhibited delayed disease progression that was exemplified with decreased bacterial corneal burdens and altered neutrophil trafficking.	resiniferatoxin	40-43	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	68-108
33956874-4	2021	Mice were treated with Resiniferatoxin (RTX), a potent activator of Transient Receptor Potential Vanilloid 1 (TRPV1) channels, which significantly ablated corneal sensory neurons, exhibited delayed disease progression that was exemplified with decreased bacterial corneal burdens and altered neutrophil trafficking.	resiniferatoxin	40-43	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	110-115
33874962-0	2021	Inhibiting BDNF/TrkB.T1 receptor improves resiniferatoxin-induced postherpetic neuralgia through decreasing ASIC3 signaling in dorsal root ganglia.	resiniferatoxin	42-57	brain-derived neurotrophic factor	Rattus norvegicus	11-15
33874962-0	2021	Inhibiting BDNF/TrkB.T1 receptor improves resiniferatoxin-induced postherpetic neuralgia through decreasing ASIC3 signaling in dorsal root ganglia.	resiniferatoxin	42-57	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	16-20
33874962-0	2021	Inhibiting BDNF/TrkB.T1 receptor improves resiniferatoxin-induced postherpetic neuralgia through decreasing ASIC3 signaling in dorsal root ganglia.	resiniferatoxin	42-57	acid sensing ion channel subunit 3	Rattus norvegicus	108-113
33874962-11	2021	RESULTS: RTX injection induced mechanical allodynia and upregulated the protein expression of BDNF, TrkB.T1, ASIC3, TRAF6, nNOS, and c-Fos, as well as increased neuronal excitability in DRGs.	resiniferatoxin	9-12	brain-derived neurotrophic factor	Rattus norvegicus	94-98
33874962-11	2021	RESULTS: RTX injection induced mechanical allodynia and upregulated the protein expression of BDNF, TrkB.T1, ASIC3, TRAF6, nNOS, and c-Fos, as well as increased neuronal excitability in DRGs.	resiniferatoxin	9-12	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	100-104
33874962-11	2021	RESULTS: RTX injection induced mechanical allodynia and upregulated the protein expression of BDNF, TrkB.T1, ASIC3, TRAF6, nNOS, and c-Fos, as well as increased neuronal excitability in DRGs.	resiniferatoxin	9-12	acid sensing ion channel subunit 3	Rattus norvegicus	109-114
33874962-11	2021	RESULTS: RTX injection induced mechanical allodynia and upregulated the protein expression of BDNF, TrkB.T1, ASIC3, TRAF6, nNOS, and c-Fos, as well as increased neuronal excitability in DRGs.	resiniferatoxin	9-12	TNF receptor associated factor 6	Rattus norvegicus	116-121
33874962-11	2021	RESULTS: RTX injection induced mechanical allodynia and upregulated the protein expression of BDNF, TrkB.T1, ASIC3, TRAF6, nNOS, and c-Fos, as well as increased neuronal excitability in DRGs.	resiniferatoxin	9-12	nitric oxide synthase 1	Rattus norvegicus	123-127
33874962-11	2021	RESULTS: RTX injection induced mechanical allodynia and upregulated the protein expression of BDNF, TrkB.T1, ASIC3, TRAF6, nNOS, and c-Fos, as well as increased neuronal excitability in DRGs.	resiniferatoxin	9-12	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	133-138
33874962-14	2021	RTX-induced BDNF upregulation was found in both neurons and satellite glia cells in DRGs.	resiniferatoxin	0-3	brain-derived neurotrophic factor	Rattus norvegicus	12-16
33382172-9	2021	However, induction of acute stress via resiniferatoxin (RTX) injection still leads to hair greying in Mc1r mutant mice, suggesting that the ACTH-MC1R pathway is not a major contributor in acute stress-induced premature hair greying.	resiniferatoxin	56-59	melanocortin 1 receptor	Mus musculus	102-106
33845214-5	2021	We selectively depleted cardiac TRPV1 afferent fibers using percutaneous epicardial application of Resiniferatoxin (RTX).	resiniferatoxin	99-114	transient receptor potential cation channel subfamily V member 1	Sus scrofa	32-37
33845214-5	2021	We selectively depleted cardiac TRPV1 afferent fibers using percutaneous epicardial application of Resiniferatoxin (RTX).	resiniferatoxin	116-119	transient receptor potential cation channel subfamily V member 1	Sus scrofa	32-37
33845214-9	2021	RESULTS: Depletion of cardiac TRPV1 afferents by RTX treatment was confirmed by absent sensory fibers, and absent functional responses to TRPV1 activators.	resiniferatoxin	49-52	transient receptor potential cation channel subfamily V member 1	Sus scrofa	30-35
33936362-3	2021	Resiniferatoxin (RTX) is a transient receptor potential vanilloid 1 (TRPV1), involved in the cardiac sympathetic afferent reflex.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	27-67
33936362-3	2021	Resiniferatoxin (RTX) is a transient receptor potential vanilloid 1 (TRPV1), involved in the cardiac sympathetic afferent reflex.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	69-74
33936362-3	2021	Resiniferatoxin (RTX) is a transient receptor potential vanilloid 1 (TRPV1), involved in the cardiac sympathetic afferent reflex.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	27-67
33936362-3	2021	Resiniferatoxin (RTX) is a transient receptor potential vanilloid 1 (TRPV1), involved in the cardiac sympathetic afferent reflex.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	69-74
33936362-15	2021	TH- and GAP43-positive nerve densities and TGF-beta1, and cx-43 protein expression were up-regulated in the MI group compared to the sham group, and they were decreased in the MI+RTX group compared to the MI group (n = 3, P<0.05).	resiniferatoxin	179-182	growth associated protein 43	Rattus norvegicus	8-13
33936362-15	2021	TH- and GAP43-positive nerve densities and TGF-beta1, and cx-43 protein expression were up-regulated in the MI group compared to the sham group, and they were decreased in the MI+RTX group compared to the MI group (n = 3, P<0.05).	resiniferatoxin	179-182	gap junction protein, alpha 1	Rattus norvegicus	58-63
33936362-16	2021	RTX can decrease serum and tissue NE and BNP levels (n = 3, P<0.05).	resiniferatoxin	0-3	natriuretic peptide B	Rattus norvegicus	41-44
33813408-7	2021	The ADM group showed a significant effect of RTX on the postoperative seroma rate, wound infections, and implant loss rate.	resiniferatoxin	45-48	adrenomedullin	Homo sapiens	4-7
33727914-0	2021	Impact of Hepatoma-Derived Growth Factor Blockade on Resiniferatoxin-Induced Neuropathy.	resiniferatoxin	53-68	heparin binding growth factor	Rattus norvegicus	10-40
33727914-11	2021	In resiniferatoxin-group rats, protein expression of hepatoma-derived growth factor was higher than controls.	resiniferatoxin	3-18	heparin binding growth factor	Rattus norvegicus	53-83
33718013-9	2021	Notably, however, when analyzing the patients with KRAS-mutant and KRAS WT tumors separately, the benefit from BTx and RTx on OS remained statistically significant only in KRAS WT patients (P=0.032 and P=0.031, respectively).	resiniferatoxin	119-122	KRAS proto-oncogene, GTPase	Homo sapiens	67-71
33609627-8	2021	Administration of PACAP restored attenuated CHS response in RTX-treated mice, and pharmacological inhibition of PACAP suppressed CHS.	resiniferatoxin	60-63	adenylate cyclase activating polypeptide 1	Mus musculus	18-23
33584270-6	2020	Intraplantar pretreatment by both compounds significantly diminished TRPV1 stimulation (resiniferatoxin)-evoked thermal allodynia developing mainly by peripheral sensitization.	resiniferatoxin	88-103	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	69-74
33551815-3	2020	Both nociceptive responses and referred hyperalgesia were abolished by the ablation of TRPV1-expressing neurons (and the consequent ablation of TRPA1+ nociceptors) by resiniferatoxin (RTX) treatment, and by the TRPA1 antagonist AP18.	resiniferatoxin	167-182	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	87-92
33551815-3	2020	Both nociceptive responses and referred hyperalgesia were abolished by the ablation of TRPV1-expressing neurons (and the consequent ablation of TRPA1+ nociceptors) by resiniferatoxin (RTX) treatment, and by the TRPA1 antagonist AP18.	resiniferatoxin	167-182	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	144-149
33551815-3	2020	Both nociceptive responses and referred hyperalgesia were abolished by the ablation of TRPV1-expressing neurons (and the consequent ablation of TRPA1+ nociceptors) by resiniferatoxin (RTX) treatment, and by the TRPA1 antagonist AP18.	resiniferatoxin	184-187	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	87-92
33551815-3	2020	Both nociceptive responses and referred hyperalgesia were abolished by the ablation of TRPV1-expressing neurons (and the consequent ablation of TRPA1+ nociceptors) by resiniferatoxin (RTX) treatment, and by the TRPA1 antagonist AP18.	resiniferatoxin	184-187	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	144-149
33551815-3	2020	Both nociceptive responses and referred hyperalgesia were abolished by the ablation of TRPV1-expressing neurons (and the consequent ablation of TRPA1+ nociceptors) by resiniferatoxin (RTX) treatment, and by the TRPA1 antagonist AP18.	resiniferatoxin	184-187	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	211-216
32946867-2	2020	We employed resiniferatoxin (ultrapotent TRPV1 agonist) induced chemo-denervation model in rats and studied the effects of TRPV1 ablation on colonic mucus secretion patterns.	resiniferatoxin	12-27	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	41-46
32955494-3	2020	Resiniferatoxin (RTX), an ultrapotent TRPV1 agonist, has been known to induce long-term desensitization of TRPV1, and this desensitization has been an alternative approach for investigating the physiological relevance of TRPV1-expressing cells.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	38-43
32790967-6	2020	The mean post-operative IAP was 7.4 +- 4.3 [1-16] mm Hg following RTX and 8.1 +- 3.7 [1-19] mm Hg in controls.	resiniferatoxin	66-69	islet amyloid polypeptide	Homo sapiens	24-27
33071817-6	2020	Furthermore, C1 significantly decreased the TRPV1 stimulation (resiniferatoxin)-evoked mechanical hyperalgesia involving central sensitization processes, while its inhibitory effect on thermal allodynia was not statistically significant.	resiniferatoxin	63-78	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	44-49
32955494-3	2020	Resiniferatoxin (RTX), an ultrapotent TRPV1 agonist, has been known to induce long-term desensitization of TRPV1, and this desensitization has been an alternative approach for investigating the physiological relevance of TRPV1-expressing cells.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	107-112
32955494-3	2020	Resiniferatoxin (RTX), an ultrapotent TRPV1 agonist, has been known to induce long-term desensitization of TRPV1, and this desensitization has been an alternative approach for investigating the physiological relevance of TRPV1-expressing cells.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	107-112
32955494-3	2020	Resiniferatoxin (RTX), an ultrapotent TRPV1 agonist, has been known to induce long-term desensitization of TRPV1, and this desensitization has been an alternative approach for investigating the physiological relevance of TRPV1-expressing cells.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	38-43
32955494-3	2020	Resiniferatoxin (RTX), an ultrapotent TRPV1 agonist, has been known to induce long-term desensitization of TRPV1, and this desensitization has been an alternative approach for investigating the physiological relevance of TRPV1-expressing cells.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	107-112
32955494-3	2020	Resiniferatoxin (RTX), an ultrapotent TRPV1 agonist, has been known to induce long-term desensitization of TRPV1, and this desensitization has been an alternative approach for investigating the physiological relevance of TRPV1-expressing cells.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	107-112
32955494-9	2020	RTX treatment can induce supraspinal-selective TRPV1 desensitization.	resiniferatoxin	0-3	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	47-52
32064609-7	2020	Perineural application of RTX caused downregulation of TRPV1, CGRP, and IB4 binding and upregulation of VIP in the corresponding DRG and the dorsal horn of the spinal cord.	resiniferatoxin	26-29	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	55-60
32064609-7	2020	Perineural application of RTX caused downregulation of TRPV1, CGRP, and IB4 binding and upregulation of VIP in the corresponding DRG and the dorsal horn of the spinal cord.	resiniferatoxin	26-29	calcitonin-related polypeptide alpha	Rattus norvegicus	62-66
32064609-7	2020	Perineural application of RTX caused downregulation of TRPV1, CGRP, and IB4 binding and upregulation of VIP in the corresponding DRG and the dorsal horn of the spinal cord.	resiniferatoxin	26-29	vasoactive intestinal peptide	Rattus norvegicus	104-107
31757360-2	2020	TRPV1 can be activated by low extracellular pH, high temperature, or naturally occurring pungent molecules such as allicin, capsaicin, or resiniferatoxin.	resiniferatoxin	138-153	transient receptor potential cation channel subfamily V member 1	Homo sapiens	0-5
32345752-4	2020	Exogenous neuropeptides CGRP, SP, and VIP partially reversed Resiniferatoxin"s effects, with VIP specifically inducing IL-10 expression.	resiniferatoxin	61-76	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	24-28
32345752-4	2020	Exogenous neuropeptides CGRP, SP, and VIP partially reversed Resiniferatoxin"s effects, with VIP specifically inducing IL-10 expression.	resiniferatoxin	61-76	vasoactive intestinal polypeptide	Mus musculus	38-41
32292906-10	2020	We also propose to further explore the use of resiniferatoxin (RTX), an ultra-potent TRPV1 agonist currently in clinical trials for cancer and osteoarthritis pain, as a possible ablating agent of TRPV1 positive pulmonary pathways in patients with advanced COVID-19 disease.	resiniferatoxin	46-61	transient receptor potential cation channel subfamily V member 1	Homo sapiens	85-90
32292906-10	2020	We also propose to further explore the use of resiniferatoxin (RTX), an ultra-potent TRPV1 agonist currently in clinical trials for cancer and osteoarthritis pain, as a possible ablating agent of TRPV1 positive pulmonary pathways in patients with advanced COVID-19 disease.	resiniferatoxin	46-61	transient receptor potential cation channel subfamily V member 1	Homo sapiens	196-201
32292906-10	2020	We also propose to further explore the use of resiniferatoxin (RTX), an ultra-potent TRPV1 agonist currently in clinical trials for cancer and osteoarthritis pain, as a possible ablating agent of TRPV1 positive pulmonary pathways in patients with advanced COVID-19 disease.	resiniferatoxin	63-66	transient receptor potential cation channel subfamily V member 1	Homo sapiens	85-90
32292906-10	2020	We also propose to further explore the use of resiniferatoxin (RTX), an ultra-potent TRPV1 agonist currently in clinical trials for cancer and osteoarthritis pain, as a possible ablating agent of TRPV1 positive pulmonary pathways in patients with advanced COVID-19 disease.	resiniferatoxin	63-66	transient receptor potential cation channel subfamily V member 1	Homo sapiens	196-201
31926196-11	2020	The reserpine-induced mechanical allodynia and the thermal hyperalgesia were abolished by TRPV1-positive fibers desensitisation induced by previous resiniferatoxin (RTX) administration.	resiniferatoxin	148-163	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	90-95
31926196-11	2020	The reserpine-induced mechanical allodynia and the thermal hyperalgesia were abolished by TRPV1-positive fibers desensitisation induced by previous resiniferatoxin (RTX) administration.	resiniferatoxin	165-168	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	90-95
31076361-4	2020	A possible causative role of humoral immune response has paved the way to anti CD-20 monoclonal antibody (rituximab; RTX).	resiniferatoxin	117-120	keratin 20	Homo sapiens	79-84
31846438-5	2020	Using epicardial Resiniferatoxin (RTX) to deplete cardiac TRPV1-expressing fibers, we dissected the role of this neural circuit in VAs after chronic MI in a porcine model.	resiniferatoxin	34-37	transient receptor potential cation channel subfamily V member 1	Homo sapiens	58-63
31846438-7	2020	Epicardial RTX depleted cardiac TRPV1 afferent fibers and abolished functional responses to TRPV1 agonists.	resiniferatoxin	11-14	transient receptor potential cation channel subfamily V member 1	Homo sapiens	32-37
31846438-7	2020	Epicardial RTX depleted cardiac TRPV1 afferent fibers and abolished functional responses to TRPV1 agonists.	resiniferatoxin	11-14	transient receptor potential cation channel subfamily V member 1	Homo sapiens	92-97
31811858-1	2020	Excessive sympathetic activity is associated with heart failure and ventricular arrhythmias, which regulated by enhanced cardiac sympathetic afferent reflex, which can be blunted by resiniferatoxin, a selective receptor agonist of transient vanilloid potential 1 (TRPV1) + primary sensory afferents.	resiniferatoxin	182-197	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	264-269
31811858-5	2020	Intrathecal resiniferatoxin significantly and selectively abolished the afferent markers expression (TRPV1 and calcitonin gene-related peptide) in dorsal horn and reduced overactivated CSNA.	resiniferatoxin	12-27	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	101-106
31811858-7	2020	Moreover, the over-activated calcium handling related protein CaMKII and RyR2 in heart failure was reversed by resiniferatoxin administration.	resiniferatoxin	111-126	ryanodine receptor 2	Rattus norvegicus	73-77
31620023-10	2019	Direct injection of resiniferatoxin into trigeminal ganglia (TG) decreased TRPV1-expressing afferents by half in the targeted region of TG.	resiniferatoxin	20-35	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	75-80
33215551-2	2020	Nocifensive behaviors resulting from orthodontic force in mice can be substantially attenuated by intraganglionic injection of resiniferatoxin (RTX), a neurotoxin that specifically ablates a subset of neurons expressing transient receptor potential vanilloid 1 (TRPV1).	resiniferatoxin	127-142	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	220-260
33215551-2	2020	Nocifensive behaviors resulting from orthodontic force in mice can be substantially attenuated by intraganglionic injection of resiniferatoxin (RTX), a neurotoxin that specifically ablates a subset of neurons expressing transient receptor potential vanilloid 1 (TRPV1).	resiniferatoxin	127-142	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	262-267
33215551-2	2020	Nocifensive behaviors resulting from orthodontic force in mice can be substantially attenuated by intraganglionic injection of resiniferatoxin (RTX), a neurotoxin that specifically ablates a subset of neurons expressing transient receptor potential vanilloid 1 (TRPV1).	resiniferatoxin	144-147	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	220-260
33215551-2	2020	Nocifensive behaviors resulting from orthodontic force in mice can be substantially attenuated by intraganglionic injection of resiniferatoxin (RTX), a neurotoxin that specifically ablates a subset of neurons expressing transient receptor potential vanilloid 1 (TRPV1).	resiniferatoxin	144-147	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	262-267
33342372-3	2020	Resiniferatoxin is the most potent known agonist of TRPV1.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	52-57
33342372-4	2020	Acute exposure of the rat bladder to resiniferatoxin has been demonstrated to result in pain-related freezing and licking behaviors that are alleviated by virally encoded IL-4.	resiniferatoxin	37-52	interleukin 4	Rattus norvegicus	171-175
33342372-11	2020	RNA-Seq analysis of resiniferatoxin- and IPSE-exposed bladders revealed differential expression of TNF/NF-kappab-related signaling pathway genes.	resiniferatoxin	20-35	tumor necrosis factor	Mus musculus	99-102
33342372-11	2020	RNA-Seq analysis of resiniferatoxin- and IPSE-exposed bladders revealed differential expression of TNF/NF-kappab-related signaling pathway genes.	resiniferatoxin	20-35	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	103-112
31600641-10	2019	RESULTS: TRPV-1 was highly expressed in the TH-expressing neurons and RTX injection significantly ablated TRPV-1/TH-positive neurons in LSG.	resiniferatoxin	70-73	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	106-112
31600641-15	2019	RTX microinjection down-regulated significantly TRPV-1, NGF and c-fos expression in the LSG compared with the control group.	resiniferatoxin	0-3	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	48-54
31600641-15	2019	RTX microinjection down-regulated significantly TRPV-1, NGF and c-fos expression in the LSG compared with the control group.	resiniferatoxin	0-3	nerve growth factor	Canis lupus familiaris	56-59
31600641-16	2019	CONCLUSION: Targeted ablation of TRPV-1/TH positive sympathetic neurons induced by RTX stellate microinjection could suppress ischemia-induced cardiac autonomic imbalances and cardiac electrophysiology instability to protect against AMI-induced VAs.	resiniferatoxin	83-86	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	33-39
31732210-9	2019	Our observations revealed a negative correlation between the C/D ratio and creatinine concentration and a positive correlation between the C/D ratio and eGFR concentration long term after RTx.	resiniferatoxin	188-191	epidermal growth factor receptor	Homo sapiens	153-157
31263706-6	2019	TRPV1 can be activated by a large array of physical (heat, mechanical stimuli) and chemical factors (e.g., protons, capsaicin, resiniferatoxin, and endogenous ligands, such as endovanilloids).	resiniferatoxin	127-142	transient receptor potential cation channel subfamily V member 1	Homo sapiens	0-5
31399015-5	2019	Expert opinion: The therapeutic effect of TRPV1 channel desensitizing agonists (capsaicin, resiniferatoxin, given intravesically) has been convincingly demonstrated in some forms of bladder overactivity.	resiniferatoxin	91-106	transient receptor potential cation channel subfamily V member 1	Homo sapiens	42-47
31180583-1	2019	OBJECTIVES: To investigate if intravesical administration during spinal shock of resiniferatoxin (RTX), an ultrapotent desensitizing agonist of transient receptor potential vanilloid-1 (TRPV1), would silence TRPV1-expressing bladder afferents at an early stage of disease progression and modulate neurogenic detrusor overactivity (NDO) emergence.	resiniferatoxin	81-96	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	144-184
31180583-1	2019	OBJECTIVES: To investigate if intravesical administration during spinal shock of resiniferatoxin (RTX), an ultrapotent desensitizing agonist of transient receptor potential vanilloid-1 (TRPV1), would silence TRPV1-expressing bladder afferents at an early stage of disease progression and modulate neurogenic detrusor overactivity (NDO) emergence.	resiniferatoxin	81-96	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	186-191
31180583-1	2019	OBJECTIVES: To investigate if intravesical administration during spinal shock of resiniferatoxin (RTX), an ultrapotent desensitizing agonist of transient receptor potential vanilloid-1 (TRPV1), would silence TRPV1-expressing bladder afferents at an early stage of disease progression and modulate neurogenic detrusor overactivity (NDO) emergence.	resiniferatoxin	81-96	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	208-213
31180583-1	2019	OBJECTIVES: To investigate if intravesical administration during spinal shock of resiniferatoxin (RTX), an ultrapotent desensitizing agonist of transient receptor potential vanilloid-1 (TRPV1), would silence TRPV1-expressing bladder afferents at an early stage of disease progression and modulate neurogenic detrusor overactivity (NDO) emergence.	resiniferatoxin	98-101	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	144-184
31180583-1	2019	OBJECTIVES: To investigate if intravesical administration during spinal shock of resiniferatoxin (RTX), an ultrapotent desensitizing agonist of transient receptor potential vanilloid-1 (TRPV1), would silence TRPV1-expressing bladder afferents at an early stage of disease progression and modulate neurogenic detrusor overactivity (NDO) emergence.	resiniferatoxin	98-101	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	186-191
31090543-5	2019	Here, we employ cryo-EM to elucidate the structure of full-length rabbit TRPV2 in complex with the agonist resiniferatoxin (RTx) in nanodiscs and amphipol.	resiniferatoxin	107-122	transient receptor potential cation channel subfamily V member 2	Homo sapiens	73-78
31090543-5	2019	Here, we employ cryo-EM to elucidate the structure of full-length rabbit TRPV2 in complex with the agonist resiniferatoxin (RTx) in nanodiscs and amphipol.	resiniferatoxin	124-127	transient receptor potential cation channel subfamily V member 2	Homo sapiens	73-78
31090543-6	2019	We show that RTx induces two-fold symmetric conformations of TRPV2 in both environments.	resiniferatoxin	13-16	transient receptor potential cation channel subfamily V member 2	Homo sapiens	61-66
30499116-5	2019	In cystometry, intercontraction intervals (ICI) after resiniferatoxin (RTx; TRPV1 agonist) irrigation was significantly reduced in the PP1alpha group in comparison with the GFP group.	resiniferatoxin	54-69	protein phosphatase 1 catalytic subunit alpha	Rattus norvegicus	135-143
31118749-8	2019	Also, treatment with 2 Hz EA reduced the protein levels of DCC and Netrin-1 and promoted the expression of UNC5H2 in the spinal dorsal horn 42 days after RTX injection.	resiniferatoxin	154-157	unc-5 netrin receptor B	Homo sapiens	107-113
31118749-10	2019	In addition, morphine inhibited the Netrin-1 protein level induced by RTX in SH-SY5Y cells.	resiniferatoxin	70-73	netrin 1	Homo sapiens	36-44
30576973-1	2019	Resiniferatoxin (RTX) is a daphnane diterpene isolated from the latex of Euphorbia resinifera O. Berg, a potent activator of transient receptor potential vanilloid 1 (TrpV1), with a potency 103-105 times greater than pure capsaicin.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	125-165
30576973-1	2019	Resiniferatoxin (RTX) is a daphnane diterpene isolated from the latex of Euphorbia resinifera O. Berg, a potent activator of transient receptor potential vanilloid 1 (TrpV1), with a potency 103-105 times greater than pure capsaicin.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	167-172
30576973-1	2019	Resiniferatoxin (RTX) is a daphnane diterpene isolated from the latex of Euphorbia resinifera O. Berg, a potent activator of transient receptor potential vanilloid 1 (TrpV1), with a potency 103-105 times greater than pure capsaicin.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	125-165
30576973-1	2019	Resiniferatoxin (RTX) is a daphnane diterpene isolated from the latex of Euphorbia resinifera O. Berg, a potent activator of transient receptor potential vanilloid 1 (TrpV1), with a potency 103-105 times greater than pure capsaicin.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	167-172
30668375-10	2019	RESULTS: Eta inhibited the TRPA1 agonist-induced Ca2+ influx [Imax = 72.4 +- 1.5%; IC50 = 0.023(0.004-0.125)microg/ml], but not TRPV1 agonist-induced, nor was able to displace [3H]-resiniferatoxin (TRPV1 agonist) binding.	resiniferatoxin	181-196	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	27-32
30341789-1	2019	Desensitization with RTX has been broadly introduced in adult LT across the ABO blood type barrier.	resiniferatoxin	21-24	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	76-79
30499116-5	2019	In cystometry, intercontraction intervals (ICI) after resiniferatoxin (RTx; TRPV1 agonist) irrigation was significantly reduced in the PP1alpha group in comparison with the GFP group.	resiniferatoxin	71-74	protein phosphatase 1 catalytic subunit alpha	Rattus norvegicus	135-143
30499116-6	2019	Moreover, RTx-induced freezing behavior events were observed significantly more frequently in the PP1alpha group than the GFP group.	resiniferatoxin	10-13	protein phosphatase 1 catalytic subunit alpha	Rattus norvegicus	98-106
30761069-6	2019	Moreover, the anti-inflammatory effect of TRPV1 activation was confirmed by another TRPV1 agonist, the resiniferatoxin (RTX), whose effects were significantly inhibited by the TRPV1 antagonist, 5-iodoresiniferatoxin (5-IRTX).	resiniferatoxin	103-118	transient receptor potential cation channel subfamily V member 1	Homo sapiens	42-47
30761069-6	2019	Moreover, the anti-inflammatory effect of TRPV1 activation was confirmed by another TRPV1 agonist, the resiniferatoxin (RTX), whose effects were significantly inhibited by the TRPV1 antagonist, 5-iodoresiniferatoxin (5-IRTX).	resiniferatoxin	103-118	transient receptor potential cation channel subfamily V member 1	Homo sapiens	84-89
30761069-6	2019	Moreover, the anti-inflammatory effect of TRPV1 activation was confirmed by another TRPV1 agonist, the resiniferatoxin (RTX), whose effects were significantly inhibited by the TRPV1 antagonist, 5-iodoresiniferatoxin (5-IRTX).	resiniferatoxin	103-118	transient receptor potential cation channel subfamily V member 1	Homo sapiens	84-89
30761069-6	2019	Moreover, the anti-inflammatory effect of TRPV1 activation was confirmed by another TRPV1 agonist, the resiniferatoxin (RTX), whose effects were significantly inhibited by the TRPV1 antagonist, 5-iodoresiniferatoxin (5-IRTX).	resiniferatoxin	120-123	transient receptor potential cation channel subfamily V member 1	Homo sapiens	42-47
30761069-6	2019	Moreover, the anti-inflammatory effect of TRPV1 activation was confirmed by another TRPV1 agonist, the resiniferatoxin (RTX), whose effects were significantly inhibited by the TRPV1 antagonist, 5-iodoresiniferatoxin (5-IRTX).	resiniferatoxin	120-123	transient receptor potential cation channel subfamily V member 1	Homo sapiens	84-89
30761069-6	2019	Moreover, the anti-inflammatory effect of TRPV1 activation was confirmed by another TRPV1 agonist, the resiniferatoxin (RTX), whose effects were significantly inhibited by the TRPV1 antagonist, 5-iodoresiniferatoxin (5-IRTX).	resiniferatoxin	120-123	transient receptor potential cation channel subfamily V member 1	Homo sapiens	84-89
30378153-1	2018	Hyperthermia enhances the anticancer effects of thymidylate synthase (TYMS) inhibitors (raltitrexed, RTX) and improves the precise biochemical mechanisms partially through enhancement of intracellular drug absorption.	resiniferatoxin	101-104	thymidylate synthetase	Homo sapiens	48-68
30713498-11	2018	Rtx (especially in low dose) brought further increase of persistent T cell activation (CD38+ T cells made up 79%).	resiniferatoxin	0-3	CD38 molecule	Homo sapiens	87-91
30644819-3	2019	It was recently discovered that four mutations in TRPV2 are sufficient to render the channel sensitive to the TRPV1-specific vanilloid agonist resiniferatoxin (RTx).	resiniferatoxin	143-158	transient receptor potential cation channel subfamily V member 2	Homo sapiens	50-55
30644819-3	2019	It was recently discovered that four mutations in TRPV2 are sufficient to render the channel sensitive to the TRPV1-specific vanilloid agonist resiniferatoxin (RTx).	resiniferatoxin	143-158	transient receptor potential cation channel subfamily V member 1	Homo sapiens	110-115
30644819-3	2019	It was recently discovered that four mutations in TRPV2 are sufficient to render the channel sensitive to the TRPV1-specific vanilloid agonist resiniferatoxin (RTx).	resiniferatoxin	160-163	transient receptor potential cation channel subfamily V member 2	Homo sapiens	50-55
30644819-3	2019	It was recently discovered that four mutations in TRPV2 are sufficient to render the channel sensitive to the TRPV1-specific vanilloid agonist resiniferatoxin (RTx).	resiniferatoxin	160-163	transient receptor potential cation channel subfamily V member 1	Homo sapiens	110-115
30399572-1	2019	Resiniferatoxin (RTX), a selective transient receptor potential vanilloid 1 (TRPV1) receptor agonist, can eliminate TRPV1+ primary sensory afferents and blunt cardiac sympathetic afferent reflex for a relatively long period.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	35-75
30399572-1	2019	Resiniferatoxin (RTX), a selective transient receptor potential vanilloid 1 (TRPV1) receptor agonist, can eliminate TRPV1+ primary sensory afferents and blunt cardiac sympathetic afferent reflex for a relatively long period.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	77-82
30399572-1	2019	Resiniferatoxin (RTX), a selective transient receptor potential vanilloid 1 (TRPV1) receptor agonist, can eliminate TRPV1+ primary sensory afferents and blunt cardiac sympathetic afferent reflex for a relatively long period.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	116-121
30399572-1	2019	Resiniferatoxin (RTX), a selective transient receptor potential vanilloid 1 (TRPV1) receptor agonist, can eliminate TRPV1+ primary sensory afferents and blunt cardiac sympathetic afferent reflex for a relatively long period.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	35-75
30399572-1	2019	Resiniferatoxin (RTX), a selective transient receptor potential vanilloid 1 (TRPV1) receptor agonist, can eliminate TRPV1+ primary sensory afferents and blunt cardiac sympathetic afferent reflex for a relatively long period.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	77-82
30399572-1	2019	Resiniferatoxin (RTX), a selective transient receptor potential vanilloid 1 (TRPV1) receptor agonist, can eliminate TRPV1+ primary sensory afferents and blunt cardiac sympathetic afferent reflex for a relatively long period.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	116-121
30399572-5	2019	Intrathecal RTX administration abolished TRPV1 expression in the dorsal horn and reduced over-activated CSNA in the TAC rat model.	resiniferatoxin	12-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	41-46
30086116-2	2018	We recently demonstrated that candesartan, an angiotensin II type 1 receptor antagonist, was neuroprotective against resiniferatoxin-induced sensory neuropathy, and that this effect is mediated by stimulation of the angiotensin II type 2 receptor (AT2R).	resiniferatoxin	117-132	angiotensin II receptor, type 2	Mus musculus	216-246
30378153-1	2018	Hyperthermia enhances the anticancer effects of thymidylate synthase (TYMS) inhibitors (raltitrexed, RTX) and improves the precise biochemical mechanisms partially through enhancement of intracellular drug absorption.	resiniferatoxin	101-104	thymidylate synthetase	Homo sapiens	70-74
30378153-7	2018	The addition of 17-AAG increased the activation of antioxidant with increased antioxidant enzymes, thus affecting the RTX efficacy.	resiniferatoxin	118-121	N-methylpurine DNA glycosylase	Homo sapiens	19-22
29746471-7	2018	We previously showed that although schistosomes contain no genes predicted to encode TRPV channels, TRPV1-selective activators such as capsaicin and resiniferatoxin elicit dramatic hyperactivity in adult worms and schistosomula.	resiniferatoxin	149-164	transient receptor potential cation channel subfamily V member 1	Homo sapiens	100-105
30013196-3	2018	A graph of IL-6 levels should be shown in place of the duplication.These results were also incorrectly described in the main text, which originally stated: "At an early time point of infection (6 h), RTX-treated mice showed higher induction of total inflammatory-protein levels in the bronchoalveolar lavage fluid (BALF) (Fig.	resiniferatoxin	200-203	interleukin 6	Mus musculus	11-15
30173779-4	2018	This study used resiniferatoxin (RTX), an ultrapotent analog of capsaicin, to generate a mouse model of SFN, leading to marked hindpaw edema (p = 0.013) and parallel the release of TNFalpha (p = 0.014), which was associated with the upregulation of Ret(+) neurons (p = 0.0043) and partial depletion of TNFR1 caused by colocalization with TRPV1 depleted by RTX.	resiniferatoxin	16-31	RNA exonuclease 2	Mus musculus	104-107
30173779-4	2018	This study used resiniferatoxin (RTX), an ultrapotent analog of capsaicin, to generate a mouse model of SFN, leading to marked hindpaw edema (p = 0.013) and parallel the release of TNFalpha (p = 0.014), which was associated with the upregulation of Ret(+) neurons (p = 0.0043) and partial depletion of TNFR1 caused by colocalization with TRPV1 depleted by RTX.	resiniferatoxin	16-31	tumor necrosis factor	Mus musculus	181-189
30173779-4	2018	This study used resiniferatoxin (RTX), an ultrapotent analog of capsaicin, to generate a mouse model of SFN, leading to marked hindpaw edema (p = 0.013) and parallel the release of TNFalpha (p = 0.014), which was associated with the upregulation of Ret(+) neurons (p = 0.0043) and partial depletion of TNFR1 caused by colocalization with TRPV1 depleted by RTX.	resiniferatoxin	16-31	ret proto-oncogene	Mus musculus	249-252
30173779-4	2018	This study used resiniferatoxin (RTX), an ultrapotent analog of capsaicin, to generate a mouse model of SFN, leading to marked hindpaw edema (p = 0.013) and parallel the release of TNFalpha (p = 0.014), which was associated with the upregulation of Ret(+) neurons (p = 0.0043) and partial depletion of TNFR1 caused by colocalization with TRPV1 depleted by RTX.	resiniferatoxin	16-31	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	302-307
30173779-4	2018	This study used resiniferatoxin (RTX), an ultrapotent analog of capsaicin, to generate a mouse model of SFN, leading to marked hindpaw edema (p = 0.013) and parallel the release of TNFalpha (p = 0.014), which was associated with the upregulation of Ret(+) neurons (p = 0.0043) and partial depletion of TNFR1 caused by colocalization with TRPV1 depleted by RTX.	resiniferatoxin	16-31	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	338-343
30173779-4	2018	This study used resiniferatoxin (RTX), an ultrapotent analog of capsaicin, to generate a mouse model of SFN, leading to marked hindpaw edema (p = 0.013) and parallel the release of TNFalpha (p = 0.014), which was associated with the upregulation of Ret(+) neurons (p = 0.0043) and partial depletion of TNFR1 caused by colocalization with TRPV1 depleted by RTX.	resiniferatoxin	33-36	RNA exonuclease 2	Mus musculus	104-107
30173779-4	2018	This study used resiniferatoxin (RTX), an ultrapotent analog of capsaicin, to generate a mouse model of SFN, leading to marked hindpaw edema (p = 0.013) and parallel the release of TNFalpha (p = 0.014), which was associated with the upregulation of Ret(+) neurons (p = 0.0043) and partial depletion of TNFR1 caused by colocalization with TRPV1 depleted by RTX.	resiniferatoxin	33-36	tumor necrosis factor	Mus musculus	181-189
30173779-4	2018	This study used resiniferatoxin (RTX), an ultrapotent analog of capsaicin, to generate a mouse model of SFN, leading to marked hindpaw edema (p = 0.013) and parallel the release of TNFalpha (p = 0.014), which was associated with the upregulation of Ret(+) neurons (p = 0.0043) and partial depletion of TNFR1 caused by colocalization with TRPV1 depleted by RTX.	resiniferatoxin	33-36	ret proto-oncogene	Mus musculus	249-252
30173779-4	2018	This study used resiniferatoxin (RTX), an ultrapotent analog of capsaicin, to generate a mouse model of SFN, leading to marked hindpaw edema (p = 0.013) and parallel the release of TNFalpha (p = 0.014), which was associated with the upregulation of Ret(+) neurons (p = 0.0043) and partial depletion of TNFR1 caused by colocalization with TRPV1 depleted by RTX.	resiniferatoxin	33-36	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	302-307
30173779-4	2018	This study used resiniferatoxin (RTX), an ultrapotent analog of capsaicin, to generate a mouse model of SFN, leading to marked hindpaw edema (p = 0.013) and parallel the release of TNFalpha (p = 0.014), which was associated with the upregulation of Ret(+) neurons (p = 0.0043) and partial depletion of TNFR1 caused by colocalization with TRPV1 depleted by RTX.	resiniferatoxin	33-36	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	338-343
30186108-6	2018	The resulting neurons elicited action potentials after current injection and released substance P (SP) in response to nociceptive agents such as anandamide and resiniferatoxin.	resiniferatoxin	160-175	tachykinin precursor 1	Homo sapiens	86-97
29577893-9	2018	In addition, TRPV1-positive sensory fibre ablation (using resiniferatoxin, 200 microg/kg, s.c.) reduced visceral nociception and mechanical or heat hypersensitivity caused by paclitaxel injection.	resiniferatoxin	58-73	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	13-18
29906340-9	2018	In order to further confirm the origin of this reflex, epidural application of a selective afferent neurotoxin (resiniferatoxin, RTX) was used to chronically ablate thoracic TRPV1-expressing afferent soma at the level of T1-T4 dorsal root ganglia pleura.	resiniferatoxin	112-127	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	174-179
29906340-9	2018	In order to further confirm the origin of this reflex, epidural application of a selective afferent neurotoxin (resiniferatoxin, RTX) was used to chronically ablate thoracic TRPV1-expressing afferent soma at the level of T1-T4 dorsal root ganglia pleura.	resiniferatoxin	129-132	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	174-179
30015705-0	2018	Long-term pain relief in canine osteoarthritis by a single intra-articular injection of resiniferatoxin, a potent TRPV1 agonist.	resiniferatoxin	88-103	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	114-119
30015705-2	2018	We report on a peripheral interventional approach that uses intra-articular injection of the ultrapotent TRPV1 agonist resiniferatoxin (RTX) to produce a selective long-term chemoinactivation of nociceptive primary afferent nerve endings for pain control in naturally occurring canine osteoarthritis.	resiniferatoxin	119-134	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	105-110
30015705-2	2018	We report on a peripheral interventional approach that uses intra-articular injection of the ultrapotent TRPV1 agonist resiniferatoxin (RTX) to produce a selective long-term chemoinactivation of nociceptive primary afferent nerve endings for pain control in naturally occurring canine osteoarthritis.	resiniferatoxin	136-139	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	105-110
30006640-0	2018	Selective ablation of TRPV1 by intrathecal injection of resiniferatoxin in rats increases renal sympathoexcitatory responses and salt sensitivity.	resiniferatoxin	56-71	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	22-27
30006640-1	2018	This study tested the hypothesis that selective ablation of transient receptor potential vanilloid type 1 (TRPV1)-positive nerve fibers by intrathecal injection of resiniferatoxin (RTX) enhances renal sympathoexcitatory responses and salt sensitivity.	resiniferatoxin	164-179	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	60-105
30006640-1	2018	This study tested the hypothesis that selective ablation of transient receptor potential vanilloid type 1 (TRPV1)-positive nerve fibers by intrathecal injection of resiniferatoxin (RTX) enhances renal sympathoexcitatory responses and salt sensitivity.	resiniferatoxin	164-179	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	107-112
30006640-1	2018	This study tested the hypothesis that selective ablation of transient receptor potential vanilloid type 1 (TRPV1)-positive nerve fibers by intrathecal injection of resiniferatoxin (RTX) enhances renal sympathoexcitatory responses and salt sensitivity.	resiniferatoxin	181-184	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	60-105
30006640-1	2018	This study tested the hypothesis that selective ablation of transient receptor potential vanilloid type 1 (TRPV1)-positive nerve fibers by intrathecal injection of resiniferatoxin (RTX) enhances renal sympathoexcitatory responses and salt sensitivity.	resiniferatoxin	181-184	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	107-112
30006640-7	2018	GAD65/67, a GABA synthetase, in the spinal cord was downregulated and tyrosine hydroxylase in the kidney upregulated in NS or HS rats treated with RTX (P &lt; 0.05).	resiniferatoxin	147-150	glutamate decarboxylase 2	Rattus norvegicus	0-5
29590555-5	2018	Pretreatment of NTS with the TRPV1 antagonist capsazepine prevented these resiniferatoxin-mediated effects.	resiniferatoxin	74-89	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	29-34
29580951-8	2018	The in vivo ablation of TRPV1-expressing neurons with resiniferatoxin did not alter IB4+ neurons in the DRG, mechanical nociception, or the effects of sigma-1 antagonism on local morphine antinociception in this type of stimulus.	resiniferatoxin	54-69	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	24-29
29452097-6	2018	We identified the AP-1 DNA binding site as the capsaicin/resiniferatoxin-responsive element.	resiniferatoxin	57-72	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	18-22
29728656-4	2018	Here, we determined two crystal structures of rabbit TRPV2 in its Ca2+-bound and resiniferatoxin (RTx)- and Ca2+-bound forms, to 3.9 A and 3.1 A, respectively.	resiniferatoxin	81-96	transient receptor potential cation channel subfamily V member 2	Oryctolagus cuniculus	53-58
29728656-4	2018	Here, we determined two crystal structures of rabbit TRPV2 in its Ca2+-bound and resiniferatoxin (RTx)- and Ca2+-bound forms, to 3.9 A and 3.1 A, respectively.	resiniferatoxin	98-101	transient receptor potential cation channel subfamily V member 2	Oryctolagus cuniculus	53-58
29888571-1	2018	OBJECTIVE: To observe the effect of different frequencies of electroacupuncture (EA) stimulation on pain threshold (PT) and expression of vascular endothelial growth factor (VEGF) in dorsal horns (DHs) of the lumbar spinal cord in resiniferatoxin (RTX)-induced post-herpetic neuralgia (PHN) rats, so as to reveal its mechanism in alleviating PHN.	resiniferatoxin	231-246	vascular endothelial growth factor A	Rattus norvegicus	138-172
29888571-10	2018	RTX administration increased the mRNA and protein expression of VEGF in the lumbar spinal cord compared with the control group (P&lt;0.	resiniferatoxin	0-3	vascular endothelial growth factor A	Rattus norvegicus	64-68
29408808-3	2018	Resiniferatoxin (RTX) is a very potent and selective TRPV1 agonist and is a promising candidate for treating many types of pain.	resiniferatoxin	0-15	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	53-58
29408808-3	2018	Resiniferatoxin (RTX) is a very potent and selective TRPV1 agonist and is a promising candidate for treating many types of pain.	resiniferatoxin	17-20	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	53-58
29452097-8	2018	Stimulation of TRPV1 channels induced an influx of Ca2+ into the cells and this rise in intracellular Ca2+ was essential for activating AP-1 in capsaicin or resiniferatoxin-stimulated cells.	resiniferatoxin	157-172	transient receptor potential cation channel subfamily V member 1	Homo sapiens	15-20
29452097-8	2018	Stimulation of TRPV1 channels induced an influx of Ca2+ into the cells and this rise in intracellular Ca2+ was essential for activating AP-1 in capsaicin or resiniferatoxin-stimulated cells.	resiniferatoxin	157-172	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	136-140
29271803-4	2018	METHODS: Resiniferatoxin was injected subcutaneously into rat hind paw several minutes before surgical incision to inactivate transient receptor potential cation channel, subfamily V, member 1-positive nerve terminals.	resiniferatoxin	9-24	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	126-192
29350427-6	2018	RESULTS: In comparison with the control group, the colitis group showed significant increases in (1) micturition frequency during cystometry; (2) resiniferatoxin-induced freezing behavior (bladder pain); (3) the number of total and degranulated mast cells in the bladder; (4) the number of microglia in the L6 spinal cord, and (5) the expression of IL-1beta, CCL3, and BDNF mRNA in the L6 spinal cord.	resiniferatoxin	146-161	interleukin 1 beta	Rattus norvegicus	349-357
29350427-6	2018	RESULTS: In comparison with the control group, the colitis group showed significant increases in (1) micturition frequency during cystometry; (2) resiniferatoxin-induced freezing behavior (bladder pain); (3) the number of total and degranulated mast cells in the bladder; (4) the number of microglia in the L6 spinal cord, and (5) the expression of IL-1beta, CCL3, and BDNF mRNA in the L6 spinal cord.	resiniferatoxin	146-161	C-C motif chemokine ligand 3	Rattus norvegicus	359-363
29350427-6	2018	RESULTS: In comparison with the control group, the colitis group showed significant increases in (1) micturition frequency during cystometry; (2) resiniferatoxin-induced freezing behavior (bladder pain); (3) the number of total and degranulated mast cells in the bladder; (4) the number of microglia in the L6 spinal cord, and (5) the expression of IL-1beta, CCL3, and BDNF mRNA in the L6 spinal cord.	resiniferatoxin	146-161	brain-derived neurotrophic factor	Rattus norvegicus	369-373
29553496-4	2018	This protocol describes an experimental model of small fiber neuropathy specifically affecting small-diameter sensory nerves with resiniferatoxin (RTX), an ultrapotent agonist of transient receptor potential vanilloid type 1 (TRPV1), through a single dose of intraperitoneal injection, referred to as RTX neuropathy.	resiniferatoxin	130-145	transient receptor potential cation channel subfamily V member 1	Homo sapiens	179-224
29361418-1	2018	OBJECTIVE: To evaluate target engagement of intracisternally (IC) delivered TRPV1 agonist, resiniferatoxin (RTX), as measured by primary afferent and dorsal horn substance P immunoreactivity (sP-IR), histopathology and thermal escape latencies in dogs.	resiniferatoxin	91-106	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	76-81
29361418-1	2018	OBJECTIVE: To evaluate target engagement of intracisternally (IC) delivered TRPV1 agonist, resiniferatoxin (RTX), as measured by primary afferent and dorsal horn substance P immunoreactivity (sP-IR), histopathology and thermal escape latencies in dogs.	resiniferatoxin	108-111	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	76-81
29553496-4	2018	This protocol describes an experimental model of small fiber neuropathy specifically affecting small-diameter sensory nerves with resiniferatoxin (RTX), an ultrapotent agonist of transient receptor potential vanilloid type 1 (TRPV1), through a single dose of intraperitoneal injection, referred to as RTX neuropathy.	resiniferatoxin	130-145	transient receptor potential cation channel subfamily V member 1	Homo sapiens	226-231
29553496-4	2018	This protocol describes an experimental model of small fiber neuropathy specifically affecting small-diameter sensory nerves with resiniferatoxin (RTX), an ultrapotent agonist of transient receptor potential vanilloid type 1 (TRPV1), through a single dose of intraperitoneal injection, referred to as RTX neuropathy.	resiniferatoxin	147-150	transient receptor potential cation channel subfamily V member 1	Homo sapiens	179-224
29553496-4	2018	This protocol describes an experimental model of small fiber neuropathy specifically affecting small-diameter sensory nerves with resiniferatoxin (RTX), an ultrapotent agonist of transient receptor potential vanilloid type 1 (TRPV1), through a single dose of intraperitoneal injection, referred to as RTX neuropathy.	resiniferatoxin	147-150	transient receptor potential cation channel subfamily V member 1	Homo sapiens	226-231
29106982-0	2018	Distinct TrkA and Ret modulated negative and positive neuropathic behaviors in a mouse model of resiniferatoxin-induced small fiber neuropathy.	resiniferatoxin	96-111	neurotrophic tyrosine kinase, receptor, type 1	Mus musculus	9-13
29106982-0	2018	Distinct TrkA and Ret modulated negative and positive neuropathic behaviors in a mouse model of resiniferatoxin-induced small fiber neuropathy.	resiniferatoxin	96-111	ret proto-oncogene	Mus musculus	18-21
29128836-4	2018	In this study, we fabricated liposome consisting of superparamagnetic iron oxide nanoparticles (SPIONs) functionalized with anti-CD20 (Rituximab; RTX).	resiniferatoxin	146-149	keratin 20	Homo sapiens	129-133
29317663-8	2018	TRPV1 modulates P2X mediated afferent responses and provides a mechanistic basis for the decrease in sensory symptoms observed following resiniferatoxin and capsaicin treatment for lower urinary tract symptoms.	resiniferatoxin	137-152	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	0-5
28960473-6	2018	The proportion of CD5+ B cells increased (P &lt; .01) and CD27+ memory B cells decreased (P &lt; .05) 12 months after treatment with RTX+DXM compared to baseline, with an inverse correlation between platelet numbers and the proportion of CD27+ B cells (R = -0.71; P &lt; .05).	resiniferatoxin	133-136	CD5 molecule	Homo sapiens	18-21
29298646-1	2018	BACKGROUND: The calcineurin inhibitor tacrolimus (Tac) is an integral part of the standard immunosuppressive regimen after renal transplantation (RTx).	resiniferatoxin	146-149	calcineurin binding protein 1	Homo sapiens	16-37
28960473-6	2018	The proportion of CD5+ B cells increased (P &lt; .01) and CD27+ memory B cells decreased (P &lt; .05) 12 months after treatment with RTX+DXM compared to baseline, with an inverse correlation between platelet numbers and the proportion of CD27+ B cells (R = -0.71; P &lt; .05).	resiniferatoxin	133-136	CD27 molecule	Homo sapiens	58-62
28960473-6	2018	The proportion of CD5+ B cells increased (P &lt; .01) and CD27+ memory B cells decreased (P &lt; .05) 12 months after treatment with RTX+DXM compared to baseline, with an inverse correlation between platelet numbers and the proportion of CD27+ B cells (R = -0.71; P &lt; .05).	resiniferatoxin	133-136	CD27 molecule	Homo sapiens	238-242
28960473-8	2018	The additional increase in CD5+ B cells after RTX+DXM is compatible with induction of Bregs.	resiniferatoxin	46-49	CD5 molecule	Homo sapiens	27-30
28945920-7	2017	The TRPV1-specific agonists capsaicin and resiniferatoxin did not affect the intracellular Ca2+ concentration.	resiniferatoxin	42-57	transient receptor potential cation channel subfamily V member 1	Homo sapiens	4-9
29041773-1	2017	Resiniferatoxin (1) belongs to a daphnane diterpenoid family and has strong agonistic effects on TRPV1, a transducer of noxious temperature and chemical stimuli.	resiniferatoxin	0-15	transient receptor potential cation channel subfamily V member 1	Homo sapiens	97-102
29129206-5	2017	While activation of TRPV1 by the vanilloids capsaicin, resiniferatoxin and anandamide results in calcium-dependent cell death, activation by protons and the oxidant chloramine-T failed to reduce cell viability.	resiniferatoxin	55-70	transient receptor potential cation channel subfamily V member 1	Homo sapiens	20-25
27794548-3	2017	We hypothesized that local injection of the TRPV1 agonist resiniferatoxin (RTX) would produce long-lasting analgesia in a rat model of pain associated with burn injury.	resiniferatoxin	58-73	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	44-49
27794548-3	2017	We hypothesized that local injection of the TRPV1 agonist resiniferatoxin (RTX) would produce long-lasting analgesia in a rat model of pain associated with burn injury.	resiniferatoxin	75-78	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	44-49
27794548-9	2017	At one week following RTX, decreased c-Fos and primary afferent neuropeptide immunoreactivities were observed in the dorsal horn, while plantar burn pathology was unaltered.	resiniferatoxin	22-25	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	37-42
28865353-5	2017	RESULTS: ET-1 induced facial heat hyperalgesia that persisted up to 6h and was prevented by BQ-123, BQ-788 or by intraganglionar RTX injection.	resiniferatoxin	129-132	endothelin 1	Rattus norvegicus	9-13
28440948-2	2017	The RDMN was fabricated by self-assembling of amphiphilic RTX-DOX conjugates (RDCs), which were synthesized by conjugating the hydrophilic Fab fragments of RTX (an anti-CD20 monoclonal antibody) and hydrophobic DOXs by a reduction-responsive linker, 3-(2-Pyridyldithio) propionyl hydrazide (PDPH).	resiniferatoxin	58-61	FA complementation group B	Homo sapiens	139-142
28440948-2	2017	The RDMN was fabricated by self-assembling of amphiphilic RTX-DOX conjugates (RDCs), which were synthesized by conjugating the hydrophilic Fab fragments of RTX (an anti-CD20 monoclonal antibody) and hydrophobic DOXs by a reduction-responsive linker, 3-(2-Pyridyldithio) propionyl hydrazide (PDPH).	resiniferatoxin	58-61	keratin 20	Homo sapiens	169-173
28882562-0	2017	Candesartan prevents resiniferatoxin-induced sensory small-fiber neuropathy in mice by promoting angiotensin II-mediated AT2 receptor stimulation.	resiniferatoxin	21-36	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	97-111
28882562-4	2017	Here, we aimed to determine whether the modulation of angiotensin II (Ang II) activity could prevent sensory neuropathy induced by RTX.	resiniferatoxin	131-134	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	54-68
28882562-4	2017	Here, we aimed to determine whether the modulation of angiotensin II (Ang II) activity could prevent sensory neuropathy induced by RTX.	resiniferatoxin	131-134	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	70-76
27976413-2	2017	TRPV1 receptors function as homotetramers responsive to heat, proinflammatory substances, lipoxygenase products, resiniferatoxin, endocannabinoids, protons, and peptide toxins.	resiniferatoxin	113-128	transient receptor potential cation channel subfamily V member 1	Homo sapiens	0-5
28892388-2	2017	While radiolabeled resiniferatoxin (RTX) has provided a powerful tool for characterization of vanilloid binding to TRPV1, TRPV1 shows 20-fold weaker binding to the human TRPV1 than to the rodent TRPV1.	resiniferatoxin	19-34	transient receptor potential cation channel subfamily V member 1	Homo sapiens	115-120
28892388-2	2017	While radiolabeled resiniferatoxin (RTX) has provided a powerful tool for characterization of vanilloid binding to TRPV1, TRPV1 shows 20-fold weaker binding to the human TRPV1 than to the rodent TRPV1.	resiniferatoxin	36-39	transient receptor potential cation channel subfamily V member 1	Homo sapiens	115-120
28760650-7	2017	Finally, ruthenium red (a nonselective TRP antagonist) or the in vivo ablation of TRPV1-expressing neurons with resiniferatoxin abolished tactile allodynia without altering grip strength deficits, indicating that the neurobiology of tactile allodynia and grip strength deficits differ.	resiniferatoxin	112-127	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	82-87
28963471-4	2017	treatment with an ultrapotent TRPV1 agonist, resiniferatoxin (RTX), on nociception and the analgesic effect of acetaminophen, which is known to mediate the activation of central TRPV1.	resiniferatoxin	62-65	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	30-35
28963471-4	2017	treatment with an ultrapotent TRPV1 agonist, resiniferatoxin (RTX), on nociception and the analgesic effect of acetaminophen, which is known to mediate the activation of central TRPV1.	resiniferatoxin	62-65	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	178-183
28963471-10	2017	administration of RTX leads to brain-selective TRPV1 desensitization in mice.	resiniferatoxin	18-21	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	47-52
28444833-4	2017	METHOD: Capsaicin-sensitive neurones were desensitized by the capsaicin analogue resiniferatoxin (RTX) in CD1 mice.	resiniferatoxin	81-96	CD1 antigen complex	Mus musculus	106-109
28444833-4	2017	METHOD: Capsaicin-sensitive neurones were desensitized by the capsaicin analogue resiniferatoxin (RTX) in CD1 mice.	resiniferatoxin	98-101	CD1 antigen complex	Mus musculus	106-109
28963471-0	2017	Supraspinal-selective TRPV1 desensitization induced by intracerebroventricular treatment with resiniferatoxin.	resiniferatoxin	94-109	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	22-27
28963471-4	2017	treatment with an ultrapotent TRPV1 agonist, resiniferatoxin (RTX), on nociception and the analgesic effect of acetaminophen, which is known to mediate the activation of central TRPV1.	resiniferatoxin	45-60	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	30-35
28963471-4	2017	treatment with an ultrapotent TRPV1 agonist, resiniferatoxin (RTX), on nociception and the analgesic effect of acetaminophen, which is known to mediate the activation of central TRPV1.	resiniferatoxin	45-60	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	178-183
28626428-7	2017	One intrathecal resiniferatoxin (RTX) dose allows for the receptor-mediated removal of TRPV1+ neurons from the peripheral nervous system.	resiniferatoxin	16-31	transient receptor potential cation channel subfamily V member 1	Homo sapiens	87-92
28626428-7	2017	One intrathecal resiniferatoxin (RTX) dose allows for the receptor-mediated removal of TRPV1+ neurons from the peripheral nervous system.	resiniferatoxin	33-36	transient receptor potential cation channel subfamily V member 1	Homo sapiens	87-92
29369297-3	2017	Resiniferatoxin (RTX) is an ultrapotent synthetic TRPV1 agonist and many different administration routes are available for different mechanisms and different effects.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	50-55
29369297-3	2017	Resiniferatoxin (RTX) is an ultrapotent synthetic TRPV1 agonist and many different administration routes are available for different mechanisms and different effects.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	50-55
29369297-8	2017	Additionally, we evaluated the expression of TRPV1 in dorsal root ganglia (DRG) by western blotting after PRE- and POST-treatment with RTX.	resiniferatoxin	135-138	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	45-50
29369297-12	2017	CONCLUSION: The presented data demonstrated that both PRE- and POST-treatment with RTX given intrathecally produced potent antiallodynic activities in CCI mice and that POST-treatment can reduce TRPV1 expression in DRG, suggesting that POST-treatment RTX can revert central sensitization and its associated allodynia.	resiniferatoxin	83-86	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	195-200
28831207-0	2017	Intrathecal Resiniferatoxin Modulates TRPV1 in DRG Neurons and Reduces TNF-Induced Pain-Related Behavior.	resiniferatoxin	12-27	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	38-43
28484490-2	2017	Resiniferatoxin (RTX) is an excitotoxin that activates TRPV1 at low concentrations and defunctionalizes TRPV1 at high concentrations.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	55-60
28484490-2	2017	Resiniferatoxin (RTX) is an excitotoxin that activates TRPV1 at low concentrations and defunctionalizes TRPV1 at high concentrations.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	104-109
28484490-2	2017	Resiniferatoxin (RTX) is an excitotoxin that activates TRPV1 at low concentrations and defunctionalizes TRPV1 at high concentrations.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	55-60
28484490-2	2017	Resiniferatoxin (RTX) is an excitotoxin that activates TRPV1 at low concentrations and defunctionalizes TRPV1 at high concentrations.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	104-109
28066142-5	2017	Pretreatment with resiniferatoxin (RTX), which depletes capsaicin receptor protein in primary afferent fibers, did not alter the paradoxical anti-allodynic effects produced by the intracisternal injection of bicuculline.	resiniferatoxin	35-38	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	56-74
28831207-9	2017	These results suggest that the involvement of TRPV1 in TNF-induced pain offers new TRPV1-based experimental therapeutic approaches and demonstrates the analgesic potential of RTX in inflammatory pain diseases.	resiniferatoxin	175-178	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	46-51
28831207-9	2017	These results suggest that the involvement of TRPV1 in TNF-induced pain offers new TRPV1-based experimental therapeutic approaches and demonstrates the analgesic potential of RTX in inflammatory pain diseases.	resiniferatoxin	175-178	tumor necrosis factor	Rattus norvegicus	55-58
28831207-0	2017	Intrathecal Resiniferatoxin Modulates TRPV1 in DRG Neurons and Reduces TNF-Induced Pain-Related Behavior.	resiniferatoxin	12-27	tumor necrosis factor	Rattus norvegicus	71-74
28831207-4	2017	We examined the effect of intrathecal administration of the ultrapotent TRPV1 agonist resiniferatoxin (RTX) on TNF-induced pain-associated behavior of rats using von Frey and hot plate behavioral testing.	resiniferatoxin	86-101	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	72-77
28831207-4	2017	We examined the effect of intrathecal administration of the ultrapotent TRPV1 agonist resiniferatoxin (RTX) on TNF-induced pain-associated behavior of rats using von Frey and hot plate behavioral testing.	resiniferatoxin	86-101	tumor necrosis factor	Rattus norvegicus	111-114
28831207-4	2017	We examined the effect of intrathecal administration of the ultrapotent TRPV1 agonist resiniferatoxin (RTX) on TNF-induced pain-associated behavior of rats using von Frey and hot plate behavioral testing.	resiniferatoxin	103-106	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	72-77
28831207-4	2017	We examined the effect of intrathecal administration of the ultrapotent TRPV1 agonist resiniferatoxin (RTX) on TNF-induced pain-associated behavior of rats using von Frey and hot plate behavioral testing.	resiniferatoxin	103-106	tumor necrosis factor	Rattus norvegicus	111-114
28831207-6	2017	The additional intrathecal administration of RTX (1.9 mug/kg) alleviates TNF-induced mechanical allodynia and thermal hyperalgesia 24 h after injection.	resiniferatoxin	45-48	tumor necrosis factor	Rattus norvegicus	73-76
27563913-1	2016	Transient Receptor Potential Vanilloid 1 (TRPV1) is a non-selective, Ca(2+) permeable cation channel activated by noxious heat, and chemical ligands, such as capsaicin and resiniferatoxin (RTX).	resiniferatoxin	172-187	transient receptor potential cation channel subfamily V member 1	Homo sapiens	0-40
27429048-8	2016	The expression of tumor necrosis factor alpha, IL-1beta, p38, and NR2B was up-regulated in RTX-induced neuropathic pain rat model and lasted for at least 49 days.	resiniferatoxin	91-94	tumor necrosis factor	Rattus norvegicus	18-45
27429048-8	2016	The expression of tumor necrosis factor alpha, IL-1beta, p38, and NR2B was up-regulated in RTX-induced neuropathic pain rat model and lasted for at least 49 days.	resiniferatoxin	91-94	interleukin 1 beta	Rattus norvegicus	47-55
27429048-8	2016	The expression of tumor necrosis factor alpha, IL-1beta, p38, and NR2B was up-regulated in RTX-induced neuropathic pain rat model and lasted for at least 49 days.	resiniferatoxin	91-94	mitogen activated protein kinase 14	Rattus norvegicus	57-60
27429048-8	2016	The expression of tumor necrosis factor alpha, IL-1beta, p38, and NR2B was up-regulated in RTX-induced neuropathic pain rat model and lasted for at least 49 days.	resiniferatoxin	91-94	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	66-70
27706207-1	2016	BACKGROUND: A few studies have investigated the role of adiponectin fraction for cardiovascular disease (CVD) in RTx recipients.	resiniferatoxin	113-116	adiponectin, C1Q and collagen domain containing	Homo sapiens	56-67
26482371-5	2016	In an ultropotent TRPV1 agonist resiniferatoxin (RTX)-induced PHN-like model, RTX treatment for 6 weeks increased netrin-1 expression in dorsal horn neurons, including NK-1-positive projection neurons.	resiniferatoxin	32-47	transient receptor potential cation channel subfamily V member 1	Homo sapiens	18-23
26482371-5	2016	In an ultropotent TRPV1 agonist resiniferatoxin (RTX)-induced PHN-like model, RTX treatment for 6 weeks increased netrin-1 expression in dorsal horn neurons, including NK-1-positive projection neurons.	resiniferatoxin	32-47	netrin 1	Homo sapiens	114-122
26482371-5	2016	In an ultropotent TRPV1 agonist resiniferatoxin (RTX)-induced PHN-like model, RTX treatment for 6 weeks increased netrin-1 expression in dorsal horn neurons, including NK-1-positive projection neurons.	resiniferatoxin	49-52	transient receptor potential cation channel subfamily V member 1	Homo sapiens	18-23
26482371-5	2016	In an ultropotent TRPV1 agonist resiniferatoxin (RTX)-induced PHN-like model, RTX treatment for 6 weeks increased netrin-1 expression in dorsal horn neurons, including NK-1-positive projection neurons.	resiniferatoxin	49-52	netrin 1	Homo sapiens	114-122
26482371-5	2016	In an ultropotent TRPV1 agonist resiniferatoxin (RTX)-induced PHN-like model, RTX treatment for 6 weeks increased netrin-1 expression in dorsal horn neurons, including NK-1-positive projection neurons.	resiniferatoxin	78-81	transient receptor potential cation channel subfamily V member 1	Homo sapiens	18-23
26482371-5	2016	In an ultropotent TRPV1 agonist resiniferatoxin (RTX)-induced PHN-like model, RTX treatment for 6 weeks increased netrin-1 expression in dorsal horn neurons, including NK-1-positive projection neurons.	resiniferatoxin	78-81	netrin 1	Homo sapiens	114-122
26482371-6	2016	In human neuroblastoma SH-SY5Y cells, we found that TRPV1 antagonist capsazepine antagonized RTX-induced upregulation of netrin-1.	resiniferatoxin	93-96	transient receptor potential cation channel subfamily V member 1	Homo sapiens	52-57
26482371-6	2016	In human neuroblastoma SH-SY5Y cells, we found that TRPV1 antagonist capsazepine antagonized RTX-induced upregulation of netrin-1.	resiniferatoxin	93-96	netrin 1	Homo sapiens	121-129
26482371-7	2016	After RTX treatment, UNC5H2 expression was gradually decreased, whereas DCC expression was significantly increased.	resiniferatoxin	6-9	unc-5 netrin receptor B	Homo sapiens	21-27
26482371-7	2016	After RTX treatment, UNC5H2 expression was gradually decreased, whereas DCC expression was significantly increased.	resiniferatoxin	6-9	DCC netrin 1 receptor	Homo sapiens	72-75
26482371-9	2016	Our results suggest that RTX treatment upregulates netrin-1 expression through activation of TRPV1 receptors and change UNC5H2-rich spinal dorsal horn into a growth-permissive environment by increasing DCC expression, thus enhancing the sprouting of myelinated afferent nerves.	resiniferatoxin	25-28	netrin 1	Homo sapiens	51-59
26482371-9	2016	Our results suggest that RTX treatment upregulates netrin-1 expression through activation of TRPV1 receptors and change UNC5H2-rich spinal dorsal horn into a growth-permissive environment by increasing DCC expression, thus enhancing the sprouting of myelinated afferent nerves.	resiniferatoxin	25-28	transient receptor potential cation channel subfamily V member 1	Homo sapiens	93-98
26482371-9	2016	Our results suggest that RTX treatment upregulates netrin-1 expression through activation of TRPV1 receptors and change UNC5H2-rich spinal dorsal horn into a growth-permissive environment by increasing DCC expression, thus enhancing the sprouting of myelinated afferent nerves.	resiniferatoxin	25-28	unc-5 netrin receptor B	Homo sapiens	120-126
26482371-9	2016	Our results suggest that RTX treatment upregulates netrin-1 expression through activation of TRPV1 receptors and change UNC5H2-rich spinal dorsal horn into a growth-permissive environment by increasing DCC expression, thus enhancing the sprouting of myelinated afferent nerves.	resiniferatoxin	25-28	DCC netrin 1 receptor	Homo sapiens	202-205
27448299-11	2016	Our results also suggest that peroxisome proliferator-activated receptor (PPAR) signaling may be involved in UC after RTx.	resiniferatoxin	118-121	peroxisome proliferator activated receptor alpha	Homo sapiens	30-72
27448299-11	2016	Our results also suggest that peroxisome proliferator-activated receptor (PPAR) signaling may be involved in UC after RTx.	resiniferatoxin	118-121	peroxisome proliferator activated receptor alpha	Homo sapiens	74-78
27559176-6	2016	Activation of TRPV1 with either the selective agonist resiniferatoxin (150 pm) or temperature augmented basal sEPSC rates but failed to alter the synchronous or asynchronous modes of release.	resiniferatoxin	54-69	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	14-19
28714350-7	2017	Resiniferatoxin also induced myelin basic protein degradation in L4-L6 dorsal root at six weeks after injection.	resiniferatoxin	0-15	myelin basic protein	Rattus norvegicus	29-49
28714350-9	2017	Conclusions Up-regulation and activation of micro-calpain located in Schwann cell may be the mechanism underlying resiniferatoxin-mediated proteolysis of myelin basic protein in dorsal root.	resiniferatoxin	114-129	myelin basic protein	Rattus norvegicus	154-174
28714350-10	2017	Calpain inhibitor MDL28170 prevents resiniferatoxin-induced sprouting of myelinated afferent fibers and mechanical allodynia through inhibition of degradation of the myelin basic protein in dorsal root.	resiniferatoxin	36-51	myelin basic protein	Rattus norvegicus	166-186
27606946-2	2016	Since the precise structure of TRPV1 was obtained by electron cryo-microscopy, the binding mode of representative agonists such as capsaicin and resiniferatoxin (RTX) has been extensively characterized; however, detailed information on the binding mode of other vanilloids remains lacking.	resiniferatoxin	145-160	transient receptor potential cation channel subfamily V member 1	Homo sapiens	31-36
27606946-2	2016	Since the precise structure of TRPV1 was obtained by electron cryo-microscopy, the binding mode of representative agonists such as capsaicin and resiniferatoxin (RTX) has been extensively characterized; however, detailed information on the binding mode of other vanilloids remains lacking.	resiniferatoxin	162-165	transient receptor potential cation channel subfamily V member 1	Homo sapiens	31-36
27563913-1	2016	Transient Receptor Potential Vanilloid 1 (TRPV1) is a non-selective, Ca(2+) permeable cation channel activated by noxious heat, and chemical ligands, such as capsaicin and resiniferatoxin (RTX).	resiniferatoxin	172-187	transient receptor potential cation channel subfamily V member 1	Homo sapiens	42-47
27563913-1	2016	Transient Receptor Potential Vanilloid 1 (TRPV1) is a non-selective, Ca(2+) permeable cation channel activated by noxious heat, and chemical ligands, such as capsaicin and resiniferatoxin (RTX).	resiniferatoxin	189-192	transient receptor potential cation channel subfamily V member 1	Homo sapiens	0-40
27563913-1	2016	Transient Receptor Potential Vanilloid 1 (TRPV1) is a non-selective, Ca(2+) permeable cation channel activated by noxious heat, and chemical ligands, such as capsaicin and resiniferatoxin (RTX).	resiniferatoxin	189-192	transient receptor potential cation channel subfamily V member 1	Homo sapiens	42-47
27529257-5	2016	Administration of the potent TRPV1 agonist resiniferatoxin (RTX) to neuronal perikarya or nerve terminals induces calcium cytotoxicity and selective lesioning of the TRPV1-expressing nociceptive primary afferent population.	resiniferatoxin	43-58	transient receptor potential cation channel subfamily V member 1	Homo sapiens	29-34
27529257-5	2016	Administration of the potent TRPV1 agonist resiniferatoxin (RTX) to neuronal perikarya or nerve terminals induces calcium cytotoxicity and selective lesioning of the TRPV1-expressing nociceptive primary afferent population.	resiniferatoxin	43-58	transient receptor potential cation channel subfamily V member 1	Homo sapiens	166-171
27529257-5	2016	Administration of the potent TRPV1 agonist resiniferatoxin (RTX) to neuronal perikarya or nerve terminals induces calcium cytotoxicity and selective lesioning of the TRPV1-expressing nociceptive primary afferent population.	resiniferatoxin	60-63	transient receptor potential cation channel subfamily V member 1	Homo sapiens	29-34
27529257-5	2016	Administration of the potent TRPV1 agonist resiniferatoxin (RTX) to neuronal perikarya or nerve terminals induces calcium cytotoxicity and selective lesioning of the TRPV1-expressing nociceptive primary afferent population.	resiniferatoxin	60-63	transient receptor potential cation channel subfamily V member 1	Homo sapiens	166-171
27306411-0	2016	EXPRESS: NGF-trkA signaling modulates the analgesic effects of prostatic acid phosphatase in resiniferatoxin-induced neuropathy.	resiniferatoxin	93-108	neurotrophic receptor tyrosine kinase 1	Homo sapiens	13-17
26434410-4	2016	RTx was performed after achieving low intravesical pressure (&lt;30 cmH2 O) with adequate bladder capacity and drainage.	resiniferatoxin	0-3	troponin T2, cardiac type	Homo sapiens	68-72
27298359-3	2016	Based on these new findings, here we have successfully introduced high-affinity binding of capsaicin and resiniferatoxin to the vanilloid-insensitive TRPV2 channel, using a rationally designed minimal set of four point mutations (F467S-S498F-L505T-Q525E, termed TRPV2_Quad).	resiniferatoxin	105-120	transient receptor potential cation channel subfamily V member 2	Homo sapiens	150-155
27298359-3	2016	Based on these new findings, here we have successfully introduced high-affinity binding of capsaicin and resiniferatoxin to the vanilloid-insensitive TRPV2 channel, using a rationally designed minimal set of four point mutations (F467S-S498F-L505T-Q525E, termed TRPV2_Quad).	resiniferatoxin	105-120	transient receptor potential cation channel subfamily V member 2	Homo sapiens	262-267
27298359-4	2016	We found that binding of resiniferatoxin activates TRPV2_Quad but the ligand-induced open state is relatively unstable, whereas binding of capsaicin to TRPV2_Quad antagonizes resiniferatoxin-induced activation likely through competition for the same binding sites.	resiniferatoxin	25-40	transient receptor potential cation channel subfamily V member 2	Homo sapiens	51-56
27298359-4	2016	We found that binding of resiniferatoxin activates TRPV2_Quad but the ligand-induced open state is relatively unstable, whereas binding of capsaicin to TRPV2_Quad antagonizes resiniferatoxin-induced activation likely through competition for the same binding sites.	resiniferatoxin	175-190	transient receptor potential cation channel subfamily V member 2	Homo sapiens	152-157
27306411-5	2016	PAP(th) neurons were categorized into small to medium neurons (25th-75th percentile: 17.1-23.7 mm); these neurons were slightly reduced by RTX (p1/40.0003).	resiniferatoxin	139-142	acid phosphatase 3	Homo sapiens	0-3
27306411-6	2016	By contrast, RTX-induced activating transcription factor 3 (ATF3), an injury marker, in PAP(th) neurons (29.0%5.6% vs. 0.2%0.2%, p1/40.0043), indicating PAP neuropathology.	resiniferatoxin	13-16	activating transcription factor 3	Homo sapiens	60-64
27306411-6	2016	By contrast, RTX-induced activating transcription factor 3 (ATF3), an injury marker, in PAP(th) neurons (29.0%5.6% vs. 0.2%0.2%, p1/40.0043), indicating PAP neuropathology.	resiniferatoxin	13-16	acid phosphatase 3	Homo sapiens	88-91
27180305-1	2016	Vanilloids including capsaicin and resiniferatoxin are potent transient receptor potential vanilloid type 1 (TRPV1) agonists.	resiniferatoxin	35-50	transient receptor potential cation channel subfamily V member 1	Homo sapiens	62-107
27180305-1	2016	Vanilloids including capsaicin and resiniferatoxin are potent transient receptor potential vanilloid type 1 (TRPV1) agonists.	resiniferatoxin	35-50	transient receptor potential cation channel subfamily V member 1	Homo sapiens	109-114
27339229-2	2016	Our results have demonstrated that capsaicin and resiniferatoxin form nanomolar complexes with calmodulin, and competitively inhibit TRPV1-calmodulin interaction.	resiniferatoxin	49-64	calmodulin 1	Homo sapiens	95-105
27339229-2	2016	Our results have demonstrated that capsaicin and resiniferatoxin form nanomolar complexes with calmodulin, and competitively inhibit TRPV1-calmodulin interaction.	resiniferatoxin	49-64	transient receptor potential cation channel subfamily V member 1	Homo sapiens	133-138
27339229-2	2016	Our results have demonstrated that capsaicin and resiniferatoxin form nanomolar complexes with calmodulin, and competitively inhibit TRPV1-calmodulin interaction.	resiniferatoxin	49-64	calmodulin 1	Homo sapiens	139-149
27574502-2	2016	Here we demonstrate that the VR1 agonists, capsaicin (CP) and resiniferatoxin (RTX), enhance antiviral CTL responses by increasing MHC class I-restricted viral antigen presentation in dendritic cells (DCs).	resiniferatoxin	62-77	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	29-32
27574502-2	2016	Here we demonstrate that the VR1 agonists, capsaicin (CP) and resiniferatoxin (RTX), enhance antiviral CTL responses by increasing MHC class I-restricted viral antigen presentation in dendritic cells (DCs).	resiniferatoxin	79-82	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	29-32
27306411-6	2016	By contrast, RTX-induced activating transcription factor 3 (ATF3), an injury marker, in PAP(th) neurons (29.0%5.6% vs. 0.2%0.2%, p1/40.0043), indicating PAP neuropathology.	resiniferatoxin	13-16	acid phosphatase 3	Homo sapiens	153-156
27306411-7	2016	Moreover, the high-affinity nerve growth factor (NGF) receptor (trkA) colocalized with PAP and showed similar profiles after RTX-induced neuropathy, and the PAP/trkA ratios correlated with the degree of mechanical allodynia (r1/40.62, p1/40.0062).	resiniferatoxin	125-128	neurotrophic receptor tyrosine kinase 1	Homo sapiens	64-68
27306411-0	2016	EXPRESS: NGF-trkA signaling modulates the analgesic effects of prostatic acid phosphatase in resiniferatoxin-induced neuropathy.	resiniferatoxin	93-108	acid phosphatase 3	Homo sapiens	63-89
27188969-3	2016	In the present study, the intracerebroventricular (icv) administration of the TRPV1 agonist resiniferatoxin (RTX) induced the activation of signal transducer and activator of transcription 3 (STAT3) in circumventricular organs (CVOs) and thermoregulation-associated brain regions with a similar patttern to the peripheral and icv administration of lipopolysaccharide (LPS).	resiniferatoxin	92-107	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	78-83
27329106-1	2016	BACKGROUND: Resiniferatoxin (RTX) is a potent analog of capsaicin and activates transient receptor potential (TRP) vanilloid type (TRPV) 1.	resiniferatoxin	12-27	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	90-138
27329106-1	2016	BACKGROUND: Resiniferatoxin (RTX) is a potent analog of capsaicin and activates transient receptor potential (TRP) vanilloid type (TRPV) 1.	resiniferatoxin	29-32	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	90-138
27329106-5	2016	Western blot analysis 4 weeks after RTX pretreatment showed that RTX pretreatment decreased the protein expression level of SNL-induced TRPM8, but not TRPV1 or TRPA1, in the DRG of SNL rats.	resiniferatoxin	36-39	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	136-141
27188969-3	2016	In the present study, the intracerebroventricular (icv) administration of the TRPV1 agonist resiniferatoxin (RTX) induced the activation of signal transducer and activator of transcription 3 (STAT3) in circumventricular organs (CVOs) and thermoregulation-associated brain regions with a similar patttern to the peripheral and icv administration of lipopolysaccharide (LPS).	resiniferatoxin	92-107	signal transducer and activator of transcription 3	Mus musculus	140-190
27188969-3	2016	In the present study, the intracerebroventricular (icv) administration of the TRPV1 agonist resiniferatoxin (RTX) induced the activation of signal transducer and activator of transcription 3 (STAT3) in circumventricular organs (CVOs) and thermoregulation-associated brain regions with a similar patttern to the peripheral and icv administration of lipopolysaccharide (LPS).	resiniferatoxin	92-107	signal transducer and activator of transcription 3	Mus musculus	192-197
27188969-3	2016	In the present study, the intracerebroventricular (icv) administration of the TRPV1 agonist resiniferatoxin (RTX) induced the activation of signal transducer and activator of transcription 3 (STAT3) in circumventricular organs (CVOs) and thermoregulation-associated brain regions with a similar patttern to the peripheral and icv administration of lipopolysaccharide (LPS).	resiniferatoxin	109-112	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	78-83
27188969-3	2016	In the present study, the intracerebroventricular (icv) administration of the TRPV1 agonist resiniferatoxin (RTX) induced the activation of signal transducer and activator of transcription 3 (STAT3) in circumventricular organs (CVOs) and thermoregulation-associated brain regions with a similar patttern to the peripheral and icv administration of lipopolysaccharide (LPS).	resiniferatoxin	109-112	signal transducer and activator of transcription 3	Mus musculus	140-190
27188969-3	2016	In the present study, the intracerebroventricular (icv) administration of the TRPV1 agonist resiniferatoxin (RTX) induced the activation of signal transducer and activator of transcription 3 (STAT3) in circumventricular organs (CVOs) and thermoregulation-associated brain regions with a similar patttern to the peripheral and icv administration of lipopolysaccharide (LPS).	resiniferatoxin	109-112	signal transducer and activator of transcription 3	Mus musculus	192-197
27177419-4	2016	Here we use biochemical and electrophysiological approaches to investigate the resiniferatoxin(RTx) binding site in TRPV1 and to explore the functional relationships between TRPV1 and TRPV2.	resiniferatoxin	79-94	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	116-121
27177419-4	2016	Here we use biochemical and electrophysiological approaches to investigate the resiniferatoxin(RTx) binding site in TRPV1 and to explore the functional relationships between TRPV1 and TRPV2.	resiniferatoxin	95-98	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	116-121
27177419-6	2016	Moreover, we show that sensitivity to RTx can be engineered into TRPV2, demonstrating that the gating and permeation properties of this channel are similar to TRPV1.	resiniferatoxin	38-41	transient receptor potential cation channel, subfamily V, member 2	Rattus norvegicus	65-70
27177419-6	2016	Moreover, we show that sensitivity to RTx can be engineered into TRPV2, demonstrating that the gating and permeation properties of this channel are similar to TRPV1.	resiniferatoxin	38-41	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	159-164
25729765-7	2015	RESULTS: Retrograde perfusion of the main pancreatic ducts of wild-type mice with NaT caused severe acute pancreatitis; severity was reduced by co-administration of resiniferatoxin.	resiniferatoxin	165-180	solute carrier family 38, member 3	Mus musculus	82-85
26719417-0	2016	Understanding TRPV1 activation by ligands: Insights from the binding modes of capsaicin and resiniferatoxin.	resiniferatoxin	92-107	transient receptor potential cation channel subfamily V member 1	Homo sapiens	14-19
26719417-4	2016	The recent cryo-electron microscopy structure of TRPV1 only provides a coarse characterization of the location of capsaicin (CAPS) and resiniferatoxin (RTX).	resiniferatoxin	135-150	transient receptor potential cation channel subfamily V member 1	Homo sapiens	49-54
26719417-4	2016	The recent cryo-electron microscopy structure of TRPV1 only provides a coarse characterization of the location of capsaicin (CAPS) and resiniferatoxin (RTX).	resiniferatoxin	152-155	transient receptor potential cation channel subfamily V member 1	Homo sapiens	49-54
26807032-1	2016	This study was performed to investigate whether an intra-articular injection of transient receptor potential vanilloid 1 (TRPV1) receptor agonist, resiniferatoxin (RTX) would alleviate behavioral signs of arthritic pain in a rat model of osteoarthritis (OA).	resiniferatoxin	147-162	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	80-120
26807032-1	2016	This study was performed to investigate whether an intra-articular injection of transient receptor potential vanilloid 1 (TRPV1) receptor agonist, resiniferatoxin (RTX) would alleviate behavioral signs of arthritic pain in a rat model of osteoarthritis (OA).	resiniferatoxin	147-162	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	122-127
26807032-1	2016	This study was performed to investigate whether an intra-articular injection of transient receptor potential vanilloid 1 (TRPV1) receptor agonist, resiniferatoxin (RTX) would alleviate behavioral signs of arthritic pain in a rat model of osteoarthritis (OA).	resiniferatoxin	164-167	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	80-120
26807032-1	2016	This study was performed to investigate whether an intra-articular injection of transient receptor potential vanilloid 1 (TRPV1) receptor agonist, resiniferatoxin (RTX) would alleviate behavioral signs of arthritic pain in a rat model of osteoarthritis (OA).	resiniferatoxin	164-167	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	122-127
26807032-2	2016	We also sought to determine the effect of RTX treatment on calcitonin gene-related peptide (CGRP) expression in the spinal cord.	resiniferatoxin	42-45	calcitonin-related polypeptide alpha	Rattus norvegicus	59-90
26807032-2	2016	We also sought to determine the effect of RTX treatment on calcitonin gene-related peptide (CGRP) expression in the spinal cord.	resiniferatoxin	42-45	calcitonin-related polypeptide alpha	Rattus norvegicus	92-96
26807032-6	2016	The MIA-induced increase in CGRP immunoreactivity in the spinal cord was decreased by RTX treatment in a dose-dependent manner.	resiniferatoxin	86-89	calcitonin-related polypeptide alpha	Rattus norvegicus	28-32
26378245-3	2015	Resiniferatoxin (RTX), like capsaicin, is a TRPV1 agonist but has greater potency.	resiniferatoxin	0-15	transient receptor potential cation channel subfamily V member 1	Sus scrofa	44-49
26378245-3	2015	Resiniferatoxin (RTX), like capsaicin, is a TRPV1 agonist but has greater potency.	resiniferatoxin	17-20	transient receptor potential cation channel subfamily V member 1	Sus scrofa	44-49
26227887-5	2015	Hypothermia was abolished in mice pre-treated with resiniferatoxin to destroy or defunctionalize peripheral TRPV1-expressing terminals, but resistant to inhibition of cyclo-oxygenases.	resiniferatoxin	51-66	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	108-113
25659068-1	2015	Resiniferatoxin (RTX) is the most potent among all known endogenous and synthetic agonists for the transient receptor potential vanilloid 1 (TRPV1) receptor, which is a calcium-permeable nonselective cation channel, expressed on the peripheral and central terminals of small-diameter sensory neurons.	resiniferatoxin	0-15	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	99-139
25659068-1	2015	Resiniferatoxin (RTX) is the most potent among all known endogenous and synthetic agonists for the transient receptor potential vanilloid 1 (TRPV1) receptor, which is a calcium-permeable nonselective cation channel, expressed on the peripheral and central terminals of small-diameter sensory neurons.	resiniferatoxin	0-15	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	141-146
25659068-1	2015	Resiniferatoxin (RTX) is the most potent among all known endogenous and synthetic agonists for the transient receptor potential vanilloid 1 (TRPV1) receptor, which is a calcium-permeable nonselective cation channel, expressed on the peripheral and central terminals of small-diameter sensory neurons.	resiniferatoxin	17-20	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	99-139
25659068-1	2015	Resiniferatoxin (RTX) is the most potent among all known endogenous and synthetic agonists for the transient receptor potential vanilloid 1 (TRPV1) receptor, which is a calcium-permeable nonselective cation channel, expressed on the peripheral and central terminals of small-diameter sensory neurons.	resiniferatoxin	17-20	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	141-146
25659068-2	2015	Prolonged calcium influx induced by RTX causes cytotoxicity and death of only those sensory neurons that express the TRPV1 ion channel leading to selective targeting and permanent deletion of the TRPV1-expressing C-fiber neuronal cell bodies in the dorsal root ganglia.	resiniferatoxin	36-39	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	117-122
25659068-2	2015	Prolonged calcium influx induced by RTX causes cytotoxicity and death of only those sensory neurons that express the TRPV1 ion channel leading to selective targeting and permanent deletion of the TRPV1-expressing C-fiber neuronal cell bodies in the dorsal root ganglia.	resiniferatoxin	36-39	transient receptor potential cation channel subfamily V member 1	Canis lupus familiaris	196-201
25568328-4	2015	Using resiniferatoxin (RTX) as the agonist, we identified multiple gain-of-function substitutions within the TRPV1 pore turret (N628P and S629A), pore helix (F638A), and selectivity filter (M644A) domains.	resiniferatoxin	6-21	transient receptor potential cation channel subfamily V member 1	Homo sapiens	109-114
25568328-4	2015	Using resiniferatoxin (RTX) as the agonist, we identified multiple gain-of-function substitutions within the TRPV1 pore turret (N628P and S629A), pore helix (F638A), and selectivity filter (M644A) domains.	resiniferatoxin	23-26	transient receptor potential cation channel subfamily V member 1	Homo sapiens	109-114
25568328-8	2015	The phenotypes of this panel of mutants were confirmed by imaging the RTX-evoked uptake of the large cationic fluorescent dye YO-PRO1.	resiniferatoxin	70-73	lamin A/C	Homo sapiens	129-133
25568328-9	2015	Whereas none of the mutations selectively altered capsaicin-induced changes in NMDG permeability, the loss-of-function phenotypes seen with RTX stimulation of G618W and M644I were recapitulated in the capsaicin-evoked YO-PRO1 uptake assay.	resiniferatoxin	140-143	lamin A/C	Homo sapiens	221-225
25899631-1	2015	Resiniferatoxin (RTX) is an ultrapotent synthetic TRPV1 (transient receptor potential vanilloid subtype 1) agonist with significant initial transient hyperalgesia followed by a prolonged analgesic effect in response to thermal stimulus.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	50-55
25899631-1	2015	Resiniferatoxin (RTX) is an ultrapotent synthetic TRPV1 (transient receptor potential vanilloid subtype 1) agonist with significant initial transient hyperalgesia followed by a prolonged analgesic effect in response to thermal stimulus.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	57-105
25899631-1	2015	Resiniferatoxin (RTX) is an ultrapotent synthetic TRPV1 (transient receptor potential vanilloid subtype 1) agonist with significant initial transient hyperalgesia followed by a prolonged analgesic effect in response to thermal stimulus.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	50-55
25899631-1	2015	Resiniferatoxin (RTX) is an ultrapotent synthetic TRPV1 (transient receptor potential vanilloid subtype 1) agonist with significant initial transient hyperalgesia followed by a prolonged analgesic effect in response to thermal stimulus.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	57-105
26884754-3	2016	TRPV1 receptors function as homotetramers that also respond to heat, proinflammatory substances, lipoxygenase products, resiniferatoxin, endocannabinoids, protons, and peptide toxins.	resiniferatoxin	120-135	transient receptor potential cation channel subfamily V member 1	Homo sapiens	0-5
26204493-8	2015	In CMG, the poreless TRPV1 vector-treated group showed a significantly smaller reduction in intercontraction intervals and voided volume after RTx infusion than the vHG-treated control group.	resiniferatoxin	143-146	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	21-26
25903376-5	2015	We also demonstrate that TRPV1- and TRPV4-specific agonists, namely resiniferatoxin and 4alpha-phorbol-12,13-didecanoate, can cause Ca(2+) influx in T cells.	resiniferatoxin	68-83	transient receptor potential cation channel subfamily V member 1	Homo sapiens	25-30
25903376-5	2015	We also demonstrate that TRPV1- and TRPV4-specific agonists, namely resiniferatoxin and 4alpha-phorbol-12,13-didecanoate, can cause Ca(2+) influx in T cells.	resiniferatoxin	68-83	transient receptor potential cation channel subfamily V member 4	Homo sapiens	36-41
25305451-6	2015	Differences after treatment with SAHA/RTx or LBH589/RTx in a sensitive and resistant culture were increased acetylated-H3, caspase-3/7 and prolonged DNA damage repair gammaH2AX/53BP1 foci.	resiniferatoxin	38-41	caspase 3	Homo sapiens	123-132
25305451-6	2015	Differences after treatment with SAHA/RTx or LBH589/RTx in a sensitive and resistant culture were increased acetylated-H3, caspase-3/7 and prolonged DNA damage repair gammaH2AX/53BP1 foci.	resiniferatoxin	52-55	caspase 3	Homo sapiens	123-132
25411361-6	2015	Prolonged desensitization of transient receptor potential vanilloid 1 (TRPV1)-expressing colonic afferents by resiniferatoxin (RTX) suppressed the spontaneous activity, as well as the anxiety- and depressive-like behaviors.	resiniferatoxin	110-125	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	29-69
25411361-6	2015	Prolonged desensitization of transient receptor potential vanilloid 1 (TRPV1)-expressing colonic afferents by resiniferatoxin (RTX) suppressed the spontaneous activity, as well as the anxiety- and depressive-like behaviors.	resiniferatoxin	110-125	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	71-76
25411361-6	2015	Prolonged desensitization of transient receptor potential vanilloid 1 (TRPV1)-expressing colonic afferents by resiniferatoxin (RTX) suppressed the spontaneous activity, as well as the anxiety- and depressive-like behaviors.	resiniferatoxin	127-130	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	29-69
25411361-6	2015	Prolonged desensitization of transient receptor potential vanilloid 1 (TRPV1)-expressing colonic afferents by resiniferatoxin (RTX) suppressed the spontaneous activity, as well as the anxiety- and depressive-like behaviors.	resiniferatoxin	127-130	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	71-76
26235164-1	2015	This review summarizes the efforts to develop a radical-mediated three-component reaction and its application to a convergent approach to synthesize the 5/7/6-tricyclic framework (ABC-rings) of the densely functionalized dephnane diterpene, resiniferatoxin.	resiniferatoxin	241-256	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	180-183
26235164-4	2015	One of the established reactions was utilized as the key assembling reaction of the ABC-tricyclic framework of resiniferatoxin.	resiniferatoxin	111-126	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	84-87
26411767-8	2015	Thus activation of TRPV1 by oxidative stress, resiniferatoxin, cannabinoid receptor (CB1) activators (i.e. anandamide) or capsaicin induced epileptic effects, and these effects could be reduced by appropriate inhibitors, including capsazepine (CPZ), 5"-iodoresiniferatoxin (IRTX), resolvins, and CB1 antagonists.	resiniferatoxin	46-61	transient receptor potential cation channel subfamily V member 1	Homo sapiens	19-24
24838827-5	2014	In contrast, treatment with the TRPV1-specific agonists, capsaicin (CAP) or resiniferatoxin (RTX) produced only a slight acceleration over a range of concentrations.	resiniferatoxin	76-91	transient receptor potential cation channel subfamily V member 1	Homo sapiens	32-37
25216685-4	2014	The vanilloid agonist resiniferatoxin dramatically reduces cathepsin K levels and osteoclast numbers in vitro, without affecting tartrate-resistant acid phosphatase expression.	resiniferatoxin	22-37	cathepsin K	Homo sapiens	59-70
24682440-5	2014	After RTx, these patients develop anti-nephrin antibodies resulting in nephrotic range proteinuria.	resiniferatoxin	6-9	NPHS1 adhesion molecule, nephrin	Homo sapiens	39-46
25422898-4	2014	Functional SFN was induced by systemic injection of resiniferatoxin (RTX, 50 microg/kg, i.p.).	resiniferatoxin	52-67	RNA exonuclease 2	Mus musculus	11-14
25422898-4	2014	Functional SFN was induced by systemic injection of resiniferatoxin (RTX, 50 microg/kg, i.p.).	resiniferatoxin	69-72	RNA exonuclease 2	Mus musculus	11-14
25422898-8	2014	RTX-treated mice expressed thermal and mechanical hypoalgesia and showed calcitonin gene-related peptide (CGRP) and substance P (SP) depletion without nerve degeneration or vascular dysfunction.	resiniferatoxin	0-3	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	73-104
25422898-8	2014	RTX-treated mice expressed thermal and mechanical hypoalgesia and showed calcitonin gene-related peptide (CGRP) and substance P (SP) depletion without nerve degeneration or vascular dysfunction.	resiniferatoxin	0-3	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	106-110
25422898-8	2014	RTX-treated mice expressed thermal and mechanical hypoalgesia and showed calcitonin gene-related peptide (CGRP) and substance P (SP) depletion without nerve degeneration or vascular dysfunction.	resiniferatoxin	0-3	tachykinin 1	Mus musculus	116-127
25422898-8	2014	RTX-treated mice expressed thermal and mechanical hypoalgesia and showed calcitonin gene-related peptide (CGRP) and substance P (SP) depletion without nerve degeneration or vascular dysfunction.	resiniferatoxin	0-3	tachykinin 1	Mus musculus	129-131
24838827-5	2014	In contrast, treatment with the TRPV1-specific agonists, capsaicin (CAP) or resiniferatoxin (RTX) produced only a slight acceleration over a range of concentrations.	resiniferatoxin	93-96	transient receptor potential cation channel subfamily V member 1	Homo sapiens	32-37
24931438-11	2014	Our findings are that activation of HCMV would induce or enhance the activation of BAFF code in RTx recipients, which may independently or cooperatively participate in renal allograft injury and decrease the long-term outcome of renal allografts.	resiniferatoxin	96-99	TNF superfamily member 13b	Homo sapiens	83-87
25077949-5	2014	We demonstrate here that resiniferatoxin ablation of TRPV1 expressing neurons significantly reduces meningeal blood flow responses to nasal administration of both TRPV1 and TRPA1 agonists.	resiniferatoxin	25-40	transient receptor potential cation channel subfamily V member 1	Homo sapiens	53-58
25077949-5	2014	We demonstrate here that resiniferatoxin ablation of TRPV1 expressing neurons significantly reduces meningeal blood flow responses to nasal administration of both TRPV1 and TRPA1 agonists.	resiniferatoxin	25-40	transient receptor potential cation channel subfamily V member 1	Homo sapiens	163-168
25077949-5	2014	We demonstrate here that resiniferatoxin ablation of TRPV1 expressing neurons significantly reduces meningeal blood flow responses to nasal administration of both TRPV1 and TRPA1 agonists.	resiniferatoxin	25-40	transient receptor potential cation channel subfamily A member 1	Homo sapiens	173-178
25077949-6	2014	Accordingly resiniferatoxin also significantly reduces TRPV1 and CGRP immunostaining and TRPV1 and TRPA1 message levels in trigeminal ganglia.	resiniferatoxin	12-27	transient receptor potential cation channel subfamily V member 1	Homo sapiens	55-60
25077949-6	2014	Accordingly resiniferatoxin also significantly reduces TRPV1 and CGRP immunostaining and TRPV1 and TRPA1 message levels in trigeminal ganglia.	resiniferatoxin	12-27	calcitonin related polypeptide alpha	Homo sapiens	65-69
25077949-6	2014	Accordingly resiniferatoxin also significantly reduces TRPV1 and CGRP immunostaining and TRPV1 and TRPA1 message levels in trigeminal ganglia.	resiniferatoxin	12-27	transient receptor potential cation channel subfamily V member 1	Homo sapiens	89-94
25077949-6	2014	Accordingly resiniferatoxin also significantly reduces TRPV1 and CGRP immunostaining and TRPV1 and TRPA1 message levels in trigeminal ganglia.	resiniferatoxin	12-27	transient receptor potential cation channel subfamily A member 1	Homo sapiens	99-104
23981530-0	2013	The carbonate analogues of 5"-halogenated resiniferatoxin as TRPV1 ligands.	resiniferatoxin	42-57	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	61-66
24792390-1	2014	Small-fiber neuropathy was induced in young adult mice by intraperitoneal injection of resiniferatoxin (RTX), a TRPV1 agonist.	resiniferatoxin	87-102	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	112-117
24792390-1	2014	Small-fiber neuropathy was induced in young adult mice by intraperitoneal injection of resiniferatoxin (RTX), a TRPV1 agonist.	resiniferatoxin	104-107	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	112-117
24188863-0	2013	Resiniferatoxin (RTX) causes a uniquely protracted musculoskeletal hyperalgesia in mice by activation of TRPV1 receptors.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	105-110
24188863-0	2013	Resiniferatoxin (RTX) causes a uniquely protracted musculoskeletal hyperalgesia in mice by activation of TRPV1 receptors.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	105-110
24188863-5	2013	In contrast, resiniferatoxin (RTX) produced a chronic (&gt;58 days) thermal antinociception, consistent with its reported ability to desensitize TRPV1 sites.	resiniferatoxin	13-28	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	145-150
24188863-5	2013	In contrast, resiniferatoxin (RTX) produced a chronic (&gt;58 days) thermal antinociception, consistent with its reported ability to desensitize TRPV1 sites.	resiniferatoxin	30-33	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	145-150
24188863-6	2013	In the same mice, RTX produced a transient hypothermia (7 hours) and a protracted (28-day) musculoskeletal hyperalgesia in spite of a 35.5% reduction in TRPV1 receptor immunoreactivity in muscle afferents.	resiniferatoxin	18-21	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	153-158
24794110-0	2014	alpha-Methylated simplified resiniferatoxin (sRTX) thiourea analogues as potent and stereospecific TRPV1 antagonists.	resiniferatoxin	28-43	transient receptor potential cation channel subfamily V member 1	Homo sapiens	99-104
24406203-8	2014	In the resiniferatoxin (RTX)-pretreated rats, a subcutaneous injection of IL-1beta did not produce thermal hyperalgesia due to the depletion of TRPV1 in the primary afferent fibers.	resiniferatoxin	24-27	interleukin 1 beta	Rattus norvegicus	74-82
24434730-5	2014	The ultrapotent TRPV1 agonist resiniferatoxin (RTX) dose-dependently deactivates TRPV1+ fibers and blocks thermal nociceptive responses in baseline or inflamed conditions.	resiniferatoxin	30-45	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	16-21
24434730-5	2014	The ultrapotent TRPV1 agonist resiniferatoxin (RTX) dose-dependently deactivates TRPV1+ fibers and blocks thermal nociceptive responses in baseline or inflamed conditions.	resiniferatoxin	30-45	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	81-86
24434730-5	2014	The ultrapotent TRPV1 agonist resiniferatoxin (RTX) dose-dependently deactivates TRPV1+ fibers and blocks thermal nociceptive responses in baseline or inflamed conditions.	resiniferatoxin	47-50	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	16-21
24434730-5	2014	The ultrapotent TRPV1 agonist resiniferatoxin (RTX) dose-dependently deactivates TRPV1+ fibers and blocks thermal nociceptive responses in baseline or inflamed conditions.	resiniferatoxin	47-50	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	81-86
24321344-0	2014	Asymmetric synthesis and receptor activity of chiral simplified resiniferatoxin (sRTX) analogues as transient receptor potential vanilloid 1 (TRPV1) ligands.	resiniferatoxin	64-79	transient receptor potential cation channel subfamily V member 1	Homo sapiens	100-140
24321344-0	2014	Asymmetric synthesis and receptor activity of chiral simplified resiniferatoxin (sRTX) analogues as transient receptor potential vanilloid 1 (TRPV1) ligands.	resiniferatoxin	64-79	transient receptor potential cation channel subfamily V member 1	Homo sapiens	142-147
24200896-3	2014	To test this we activated heat-sensitive TRPV1 receptors in mice by water that is warmer than body temperature (41  C) or a low dose of resiniferatoxin (RTX).	resiniferatoxin	136-151	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	41-46
24200896-3	2014	To test this we activated heat-sensitive TRPV1 receptors in mice by water that is warmer than body temperature (41  C) or a low dose of resiniferatoxin (RTX).	resiniferatoxin	153-156	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	41-46
24200896-5	2014	Although a desensitizing regimen of RTX (3-5 injections of 0.1 mg/kg s.c.) decreased immobility during swims at 26  C, it did not during swims at 41  C. In contrast, low dose of RTX (0.02 mg/kg s.c.) enhanced immobility, but only during swims at 41  C. Thus, activation of TRPV1 receptors, endogenously or exogenously, enhances immobility and these sites are activated by cold rather than warmth.	resiniferatoxin	36-39	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	273-278
24200896-5	2014	Although a desensitizing regimen of RTX (3-5 injections of 0.1 mg/kg s.c.) decreased immobility during swims at 26  C, it did not during swims at 41  C. In contrast, low dose of RTX (0.02 mg/kg s.c.) enhanced immobility, but only during swims at 41  C. Thus, activation of TRPV1 receptors, endogenously or exogenously, enhances immobility and these sites are activated by cold rather than warmth.	resiniferatoxin	178-181	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	273-278
24200896-8	2014	), each inhibited the increase in immobility induced by the low dose of RTX, verifying its mediation by TRPV1 sites.	resiniferatoxin	72-75	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	104-109
23685168-7	2013	When the transient receptor potential cation channel subfamily V member 1 (TRPV1) receptor agonist resiniferatoxin (RTX) was administered subcutaneously before the start of LPA treatment, LPA-induced mechanical allodynia and Abeta and Adelta fiber hypersensitivity demonstrated by neurometry were not affected, indicating that TRPV1-expressing nerve fibers (possibly C fibers) might not be essential for LPA-induced allodynia.	resiniferatoxin	99-114	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	9-73
23685168-7	2013	When the transient receptor potential cation channel subfamily V member 1 (TRPV1) receptor agonist resiniferatoxin (RTX) was administered subcutaneously before the start of LPA treatment, LPA-induced mechanical allodynia and Abeta and Adelta fiber hypersensitivity demonstrated by neurometry were not affected, indicating that TRPV1-expressing nerve fibers (possibly C fibers) might not be essential for LPA-induced allodynia.	resiniferatoxin	99-114	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	75-80
23685168-7	2013	When the transient receptor potential cation channel subfamily V member 1 (TRPV1) receptor agonist resiniferatoxin (RTX) was administered subcutaneously before the start of LPA treatment, LPA-induced mechanical allodynia and Abeta and Adelta fiber hypersensitivity demonstrated by neurometry were not affected, indicating that TRPV1-expressing nerve fibers (possibly C fibers) might not be essential for LPA-induced allodynia.	resiniferatoxin	99-114	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	327-332
23685168-7	2013	When the transient receptor potential cation channel subfamily V member 1 (TRPV1) receptor agonist resiniferatoxin (RTX) was administered subcutaneously before the start of LPA treatment, LPA-induced mechanical allodynia and Abeta and Adelta fiber hypersensitivity demonstrated by neurometry were not affected, indicating that TRPV1-expressing nerve fibers (possibly C fibers) might not be essential for LPA-induced allodynia.	resiniferatoxin	116-119	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	9-73
23685168-7	2013	When the transient receptor potential cation channel subfamily V member 1 (TRPV1) receptor agonist resiniferatoxin (RTX) was administered subcutaneously before the start of LPA treatment, LPA-induced mechanical allodynia and Abeta and Adelta fiber hypersensitivity demonstrated by neurometry were not affected, indicating that TRPV1-expressing nerve fibers (possibly C fibers) might not be essential for LPA-induced allodynia.	resiniferatoxin	116-119	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	75-80
23551937-3	2013	Systemic injection of resiniferatoxin (RTX), an ultrapotent analog of TRPV1 agonist, in adult rats can reproduce the clinical symptoms of PHN by ablating TRPV1-expressing sensory neurons.	resiniferatoxin	22-37	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	70-75
23906230-2	2013	On day 7 after RTX administration (RTXd7), the substance P (SP)(+) IENFs were completely depleted compared with the vehicle group (p &lt; 0.0001), whereas the calcitonin gene-related peptide (CGRP)(+) IENFs were dramatically, but not completely, depleted (p &lt; 0.0001).	resiniferatoxin	15-18	tachykinin 1	Mus musculus	47-58
23906230-7	2013	In the current study, the significant promotion of reinnervation of CGRP(+) IENFs and thermal latencies on RTXd35 by 4MC indicated that CGRP(+) IENFs were responsible for the thermal transmission in chronic phase of RTX-induced neuropathy.	resiniferatoxin	107-110	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	136-140
23615109-0	2013	The role of nerve growth factor in neuropathic pain inhibition produced by resiniferatoxin treatment in the dorsal root ganglia.	resiniferatoxin	75-90	nerve growth factor	Rattus norvegicus	12-31
23615109-1	2013	BACKGROUND: Resiniferatoxin (RTX), an excitotoxic agonist for vanilloid receptor 1, is a promising candidate for intractable pain treatment.	resiniferatoxin	12-27	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	62-82
23615109-1	2013	BACKGROUND: Resiniferatoxin (RTX), an excitotoxic agonist for vanilloid receptor 1, is a promising candidate for intractable pain treatment.	resiniferatoxin	29-32	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	62-82
23615109-2	2013	OBJECTIVE: We evaluated the effects of RTX, applied to dorsal root ganglia (DRG) at high doses (1200 ng), in sensory-motor function and nerve growth factor (NGF) alterations in a photochemical sciatic nerve injury rat model.	resiniferatoxin	39-42	nerve growth factor	Rattus norvegicus	136-155
23615109-2	2013	OBJECTIVE: We evaluated the effects of RTX, applied to dorsal root ganglia (DRG) at high doses (1200 ng), in sensory-motor function and nerve growth factor (NGF) alterations in a photochemical sciatic nerve injury rat model.	resiniferatoxin	39-42	nerve growth factor	Rattus norvegicus	157-160
23615109-6	2013	After RTX treatment, TrkA and p75 altered their expressions from one neuronal type to another in the DRG.	resiniferatoxin	6-9	neurotrophic receptor tyrosine kinase 1	Rattus norvegicus	21-25
23615109-6	2013	After RTX treatment, TrkA and p75 altered their expressions from one neuronal type to another in the DRG.	resiniferatoxin	6-9	nerve growth factor receptor	Rattus norvegicus	30-33
23615109-7	2013	NGF and p75 expression changed from the small-size neurons in neuropathic rat DRG to the large- and medium-size neurons in non-neuropathic and RTX-treated animals, concomitantly with neuropathic pain suppression.	resiniferatoxin	143-146	nerve growth factor	Rattus norvegicus	0-3
23615109-7	2013	NGF and p75 expression changed from the small-size neurons in neuropathic rat DRG to the large- and medium-size neurons in non-neuropathic and RTX-treated animals, concomitantly with neuropathic pain suppression.	resiniferatoxin	143-146	nerve growth factor receptor	Rattus norvegicus	8-11
23615109-8	2013	TrkA was expressed in the small-size neurons in neuropathic rat DRG, and was drastically reduced in all size neurons after RTX treatment.	resiniferatoxin	123-126	neurotrophic receptor tyrosine kinase 1	Rattus norvegicus	0-4
23911956-7	2013	Moreover, nociception induced by either capsaicin or AITC was reduced by the desensitisation of TRPV1-positive sensory fibres with resiniferatoxin (73 +- 18 and 76 +- 15% inhibitions, respectively) and by the NK1 receptor antagonist aprepitant (56 +- 5 and 53 +- 8% inhibitions, respectively).	resiniferatoxin	131-146	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	96-101
23639808-6	2013	In rats, blocking TRPV1 by capsazepine or TRPM5 by triphenylphosphine oxide inhibited the tonic NaCl + Bz CT response and shifted the relationship between RTX concentration and the magnitude of the tonic CT response to higher RTX concentrations.	resiniferatoxin	155-158	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	18-23
23639808-6	2013	In rats, blocking TRPV1 by capsazepine or TRPM5 by triphenylphosphine oxide inhibited the tonic NaCl + Bz CT response and shifted the relationship between RTX concentration and the magnitude of the tonic CT response to higher RTX concentrations.	resiniferatoxin	155-158	transient receptor potential cation channel, subfamily M, member 5	Rattus norvegicus	42-47
23468425-8	2013	The intravenous administration of a TRPV1 agonist resiniferatoxin (RTX) prominently induced Fos expression at astrocytes in the OVLT, SFO, and AP and neurons in adjacent related nuclei of the median preoptic nuclei (MnPO) and nucleus of the solitary tract (Sol) of wild-type but not TRPV1-knockout mice.	resiniferatoxin	50-65	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	36-41
23468425-8	2013	The intravenous administration of a TRPV1 agonist resiniferatoxin (RTX) prominently induced Fos expression at astrocytes in the OVLT, SFO, and AP and neurons in adjacent related nuclei of the median preoptic nuclei (MnPO) and nucleus of the solitary tract (Sol) of wild-type but not TRPV1-knockout mice.	resiniferatoxin	50-65	FBJ osteosarcoma oncogene	Mus musculus	92-95
23468425-8	2013	The intravenous administration of a TRPV1 agonist resiniferatoxin (RTX) prominently induced Fos expression at astrocytes in the OVLT, SFO, and AP and neurons in adjacent related nuclei of the median preoptic nuclei (MnPO) and nucleus of the solitary tract (Sol) of wild-type but not TRPV1-knockout mice.	resiniferatoxin	50-65	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	283-288
23468425-8	2013	The intravenous administration of a TRPV1 agonist resiniferatoxin (RTX) prominently induced Fos expression at astrocytes in the OVLT, SFO, and AP and neurons in adjacent related nuclei of the median preoptic nuclei (MnPO) and nucleus of the solitary tract (Sol) of wild-type but not TRPV1-knockout mice.	resiniferatoxin	67-70	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	36-41
23468425-8	2013	The intravenous administration of a TRPV1 agonist resiniferatoxin (RTX) prominently induced Fos expression at astrocytes in the OVLT, SFO, and AP and neurons in adjacent related nuclei of the median preoptic nuclei (MnPO) and nucleus of the solitary tract (Sol) of wild-type but not TRPV1-knockout mice.	resiniferatoxin	67-70	FBJ osteosarcoma oncogene	Mus musculus	92-95
23468425-8	2013	The intravenous administration of a TRPV1 agonist resiniferatoxin (RTX) prominently induced Fos expression at astrocytes in the OVLT, SFO, and AP and neurons in adjacent related nuclei of the median preoptic nuclei (MnPO) and nucleus of the solitary tract (Sol) of wild-type but not TRPV1-knockout mice.	resiniferatoxin	67-70	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	283-288
23468425-9	2013	The intracerebroventricular infusion of RTX induced Fos expression at both astrocytes and neurons in the CVOs, MnPO, and Sol.	resiniferatoxin	40-43	FBJ osteosarcoma oncogene	Mus musculus	52-55
23551937-3	2013	Systemic injection of resiniferatoxin (RTX), an ultrapotent analog of TRPV1 agonist, in adult rats can reproduce the clinical symptoms of PHN by ablating TRPV1-expressing sensory neurons.	resiniferatoxin	22-37	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	154-159
23551937-3	2013	Systemic injection of resiniferatoxin (RTX), an ultrapotent analog of TRPV1 agonist, in adult rats can reproduce the clinical symptoms of PHN by ablating TRPV1-expressing sensory neurons.	resiniferatoxin	39-42	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	70-75
23551937-3	2013	Systemic injection of resiniferatoxin (RTX), an ultrapotent analog of TRPV1 agonist, in adult rats can reproduce the clinical symptoms of PHN by ablating TRPV1-expressing sensory neurons.	resiniferatoxin	39-42	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	154-159
23551937-12	2013	EA treatment at 2 and 15 Hz recovered the loss of TRPV1-positive dorsal root ganglion neurons and their central terminals of afferent fibers in the spinal superficial dorsal horn of RTX-treated rats.	resiniferatoxin	182-185	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	50-55
23353568-7	2013	Serum levels of BAFF were significantly elevated in groups 1, 2 and 3; in particular, group 1 patients showed marked elevation of the serum BAFF at 6 and 12months after RTx.	resiniferatoxin	169-172	TNF superfamily member 13b	Homo sapiens	16-20
23352977-5	2013	TRPV1 antagonist capsazepine did not affect the capsaicin activity, and powerful TRPV1 agonist resiniferatoxin had no effect on CAPs, indicating no involvement of TRPV1 channels.	resiniferatoxin	95-110	transient receptor potential cation channel subfamily V member 1	Homo sapiens	81-86
23352977-5	2013	TRPV1 antagonist capsazepine did not affect the capsaicin activity, and powerful TRPV1 agonist resiniferatoxin had no effect on CAPs, indicating no involvement of TRPV1 channels.	resiniferatoxin	95-110	transient receptor potential cation channel subfamily V member 1	Homo sapiens	81-86
23402345-9	2013	There was a significant reduction at 10d in vascular endothelial growth factor (VEGF)-R2 in LG in the RTx group that was prevented in the AdEpo+RTx group.	resiniferatoxin	102-105	vascular endothelial growth factor A	Mus musculus	44-78
23402345-9	2013	There was a significant reduction at 10d in vascular endothelial growth factor (VEGF)-R2 in LG in the RTx group that was prevented in the AdEpo+RTx group.	resiniferatoxin	102-105	vascular endothelial growth factor A	Mus musculus	80-84
23402345-9	2013	There was a significant reduction at 10d in vascular endothelial growth factor (VEGF)-R2 in LG in the RTx group that was prevented in the AdEpo+RTx group.	resiniferatoxin	144-147	vascular endothelial growth factor A	Mus musculus	44-78
23402345-9	2013	There was a significant reduction at 10d in vascular endothelial growth factor (VEGF)-R2 in LG in the RTx group that was prevented in the AdEpo+RTx group.	resiniferatoxin	144-147	vascular endothelial growth factor A	Mus musculus	80-84
23353568-7	2013	Serum levels of BAFF were significantly elevated in groups 1, 2 and 3; in particular, group 1 patients showed marked elevation of the serum BAFF at 6 and 12months after RTx.	resiniferatoxin	169-172	TNF superfamily member 13b	Homo sapiens	140-144
23380985-8	2012	In Rtx patients, CIMT was positively correlated with age, BMI, serum phosphorus, low-density lipoprotein, and hs-CRP.	resiniferatoxin	3-6	CIMT	Homo sapiens	17-21
23054585-0	2013	Resiniferatoxin and tetrodotoxin induced NPY and TH immunoreactivity changes within the paracervical ganglion neurons supplying the urinary bladder.	resiniferatoxin	0-15	neuropeptide Y	Sus scrofa	41-44
23054585-2	2013	The aim of this study was to establish the effect of intravesical administration of RTX and TTX on neuropeptides Y (NPY) and tyrosine hydroxylase (TH) relationship in the paracervical ganglion (PCG) neurons supplying the urinary bladder in the pig.	resiniferatoxin	84-87	neuropeptide Y	Sus scrofa	116-119
23054585-7	2013	Intravesical infusion of RTX resulted upregulation of the NPY-IR neurons to 82.97 % and TH-IR to 43.78 %.	resiniferatoxin	25-28	neuropeptide Y	Sus scrofa	58-61
23174234-8	2013	Resiniferatoxin administration significantly increased tumor necrosis factor-alpha mRNA and protein levels in the bladder in controls.	resiniferatoxin	0-15	tumor necrosis factor	Rattus norvegicus	55-82
23139219-13	2013	Conversely capsaicin, resiniferatoxin, and N-oleoyldopamine raised intracellular calcium ([Ca(2+)](i)) in T84 cells and AMG-9810 blocked the rise in [Ca(2+)](i) induced by capsaicin and resiniferatoxin suggesting the presence of a functional TRPV1 channel.	resiniferatoxin	22-37	transient receptor potential cation channel subfamily V member 1	Homo sapiens	242-247
23155193-3	2013	METHODS: We examined the effect of NXN-188 on: (1) KCl-, capsaicin- and resiniferatoxin (RTX)-induced immunoreactive CGRP (iCGRP) release from isolated preparation of rat dura mater, trigeminal ganglion (TG) and trigeminal nucleus caudalis (TNC); and (2) capsaicin- and electrical stimulation (ES)-induced middle meningeal artery (MMA) dilation in a rat closed-cranial window.	resiniferatoxin	72-87	calcitonin-related polypeptide alpha	Rattus norvegicus	117-121
23155193-3	2013	METHODS: We examined the effect of NXN-188 on: (1) KCl-, capsaicin- and resiniferatoxin (RTX)-induced immunoreactive CGRP (iCGRP) release from isolated preparation of rat dura mater, trigeminal ganglion (TG) and trigeminal nucleus caudalis (TNC); and (2) capsaicin- and electrical stimulation (ES)-induced middle meningeal artery (MMA) dilation in a rat closed-cranial window.	resiniferatoxin	89-92	calcitonin-related polypeptide alpha	Rattus norvegicus	117-121
26779292-2	2013	Like capsaicin, RTX is a vanilloid receptor (TRPV1) agonist, only more potent.	resiniferatoxin	16-19	transient receptor potential cation channel subfamily V member 1	Homo sapiens	45-50
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	114-129	transient receptor potential cation channel subfamily V member 1	Homo sapiens	84-89
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	114-129	heat shock protein family A (Hsp70) member 4	Homo sapiens	169-174
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	114-129	heat shock protein 90 alpha family class A member 1	Homo sapiens	176-181
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	114-129	heat shock protein family B (small) member 1	Homo sapiens	186-191
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	114-129	heat shock protein family A (Hsp70) member 4	Homo sapiens	196-201
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	114-129	heat shock protein 90 alpha family class A member 1	Homo sapiens	206-211
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	114-129	transient receptor potential cation channel subfamily V member 1	Homo sapiens	236-241
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	114-129	heat shock protein family A (Hsp70) member 4	Homo sapiens	196-201
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	114-129	heat shock protein 90 alpha family class A member 1	Homo sapiens	206-211
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	114-129	heat shock protein family B (small) member 1	Homo sapiens	329-334
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	114-129	heat shock protein family A (Hsp70) member 4	Homo sapiens	196-201
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	114-129	heat shock protein 90 alpha family class A member 1	Homo sapiens	206-211
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	131-134	transient receptor potential cation channel subfamily V member 1	Homo sapiens	84-89
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	131-134	heat shock protein family A (Hsp70) member 4	Homo sapiens	169-174
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	131-134	heat shock protein 90 alpha family class A member 1	Homo sapiens	176-181
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	131-134	heat shock protein family B (small) member 1	Homo sapiens	186-191
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	131-134	heat shock protein family A (Hsp70) member 4	Homo sapiens	196-201
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	131-134	heat shock protein 90 alpha family class A member 1	Homo sapiens	206-211
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	131-134	transient receptor potential cation channel subfamily V member 1	Homo sapiens	236-241
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	131-134	heat shock protein family A (Hsp70) member 4	Homo sapiens	196-201
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	131-134	heat shock protein 90 alpha family class A member 1	Homo sapiens	206-211
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	131-134	heat shock protein family B (small) member 1	Homo sapiens	329-334
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	131-134	heat shock protein family A (Hsp70) member 4	Homo sapiens	196-201
23468922-4	2013	We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively.	resiniferatoxin	131-134	heat shock protein 90 alpha family class A member 1	Homo sapiens	206-211
22820265-8	2012	Besides, the pretreatment with resiniferatoxin (RTX), a potent TRPV1 agonist, abolished the cinnamaldehyde-induced heat hyperalgesia.	resiniferatoxin	31-46	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	63-68
22528458-1	2012	Pretreatment with the ultrapotent capsaicin analog resiniferatoxin (RTX) has been applied as a selective pharmacological tool in inflammation and pain studies to desensitize transient receptor potential vanilloid 1 (TRPV1) receptor-expressing sensory nerve endings.	resiniferatoxin	51-66	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	174-214
22528458-1	2012	Pretreatment with the ultrapotent capsaicin analog resiniferatoxin (RTX) has been applied as a selective pharmacological tool in inflammation and pain studies to desensitize transient receptor potential vanilloid 1 (TRPV1) receptor-expressing sensory nerve endings.	resiniferatoxin	51-66	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	216-221
22528458-1	2012	Pretreatment with the ultrapotent capsaicin analog resiniferatoxin (RTX) has been applied as a selective pharmacological tool in inflammation and pain studies to desensitize transient receptor potential vanilloid 1 (TRPV1) receptor-expressing sensory nerve endings.	resiniferatoxin	68-71	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	174-214
22528458-1	2012	Pretreatment with the ultrapotent capsaicin analog resiniferatoxin (RTX) has been applied as a selective pharmacological tool in inflammation and pain studies to desensitize transient receptor potential vanilloid 1 (TRPV1) receptor-expressing sensory nerve endings.	resiniferatoxin	68-71	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	216-221
22820265-8	2012	Besides, the pretreatment with resiniferatoxin (RTX), a potent TRPV1 agonist, abolished the cinnamaldehyde-induced heat hyperalgesia.	resiniferatoxin	48-51	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	63-68
22820265-9	2012	Here, we showed that intrathecal RTX results in a decrease in TRPA1 and TRPV1 immunoreactivity in dorsal root ganglion.	resiniferatoxin	33-36	transient receptor potential cation channel, subfamily A, member 1	Rattus norvegicus	62-67
22820265-9	2012	Here, we showed that intrathecal RTX results in a decrease in TRPA1 and TRPV1 immunoreactivity in dorsal root ganglion.	resiniferatoxin	33-36	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	72-77
22588258-3	2012	JTS-653 displaced [(3)H]resiniferatoxin binding to human and rat TRPV1.	resiniferatoxin	24-39	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	65-70
22903083-0	2012	Upregulation of LENK and VIP in paracervical ganglion neurons supplying the urinary bladder of tetrodotoxin- and resiniferatoxin-treated female pigs.	resiniferatoxin	113-128	vasoactive intestinal peptide	Sus scrofa	25-28
22903083-6	2012	Intravesical infusion of RTX resulted in an increase in the number of LENKIR neurons to 48.19% and VIP-IR perikarya to 11.25%.	resiniferatoxin	25-28	vasoactive intestinal peptide	Sus scrofa	99-102
22903083-9	2012	Furthermore, the results indicate a possible involvement of LENK and VIP neurons in the mechanisms of action of RTX and TTX in the therapy of overactive bladder disorder.	resiniferatoxin	112-115	vasoactive intestinal peptide	Sus scrofa	69-72
22679016-8	2012	The reduction in postsynaptic NMDAR currents caused by morphine was prevented by resiniferatoxin pretreatment to ablate TRPV1-expressing primary afferents.	resiniferatoxin	81-96	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	120-125
22828682-1	2012	BACKGROUND: Resiniferatoxin (RTX) is a potent synthetic agonist for transient receptor potential vanilloid subtype 1 (TRPV1), which has a selectivity for antinociception.	resiniferatoxin	12-27	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	68-116
22828682-1	2012	BACKGROUND: Resiniferatoxin (RTX) is a potent synthetic agonist for transient receptor potential vanilloid subtype 1 (TRPV1), which has a selectivity for antinociception.	resiniferatoxin	12-27	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	118-123
22828682-1	2012	BACKGROUND: Resiniferatoxin (RTX) is a potent synthetic agonist for transient receptor potential vanilloid subtype 1 (TRPV1), which has a selectivity for antinociception.	resiniferatoxin	29-32	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	68-116
22828682-1	2012	BACKGROUND: Resiniferatoxin (RTX) is a potent synthetic agonist for transient receptor potential vanilloid subtype 1 (TRPV1), which has a selectivity for antinociception.	resiniferatoxin	29-32	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	118-123
22546668-1	2012	The structure-activity relationships of N-(3-acyloxy-2-benzylpropyl)-N"-4-[(methylsulfonylamino)benzyl] thioureas, which represent simplified RTX-based vanilloids, were investigated by varying the distances between the four principal pharmacophores and assessing binding and antagonistic activity on rTRPV1.	resiniferatoxin	142-145	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	300-306
22493457-1	2012	TRPV1 receptor agonists such as the vanilloid capsaicin and the potent analog resiniferatoxin are well known potent analgesics.	resiniferatoxin	78-93	transient receptor potential cation channel subfamily V member 1	Homo sapiens	0-5
22335898-11	2012	The elevated level of BDNF in L1 DRG by colonic inflammation was blunted by prolonged pre-treatment of the animals with the neurotoxin resiniferatoxin (RTX).	resiniferatoxin	135-150	brain-derived neurotrophic factor	Rattus norvegicus	22-26
22391132-0	2012	P2X3-mediated peripheral sensitization of neuropathic pain in resiniferatoxin-induced neuropathy.	resiniferatoxin	62-77	purinergic receptor P2X, ligand-gated ion channel, 3	Mus musculus	0-4
22391132-5	2012	After RTX treatment, dorsal root ganglion (DRG) neurons of the peripherin type were depleted (p=0.012), while neurofilament (+) DRG neurons were not affected (p=0.62).	resiniferatoxin	6-9	peripherin	Mus musculus	63-73
22391132-6	2012	In addition, RTX caused a shift in neuronal profiles of DRG: (1) increased in P2X3 receptor (p=0.0002) and ATF3 (p=0.0006) but (2) reduced TRPV1 (p=0.036) and CGRP (p=0.015).	resiniferatoxin	13-16	purinergic receptor P2X, ligand-gated ion channel, 3	Mus musculus	78-82
22391132-6	2012	In addition, RTX caused a shift in neuronal profiles of DRG: (1) increased in P2X3 receptor (p=0.0002) and ATF3 (p=0.0006) but (2) reduced TRPV1 (p=0.036) and CGRP (p=0.015).	resiniferatoxin	13-16	activating transcription factor 3	Mus musculus	107-111
22391132-6	2012	In addition, RTX caused a shift in neuronal profiles of DRG: (1) increased in P2X3 receptor (p=0.0002) and ATF3 (p=0.0006) but (2) reduced TRPV1 (p=0.036) and CGRP (p=0.015).	resiniferatoxin	13-16	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	139-144
22391132-6	2012	In addition, RTX caused a shift in neuronal profiles of DRG: (1) increased in P2X3 receptor (p=0.0002) and ATF3 (p=0.0006) but (2) reduced TRPV1 (p=0.036) and CGRP (p=0.015).	resiniferatoxin	13-16	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	159-163
22391132-9	2012	In conclusion, RTX-induced sensory neuropathy with upregulation of P2X3 receptor for peripheral sensitization of mechanical allodynia, which provides a new therapeutic target for neuropathic pain after skin denervation.	resiniferatoxin	15-18	purinergic receptor P2X, ligand-gated ion channel, 3	Mus musculus	67-71
22262838-6	2012	After stimulation with resiniferatoxin, TRPV1 dimers tetramerize.	resiniferatoxin	23-38	transient receptor potential cation channel subfamily V member 1	Homo sapiens	40-45
22168801-6	2012	Transient receptor potential vanilloid 1 expressing neurons were selectively lesioned with resiniferatoxin.	resiniferatoxin	91-106	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	0-40
22168801-9	2012	The PAR-2 agonist enhancement of colonic contraction was eliminated when TRPV1 expressing neurons were lesioned with resiniferatoxin, but the PAR-2 agonist induced hypersensitivity remained in the lesioned animals.	resiniferatoxin	117-132	F2R like trypsin receptor 1	Rattus norvegicus	4-9
22168801-9	2012	The PAR-2 agonist enhancement of colonic contraction was eliminated when TRPV1 expressing neurons were lesioned with resiniferatoxin, but the PAR-2 agonist induced hypersensitivity remained in the lesioned animals.	resiniferatoxin	117-132	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	73-78
22242698-8	2012	In stark contrast to the untreated fibroblasts, significant calcium signaling in response to capsaicin and resiniferatoxin in HPBFs treated for 24 and 48 hours with TNF-alpha, LPS, or IL-1alpha was also observed.	resiniferatoxin	107-122	tumor necrosis factor	Homo sapiens	165-174
22242698-8	2012	In stark contrast to the untreated fibroblasts, significant calcium signaling in response to capsaicin and resiniferatoxin in HPBFs treated for 24 and 48 hours with TNF-alpha, LPS, or IL-1alpha was also observed.	resiniferatoxin	107-122	interleukin 1 alpha	Homo sapiens	184-193
22335898-11	2012	The elevated level of BDNF in L1 DRG by colonic inflammation was blunted by prolonged pre-treatment of the animals with the neurotoxin resiniferatoxin (RTX).	resiniferatoxin	152-155	brain-derived neurotrophic factor	Rattus norvegicus	22-26
21908651-4	2011	In vitro, activation of TRPV1 by the specific agonists capsaicin and resiniferatoxin dose-dependently increased cytosolic calcium and significantly reduced the accumulation of lipids in VSMC from C57BL/6J mice but not from TRPV1(-/-) mice.	resiniferatoxin	69-84	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	24-29
21908651-4	2011	In vitro, activation of TRPV1 by the specific agonists capsaicin and resiniferatoxin dose-dependently increased cytosolic calcium and significantly reduced the accumulation of lipids in VSMC from C57BL/6J mice but not from TRPV1(-/-) mice.	resiniferatoxin	69-84	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	223-228
21763717-6	2011	The previous desensitization with resiniferatoxin (RTX) largely reduced the spermine-induced nociception and TRPV1 expression in the sciatic nerve, with reductions of 82 +- 9% and 67 +- 11%, respectively.	resiniferatoxin	34-49	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	109-114
21763717-6	2011	The previous desensitization with resiniferatoxin (RTX) largely reduced the spermine-induced nociception and TRPV1 expression in the sciatic nerve, with reductions of 82 +- 9% and 67 +- 11%, respectively.	resiniferatoxin	51-54	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	109-114
21620567-4	2011	Desensitization of TRPV1-positive fibers with systemic resiniferatoxin (RTX) abolished spinal nerve ligation (SNL) injury-induced thermal hypersensitivity and spontaneous pain, but had no effect on tactile hypersensitivity.	resiniferatoxin	55-70	transient receptor potential cation channel subfamily V member 1	Homo sapiens	19-24
21680254-1	2011	UNLABELLED: Resiniferatoxin (RTX) is a potent agonist of TRPV1, which possesses unique properties that can be utilized to treat certain modalities of pain.	resiniferatoxin	12-27	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	57-62
21680254-1	2011	UNLABELLED: Resiniferatoxin (RTX) is a potent agonist of TRPV1, which possesses unique properties that can be utilized to treat certain modalities of pain.	resiniferatoxin	29-32	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	57-62
21680254-7	2011	administration of RTX prevented TRPV1-induced nocifensive behavior and inflammatory thermal hypersensitivity.	resiniferatoxin	18-21	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	32-37
21680254-27	2011	PERSPECTIVE: Localized administration of RTX in spinal cord could be a useful strategy to treat chronic debilitating pain arising from certain conditions such as cancer and at the same time could maintain normal physiological peripheral efferent functions mediated by TRPV1.	resiniferatoxin	41-44	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	268-273
21620567-4	2011	Desensitization of TRPV1-positive fibers with systemic resiniferatoxin (RTX) abolished spinal nerve ligation (SNL) injury-induced thermal hypersensitivity and spontaneous pain, but had no effect on tactile hypersensitivity.	resiniferatoxin	72-75	transient receptor potential cation channel subfamily V member 1	Homo sapiens	19-24
21925447-14	2011	RESULTS: RTX is an effective drug in three groups of patients with RA: patients who fail to MTX, those who fail anti-TNF and in patients with no prior exposure to MTX.	resiniferatoxin	9-12	metaxin 1	Homo sapiens	92-95
21925447-14	2011	RESULTS: RTX is an effective drug in three groups of patients with RA: patients who fail to MTX, those who fail anti-TNF and in patients with no prior exposure to MTX.	resiniferatoxin	9-12	tumor necrosis factor	Homo sapiens	117-120
21925447-14	2011	RESULTS: RTX is an effective drug in three groups of patients with RA: patients who fail to MTX, those who fail anti-TNF and in patients with no prior exposure to MTX.	resiniferatoxin	9-12	metaxin 1	Homo sapiens	163-166
21925447-18	2011	It was impossible to identify a larger increase in the number of severe infections, probably due to methodological problems, however, the risk of developing infections in patients treated with RTX seems to be comparable to that of other anti-TNF and biologics.	resiniferatoxin	193-196	tumor necrosis factor	Homo sapiens	242-245
21832173-8	2011	Moreover, behavioral assays of TRPV1/TRPV2 double knock-out mice or of TRPV2 knock-out mice treated with resiniferatoxin to desensitize TRPV1-expressing afferents revealed no thermosensory consequences of TRPV2 absence.	resiniferatoxin	105-120	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	136-141
21069423-5	2011	TRPV1 agonist resiniferatoxin induced hypothermia and tail vasodilatation was markedly inhibited in knockdown mice.	resiniferatoxin	14-29	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	0-5
21794120-8	2011	Intrathecal administration of resiniferatoxin (RTX), a potent TRPV1 agonist, significantly attenuated STZ-induced thermal hyperalgesia, but not mechanical allodynia.	resiniferatoxin	30-45	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	62-67
21794120-8	2011	Intrathecal administration of resiniferatoxin (RTX), a potent TRPV1 agonist, significantly attenuated STZ-induced thermal hyperalgesia, but not mechanical allodynia.	resiniferatoxin	47-50	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	62-67
21794120-9	2011	RTX treatment also prevented the increase in TRPV1-mediated neuropeptide release in the spinal cord tissue.	resiniferatoxin	0-3	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	45-50
21794120-10	2011	CONCLUSIONS: From these results, it is concluded that TRPV1 is an integral component of initiating and maintaining inflammatory thermal hyperalgesia, which can be alleviated by intrathecal administration of RTX.	resiniferatoxin	207-210	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	54-59
21237298-4	2011	We report that in osteoclasts from osteoporotic patients, TRPV1 channels are upregulated and, if persistently stimulated with resiniferatoxin, become clustered to the plasma membrane while inducing a massive over-expression of CB2 receptors.	resiniferatoxin	126-141	transient receptor potential cation channel subfamily V member 1	Homo sapiens	58-63
21221027-12	2011	RTX treatment of allodynic rats changed the NT3 distribution to a nonallodynic pattern.	resiniferatoxin	0-3	neurotrophin 3	Rattus norvegicus	44-47
21276877-6	2011	The TRPV1 agonist, resiniferatoxin (0.65-1.0mM/L in 100nL), prolonged the LCR after bilateral injection into the NTS even when the body temperature of each piglet was normal.	resiniferatoxin	19-34	transient receptor potential cation channel subfamily V member 1	Homo sapiens	4-9
21448716-4	2011	We experimentally evaluated by mutational analysis the contribution of residues of rTRPV1 contributing to ligand binding by the prototypical TRPV1 agonists, capsaicin and resiniferatoxin (RTX).	resiniferatoxin	171-186	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	83-89
21448716-4	2011	We experimentally evaluated by mutational analysis the contribution of residues of rTRPV1 contributing to ligand binding by the prototypical TRPV1 agonists, capsaicin and resiniferatoxin (RTX).	resiniferatoxin	171-186	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	84-89
21448716-4	2011	We experimentally evaluated by mutational analysis the contribution of residues of rTRPV1 contributing to ligand binding by the prototypical TRPV1 agonists, capsaicin and resiniferatoxin (RTX).	resiniferatoxin	188-191	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	83-89
21448716-4	2011	We experimentally evaluated by mutational analysis the contribution of residues of rTRPV1 contributing to ligand binding by the prototypical TRPV1 agonists, capsaicin and resiniferatoxin (RTX).	resiniferatoxin	188-191	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	84-89
21448716-7	2011	Additionally, the binding mode of a simplified RTX (sRTX) ligand as predicted by the modeling agreed well with those of capsaicin and RTX, accounting for the high binding affinity of the sRTX ligand for TRPV1.	resiniferatoxin	47-50	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	203-208
21098091-4	2011	AS1928370 bound to the resiniferatoxin-binding site on TRPV1 and inhibited capsaicin-mediated inward currents with an IC50 value of 32.5 nM.	resiniferatoxin	23-38	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	55-60
21383614-7	2011	Furthermore, after cecal ligation and puncture, increased mortality in resiniferatoxin-treated WT animals was associated with higher blood bacterial count (P = 0.0004) and higher nitrate/nitrite concentrations and down-regulation of tumor necrosis factor alpha expression (P = 0.004) compared with controls.	resiniferatoxin	71-86	tumor necrosis factor	Mus musculus	233-260
21222484-7	2011	Surprisingly, even though UNG is the only DNA glycosylase in DT40 cells that can act on U A base pairs derived from dUTP incorporation, an isogenic ung(-/-) DT40 cell line showed little change in its sensitivity to RTX as compared to control cells.	resiniferatoxin	215-218	uracil DNA glycosylase	Gallus gallus	26-29
21222484-1	2011	5-Fluorouracil (5-FU), 5-fluorodeoxyuridine (5-dUrd), and raltitrixed (RTX) are anticancer agents that target thymidylate synthase (TS), thereby blocking the conversion of dUMP into dTMP.	resiniferatoxin	71-74	thymidylate synthetase	Homo sapiens	110-130
21219650-8	2011	Pretreatment with resiniferatoxin (RTX), an ultrapotent capsaicin analogue known to produce long-lasting desensitization of TRPV1 positive afferents, fully blocked CFA-induced thermal hypersensitivity and abolished the CPP elicited by administration of popliteal fossa lidocaine 24 hrs post-CFA.	resiniferatoxin	18-33	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	124-129
21219650-8	2011	Pretreatment with resiniferatoxin (RTX), an ultrapotent capsaicin analogue known to produce long-lasting desensitization of TRPV1 positive afferents, fully blocked CFA-induced thermal hypersensitivity and abolished the CPP elicited by administration of popliteal fossa lidocaine 24 hrs post-CFA.	resiniferatoxin	35-38	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	124-129
21671878-0	2011	Therapeutic targeting of TRPV1 by resiniferatoxin, from preclinical studies to clinical trials.	resiniferatoxin	34-49	transient receptor potential cation channel subfamily V member 1	Homo sapiens	25-30
21111618-0	2011	Receptor activity and conformational analysis of 5"-halogenated resiniferatoxin analogs as TRPV1 ligands.	resiniferatoxin	64-79	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	91-96
21671878-4	2011	This has rekindled interest in desensitization of nociceptive neurons to TRPV1 agonists (e.g. capsaicin and its ultrapotent analog resiniferatoxin) as an alternative pharmacological approach to block pain in the periphery where it is generated.	resiniferatoxin	131-146	transient receptor potential cation channel subfamily V member 1	Homo sapiens	73-78
21671879-2	2011	The identification of resiniferatoxin as an ultrapotent ligand partially able to dissect the acute activation of TRPV1 from subsequent desensitization and the subsequent intense efforts in medicinal chemistry have revealed that TRPV1 affords a dramatic landscape of opportunities for pharmacological manipulation.	resiniferatoxin	22-37	transient receptor potential cation channel subfamily V member 1	Homo sapiens	113-118
21671879-2	2011	The identification of resiniferatoxin as an ultrapotent ligand partially able to dissect the acute activation of TRPV1 from subsequent desensitization and the subsequent intense efforts in medicinal chemistry have revealed that TRPV1 affords a dramatic landscape of opportunities for pharmacological manipulation.	resiniferatoxin	22-37	transient receptor potential cation channel subfamily V member 1	Homo sapiens	228-233
21167052-1	2010	BACKGROUND: Ablation of TRPV1-expressing nociceptive fibers with the potent capsaicin analog resiniferatoxin (RTX) results in long lasting pain relief.	resiniferatoxin	93-108	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	24-29
21167052-1	2010	BACKGROUND: Ablation of TRPV1-expressing nociceptive fibers with the potent capsaicin analog resiniferatoxin (RTX) results in long lasting pain relief.	resiniferatoxin	110-113	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	24-29
20452292-0	2010	Brain-derived neurotrophic factor redistribution in the dorsal root ganglia correlates with neuropathic pain inhibition after resiniferatoxin treatment.	resiniferatoxin	126-141	brain-derived neurotrophic factor	Rattus norvegicus	0-33
20884761-6	2010	Bath application of 2AG or the TRPV1 agonists capsaicin and resiniferatoxin mimicked LTD and both capsaicin- and 2AG-induced depression were blocked by capsazepine.	resiniferatoxin	60-75	transient receptor potential cation channel subfamily V member 1	Homo sapiens	31-36
20501335-3	2010	Inflammation was induced by intracolonic instillation of trinitrobenzene sulfonic acid (TNBS, 12.5mg/kg), and desensitization of TRPV1 receptors was evoked by intracolonic resiniferatoxin (RTX, 10(-)(7)M).	resiniferatoxin	172-187	transient receptor potential cation channel subfamily V member 1	Homo sapiens	129-134
20501335-3	2010	Inflammation was induced by intracolonic instillation of trinitrobenzene sulfonic acid (TNBS, 12.5mg/kg), and desensitization of TRPV1 receptors was evoked by intracolonic resiniferatoxin (RTX, 10(-)(7)M).	resiniferatoxin	189-192	transient receptor potential cation channel subfamily V member 1	Homo sapiens	129-134
20501335-11	2010	RTX pretreatment did not affect CGRP concentration in the urinary bladder; however, it caused a reduction in CGRP release from lumbosacral DRG neurons during acute phase (3 and 5 days post-TNBS).	resiniferatoxin	0-3	calcitonin related polypeptide alpha	Homo sapiens	109-113
20638179-7	2010	Double staining showed that the expression of TrkA but not TrkB was increased in the specifically labeled colonic afferent neurons in the L1 and S1 DRGs during colitis; this increase in TrkA level was attenuated by pretreatment with resiniferatoxin.	resiniferatoxin	233-248	neurotrophic receptor tyrosine kinase 1	Homo sapiens	46-50
20638179-7	2010	Double staining showed that the expression of TrkA but not TrkB was increased in the specifically labeled colonic afferent neurons in the L1 and S1 DRGs during colitis; this increase in TrkA level was attenuated by pretreatment with resiniferatoxin.	resiniferatoxin	233-248	neurotrophic receptor tyrosine kinase 1	Homo sapiens	186-190
20452292-3	2010	Resiniferatoxin (RTX) is an excitotoxic agonist of the vanilloid receptor 1 (VR1), a cation channel protein considered an integrator for nociception.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	55-75
20452292-3	2010	Resiniferatoxin (RTX) is an excitotoxic agonist of the vanilloid receptor 1 (VR1), a cation channel protein considered an integrator for nociception.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	77-80
20452292-3	2010	Resiniferatoxin (RTX) is an excitotoxic agonist of the vanilloid receptor 1 (VR1), a cation channel protein considered an integrator for nociception.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	55-75
20452292-3	2010	Resiniferatoxin (RTX) is an excitotoxic agonist of the vanilloid receptor 1 (VR1), a cation channel protein considered an integrator for nociception.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	77-80
20452292-4	2010	Resiniferatoxin, administered into the dorsal root ganglia (DRG), selectively eliminates the VR1-positive neurons and improves tactile allodynia in a neuropathic pain rat model.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	93-96
20452292-10	2010	A high-dose RTX injection in the DRG of neuropathic rats led to elimination of both thermal hyperalgesia and tactile allodynia and also upregulated BDNF in the large-size neurons, similar to the nonallodynic rats.	resiniferatoxin	12-15	brain-derived neurotrophic factor	Rattus norvegicus	148-152
20452292-12	2010	CONCLUSION: Resiniferatoxin injection in the DRG of neuropathic rats upregulates BDNF expression in the same pattern as in the large-size neurons of non-neuropathic rats.	resiniferatoxin	12-27	brain-derived neurotrophic factor	Rattus norvegicus	81-85
19853036-2	2010	Resiniferotoxin (RTX), a potent TrpV1 agonist, administered either by direct injection in the ganglion or intrathecally killed approximately 70% of TrpV1 cells and resulted in modest thermal analgesia.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	32-37
20403666-0	2010	Prolonged analgesic response of cornea to topical resiniferatoxin, a potent TRPV1 agonist.	resiniferatoxin	50-65	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	76-81
20403666-3	2010	Resiniferatoxin (RTX), a potent TRPV1 agonist, produces transient analgesia when injected peripherally by inactivating TRPV1-expressing nerve terminals through excessive calcium influx.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	32-37
20403666-3	2010	Resiniferatoxin (RTX), a potent TRPV1 agonist, produces transient analgesia when injected peripherally by inactivating TRPV1-expressing nerve terminals through excessive calcium influx.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	119-124
20403666-3	2010	Resiniferatoxin (RTX), a potent TRPV1 agonist, produces transient analgesia when injected peripherally by inactivating TRPV1-expressing nerve terminals through excessive calcium influx.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	32-37
20403666-3	2010	Resiniferatoxin (RTX), a potent TRPV1 agonist, produces transient analgesia when injected peripherally by inactivating TRPV1-expressing nerve terminals through excessive calcium influx.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	119-124
19800272-0	2010	Antinociceptive desensitizing actions of TRPV1 receptor agonists capsaicin, resiniferatoxin and N-oleoyldopamine as measured by determination of the noxious heat and cold thresholds in the rat.	resiniferatoxin	76-91	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	41-46
19800272-7	2010	In conclusion, using measurement of threshold temperatures eliciting nocifensive reactions in rats both in the hot and cold range revealed that capsaicin and RTX impair thermosensation in both noxious ranges due to a functional desensitization of peripheral terminals of TRPV1-expressing sensory neurons responsible for noxious heat and cold responsiveness.	resiniferatoxin	158-161	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	271-276
19800272-8	2010	This could be differentiated from desensitization of TRPV1 receptor evoked by lower doses of resiniferatoxin or N-oleoyldopamine.	resiniferatoxin	93-108	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	53-58
20230457-9	2010	Clinical use of resiniferatoxin, another ancient but potent TRPV1 agonist, is also being explored as a therapy for refractory pain.	resiniferatoxin	16-31	transient receptor potential cation channel subfamily V member 1	Homo sapiens	60-65
20032236-3	2010	An increase in PIP(2) by topical lingual application of U73122 (a phospholipase C blocker) or diC8-PIP(2) (a short chain synthetic PIP(2)) inhibited the control NaCl + Bz CT response and decreased its sensitivity to RTX.	resiniferatoxin	216-219	prolactin induced protein	Mus musculus	15-18
20032236-4	2010	A decrease in PIP(2) by topical lingual application of phenylarsine oxide (a phosphoinositide 4 kinase blocker) enhanced the control NaCl + Bz CT response, increased its sensitivity to RTX stimulation, and inhibited the desensitization of the CT response at RTX concentrations &gt;1 x 10(-6) M. The ENaC-dependent NaCl CT responses were not altered by changes in PIP(2).	resiniferatoxin	185-188	prolactin induced protein	Mus musculus	14-17
20032236-4	2010	A decrease in PIP(2) by topical lingual application of phenylarsine oxide (a phosphoinositide 4 kinase blocker) enhanced the control NaCl + Bz CT response, increased its sensitivity to RTX stimulation, and inhibited the desensitization of the CT response at RTX concentrations &gt;1 x 10(-6) M. The ENaC-dependent NaCl CT responses were not altered by changes in PIP(2).	resiniferatoxin	258-261	prolactin induced protein	Mus musculus	14-17
19926130-3	2010	Pretreatment with SP or HK-1 enhanced the induction of scratching behavior by resiniferatoxin, a TRPV1 agonist, whereas scratching behavior induced by menthol, a TRPM8 agonist, was suppressed by pretreatment with these peptides.	resiniferatoxin	78-93	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	97-102
20383340-6	2010	The results indicate that CAP and high concentrations of RTX are more neurotoxic to cultured rat DRG neurons while the inability of the neurons to express SP or TRPV1 after acute exposure to the lower concentration of RTX could be partially reversed after a period of incubation.	resiniferatoxin	218-221	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	161-166
19853036-2	2010	Resiniferotoxin (RTX), a potent TrpV1 agonist, administered either by direct injection in the ganglion or intrathecally killed approximately 70% of TrpV1 cells and resulted in modest thermal analgesia.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	148-153
19853036-4	2010	This additional carageenan and RTX-induced analgesia was transient, lasting less than 2 days, and likely resulted from deafferentation of remaining TrpV1 neurons.	resiniferatoxin	31-34	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	148-153
19778582-2	2009	Resiniferatoxin (RTX) has a much higher affinity for TRPV1 than capsaicin, but its ability to modulate excitatory transmission is unclear.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	53-58
19778582-2	2009	Resiniferatoxin (RTX) has a much higher affinity for TRPV1 than capsaicin, but its ability to modulate excitatory transmission is unclear.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	53-58
19778582-9	2009	RTX enhances the spontaneous release of L-glutamate from nerve terminals with similar efficacy as capsaicin and produces a membrane depolarization by activating TRPV1 in the SG, with fast desensitization and slow recovery from desensitization.	resiniferatoxin	0-3	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	161-166
19695100-3	2009	RESULTS: Fluorescent imaging of Fura-2 loaded human SW982 synoviocytes reveals immediate and delayed cytosolic calcium oscillations elicited by (1) TRPV1 agonists capsaicin and resiniferatoxin (20-40% of cells), (2) moderate and noxious temperature change, and (3) osmotic stress TRPV4 activation (11.5% of cells).	resiniferatoxin	177-192	transient receptor potential cation channel subfamily V member 1	Homo sapiens	148-153
19726694-4	2009	Resiniferatoxin (RTX), an ultrapotent analog of capsaicin, was used to ablate TRPV1-expressing afferent neurons and fibers in adult rats.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	78-83
19726694-4	2009	Resiniferatoxin (RTX), an ultrapotent analog of capsaicin, was used to ablate TRPV1-expressing afferent neurons and fibers in adult rats.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	78-83
19726694-6	2009	RTX treatment eliminated TRPV1 immunoreactivities in the aorta, nodose ganglion, and solitary tract.	resiniferatoxin	0-3	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	25-30
19772627-5	2009	To determine whether spontaneous activity from C- or A-fibers is required for microglial activation, we used resiniferatoxin (RTX) to block the conduction of transient receptor potential vanilloid subtype 1 (TRPV1) positive fibers (mostly C- and Adelta-fibers) and bupivacaine microspheres to block all fibers of the sciatic nerve in rats before spared nerve injury (SNI), and observed spinal microglial changes 2 days later.	resiniferatoxin	109-124	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	158-206
19772627-5	2009	To determine whether spontaneous activity from C- or A-fibers is required for microglial activation, we used resiniferatoxin (RTX) to block the conduction of transient receptor potential vanilloid subtype 1 (TRPV1) positive fibers (mostly C- and Adelta-fibers) and bupivacaine microspheres to block all fibers of the sciatic nerve in rats before spared nerve injury (SNI), and observed spinal microglial changes 2 days later.	resiniferatoxin	109-124	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	208-213
19772627-5	2009	To determine whether spontaneous activity from C- or A-fibers is required for microglial activation, we used resiniferatoxin (RTX) to block the conduction of transient receptor potential vanilloid subtype 1 (TRPV1) positive fibers (mostly C- and Adelta-fibers) and bupivacaine microspheres to block all fibers of the sciatic nerve in rats before spared nerve injury (SNI), and observed spinal microglial changes 2 days later.	resiniferatoxin	126-129	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	158-206
19772627-5	2009	To determine whether spontaneous activity from C- or A-fibers is required for microglial activation, we used resiniferatoxin (RTX) to block the conduction of transient receptor potential vanilloid subtype 1 (TRPV1) positive fibers (mostly C- and Adelta-fibers) and bupivacaine microspheres to block all fibers of the sciatic nerve in rats before spared nerve injury (SNI), and observed spinal microglial changes 2 days later.	resiniferatoxin	126-129	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	208-213
19753113-2	2009	Resiniferatoxin (RTX), a potent agonist of Transient Receptor Potential Vanilloid 1 (TRPV1), causes a slow, sustained and irreversible activation of TRPV1 and increases the frequency of spontaneous excitatory postsynaptic currents, but causes significant depression of evoked EPSCs due to nerve terminal depolarization block.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	43-83
19753113-2	2009	Resiniferatoxin (RTX), a potent agonist of Transient Receptor Potential Vanilloid 1 (TRPV1), causes a slow, sustained and irreversible activation of TRPV1 and increases the frequency of spontaneous excitatory postsynaptic currents, but causes significant depression of evoked EPSCs due to nerve terminal depolarization block.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	85-90
19753113-2	2009	Resiniferatoxin (RTX), a potent agonist of Transient Receptor Potential Vanilloid 1 (TRPV1), causes a slow, sustained and irreversible activation of TRPV1 and increases the frequency of spontaneous excitatory postsynaptic currents, but causes significant depression of evoked EPSCs due to nerve terminal depolarization block.	resiniferatoxin	0-15	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	149-154
19753113-2	2009	Resiniferatoxin (RTX), a potent agonist of Transient Receptor Potential Vanilloid 1 (TRPV1), causes a slow, sustained and irreversible activation of TRPV1 and increases the frequency of spontaneous excitatory postsynaptic currents, but causes significant depression of evoked EPSCs due to nerve terminal depolarization block.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	43-83
19753113-2	2009	Resiniferatoxin (RTX), a potent agonist of Transient Receptor Potential Vanilloid 1 (TRPV1), causes a slow, sustained and irreversible activation of TRPV1 and increases the frequency of spontaneous excitatory postsynaptic currents, but causes significant depression of evoked EPSCs due to nerve terminal depolarization block.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	85-90
19753113-2	2009	Resiniferatoxin (RTX), a potent agonist of Transient Receptor Potential Vanilloid 1 (TRPV1), causes a slow, sustained and irreversible activation of TRPV1 and increases the frequency of spontaneous excitatory postsynaptic currents, but causes significant depression of evoked EPSCs due to nerve terminal depolarization block.	resiniferatoxin	17-20	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	149-154
19753113-3	2009	Intrathecal administration of RTX to rats in the short-term inhibits nociceptive synaptic transmission, and in the long-term causes a localized, selective ablation of TRPV1-expressing central sensory nerve terminals leading to long lasting analgesia in behavioral models.	resiniferatoxin	30-33	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	167-172
19632157-5	2009	We also show that RA patients produced anti-IL-8 autoantibodies and that their levels dropped after RTX treatment.	resiniferatoxin	100-103	C-X-C motif chemokine ligand 8	Homo sapiens	44-48
19632157-6	2009	Moreover, we identified antibody-IL-8 immune complexes in the synovial fluid and serum of RA patients, and found that the amount of these complexes decreased after the administration of RTX.	resiniferatoxin	186-189	C-X-C motif chemokine ligand 8	Homo sapiens	33-37
19553475-7	2009	We conclude that TRPV1 or its variant TRPV1t is phosphorylated and dephosphorylated by PKC and PP2B, respectively, and either sensitizes or desensitizes the Bz-insensitive NaCl chorda tympani responses to RTX stimulation.	resiniferatoxin	205-208	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	17-22
19553475-7	2009	We conclude that TRPV1 or its variant TRPV1t is phosphorylated and dephosphorylated by PKC and PP2B, respectively, and either sensitizes or desensitizes the Bz-insensitive NaCl chorda tympani responses to RTX stimulation.	resiniferatoxin	205-208	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	38-43
19531269-7	2009	TRPV1 was stimulated with capsaicin or its potent analog, resiniferatoxin.	resiniferatoxin	58-73	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	0-5
19531269-12	2009	The PBN blocks increases in TNFR1 and ROS production induced by capsaicin/resiniferatoxin.	resiniferatoxin	74-89	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	28-33
19406878-8	2009	Activation of TRPV1 with resiniferatoxin also reduced field potential amplitude to 84 +/- 8% of control values.	resiniferatoxin	25-40	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	14-19
19294370-2	2009	TRPV1 receptors can be activated by noxious heat, acid, capsaicin and resiniferatoxin, leading to burning pain or itch mediated by discharges in C polymodal and Adelta mechano-heat nociceptors and in central neurons, including spinothalamic tract (STT) cells.	resiniferatoxin	70-85	transient receptor potential cation channel subfamily V member 1	Homo sapiens	0-5
19147859-2	2009	We demonstrated recently that the preischemic treatment with resiniferatoxin, a transient receptor potential vanilloid 1 (TRPV1) agonist, attenuates renal TNF-alpha mRNA expression and improves ischemia/reperfusion-induced renal injury in rats.	resiniferatoxin	61-76	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	80-120
19236852-11	2009	Disruption of abdominal TRPV1 receptor function by injection of the TRPV1 receptor agonist, resiniferatoxin (20 microg/kg, i.p.	resiniferatoxin	92-107	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	24-29
19236852-11	2009	Disruption of abdominal TRPV1 receptor function by injection of the TRPV1 receptor agonist, resiniferatoxin (20 microg/kg, i.p.	resiniferatoxin	92-107	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	68-73
19147859-2	2009	We demonstrated recently that the preischemic treatment with resiniferatoxin, a transient receptor potential vanilloid 1 (TRPV1) agonist, attenuates renal TNF-alpha mRNA expression and improves ischemia/reperfusion-induced renal injury in rats.	resiniferatoxin	61-76	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	122-127
19147859-2	2009	We demonstrated recently that the preischemic treatment with resiniferatoxin, a transient receptor potential vanilloid 1 (TRPV1) agonist, attenuates renal TNF-alpha mRNA expression and improves ischemia/reperfusion-induced renal injury in rats.	resiniferatoxin	61-76	tumor necrosis factor	Rattus norvegicus	155-164